Innovation, Sciences et Développement économique Canada
Office de la Propriété Intellectuelle du Canada

Innovation, Science and Economic Development Canada
Canadian Intellectual Property Office

CA 3017048 A1 2017/09/28

(21) 3 017 048

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2017/02/21
(87) Date publication PCT/PCT Publication Date: 2017/09/28
(85) Entrée phase nationale/National Entry: 2018/09/07
(86) N° demande PCT/PCT Application No.: EP 2017/053937
(87) N° publication PCT/PCT Publication No.: 2017/162390
(30) Priorité/Priority: 2016/03/22 (US62/311,573)

(51) Cl.Int./Int.Cl. *C07C 311/00* (2006.01), *C07C 317/14* (2006.01), *C07C 317/26* (2006.01), *C07D 209/04* (2006.01), *C07D 239/26* (2006.01)

(71) Demandeur/Applicant:
HELSINN HEALTHCARE SA, CH

(72) Inventeurs/Inventors:
GIULIANO, CLAUDIO, IT;
DAINA, ANTOINE, CH;
PIETRA, CLAUDIO, IT

(74) Agent: SMART & BIGGAR

(54) Titre : UREES ASYMETRIQUES DE BENZENESULFONYLE ET LEURS UTILISATIONS MEDICALES
(54) Title: BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF

(57) Abrégé/Abstract:
New benzenesulfonyl asymmetric ureas are herein disclosed, corresponding to the general formulas (I) →(IV) and pharmaceutically acceptable salts thereof, whose structure and substituents are detailed in the specification. Procedures for the synthesis of these compounds are disclosed. The compounds are active on the ghrelin receptors, in particular they have inverse agonist activity; they are useful in preventing and/or treating diseases pathophysiologically mediated by the ghrelin receptor, like e.g. obesity, diabetes and substance abuse. Also disclosed are pharmaceutical compositions comprising a compound as herein defined and a pharmaceutically acceptable carrier or vehicle.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 September 2017 (28.09.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/162390 A1

(51) **International Patent Classification**:
C07C 311/00 (2006.01) ***C07C 317/26*** (2006.01)
C07D 239/26 (2006.01) ***C07D 209/04*** (2006.01)
C07C 317/14 (2006.01)

(21) **International Application Number**:
PCT/EP2017/053937

(22) **International Filing Date**:
21 February 2017 (21.02.2017)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
62/311,573 22 March 2016 (22.03.2016) US

(71) **Applicant**: **HELSINN HEALTHCARE SA** [CH/CH]; Via Pian Scairolo 9, 6912 Lugano / Pazzallo (CH).

(72) **Inventors**: **GIULIANO, Claudio**; Via Prudenziana No. 28/A, 22100 Como (IT). **DAINA, Antoine**; Quartier Sorge, Batiment Genopode, 1015 Lausanne (CH). **PIETRA, Claudio**; Via G. Scalabrini 56, 22100 Como (IT).

(74) **Agent**: **ZARDI, Marco**; c/o M. ZARDI & Co SA, Via Pioda, 6, 6900 Lugano (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2017/162390 A1

(54) **Title**: BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF

(57) **Abstract**: New benzenesulfonyl asymmetric ureas are herein disclosed, corresponding to the general formulas (I) –(IV) and pharmaceutically acceptable salts thereof, whose structure and substituents are detailed in the specification. Procedures for the synthesis of these compounds are disclosed. The compounds are active on the ghrelin receptors, in particular they have inverse agonist activity; they are useful in preventing and/or treating diseases pathophysiologically mediated by the ghrelin receptor, like e.g. obesity, diabetes and substance abuse. Also disclosed are pharmaceutical compositions comprising a compound as herein defined and a pharmaceutically acceptable carrier or vehicle.

BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF

FIELD OF THE INVENTION

The present invention relates to novel asymmetric urea compounds, medical uses thereof, particularly in the treatment of medical conditions modulated by the ghrelin receptor.

BACKGROUND

The growth hormone secretagogue receptor (GHS-R) regulates a number of physiological processes, including growth hormone (GH) release, metabolism, and appetite. Ghrelin, a circulating hormone produced predominantly by endocrine cells in the stomach, is its endogenous ligand. Ghrelin is a 28 amino acid peptide with an acyl side chain required for biological activity (Kojima et al., Nature, 402, 656-660, 1999). Ghrelin has been shown to stimulate growth hormone (GH) release and to increase food intake when administered both centrally and peripherally (Wren et al., Endocrinology, 141, 4325-4328, 2000).

Endogenous levels of ghrelin rise on fasting and fall on re-feeding in humans (Cummings et al., Diabetes, 50, 1714-1719, 2001). Ghrelin also appears to play a role in maintaining long term energy balance and appetite regulation. Chronic administration of ghrelin in rodents leads to hyperphagia and weight gain that are independent of growth hormone secretion (Tschop et al., Nature, 407, 908-913, 2000). Circulating ghrelin levels decrease in response to chronic overfeeding and increase in response to chronic negative energy balance associated with anorexia or exercise. Obese people generally have low plasma ghrelin levels (Tschop et al., Diabetes, 50, 707-709, 2001) according to the physiological response of the body in reducing calories intake. Intravenous ghrelin is effective in stimulating food intake in humans. A recent study showed a 28% food intake increase from a buffet meal with a ghrelin infusion compared with saline control (Wren et al., J. Clin. Endocrinology and Metabolism, 86, 5992, 2001).

In view of the above experimental evidence, compounds that modulate ghrelin receptor activity have been proposed for preventing and/or treating disorders associated with ghrelin receptor physiology. For example, antagonists at ghrelin receptor might one day be developed to

reduce appetite, reduce food intake, induce weight loss and treat obesity without affecting or reducing the circulating growth hormone levels. On the other hand, agonists at ghrelin receptor might also be developed for stimulating food intake and thus be useful in treating eating disorders, for example anorexia nervosa, or in treating cachexia resulting from cancer, AIDS or Chronic Obstructive Pulmonary Disease (COPD). Ghrelin agonists may also be useful as gastroprokinetic agents which can enhance gastrointestinal motility by increasing the frequency of contractions in the small intestine or making them stronger, but without disrupting their rhythm. Gastroprokinetic agents are used to relieve gastrointestinal symptoms such as abdominal discomfort, bloating, constipation, heart burn, nausea, and vomiting, and are used to treat a number of gastrointestinal disorders, including but not limiting to, irritable bowel syndrome, gastritis, acid reflux disease, gastroparesis, and functional dyspepsia. Furthermore, compounds that modulate ghrelin receptor activity might also be used to prevent or treat diseases related to substance abuse, for example, alcohol or drug (e.g., amphetamines, barbiturates, benzodiazepines, cocaine, methaqualone, and opioids) abuse, which refers to a maladaptive pattern of use of a substance that is not considered dependent.

Ghrelin receptor possesses a naturally high constitutive activity representing 50% of its maximal activity. Given the role that ghrelin and its receptor play in food intake and appetite control, a ghrelin receptor inverse agonist may be used as anti-obesity drug. An inverse agonist would decrease the receptor's activity to below the basal or constitutive level.


A number of compounds acting on the ghrelin receptor have been reported in the literature. YIL-781, for example, is a small molecule ghrelin receptor antagonist from Bayer that reportedly improves glucose tolerance, suppresses appetite and promotes weigh loss (Esler et al., Endocrinology 148 (11):5175-5185); LY444711 is an orally active ghrelin receptor agonist from Lilly that reportedly induces adiposity by stimulating food consumption and sparing fat utilization (Bioorg. & Med. Chem. Lett., 2004, 14, 5873-5876); anamorelin is an orally available ghrelin receptor small molecule agonist from Helsinn Therapeutics that is in clinical trials for the treatment of anorexia and cachexia in cancer patients. Ghrelin receptor agonists and antagonists based on asymmetric ureas are disclosed in US 2012/0220629, which is incorporated herein by reference in its entirety. Other small molecule ghrelin receptor modulators can be found in WO 2008/092681, US 2009/0253673, WO 2008/148853, WO 2008/148856, US 2007/0270473 and US 2009/0186870.

In view of the above, it is desirable to find new compounds which modulate ghrelin receptor activity.


SUMMARY

The present inventors have, through intensive research and experimentation, unexpectedly discovered a novel series of compounds having inverse agonist activity against the ghrelin receptors.


The present invention provides compounds of Formulae I-IV:




I,



II,



III,



IV,

with U, W, X, Y, Z, Cy^1, Cy^2, R, R', R^1-R^5, R^{16}, R^{17}, k, l, m, n, and p as defined herein, and pharmaceutically acceptable salts thereof.


Compounds of Formulae I-IV, also referred to herein as sulfonyl-asymmetric ureas, are particularly useful for preventing and/or treating diseases that are pathophysiologically related to the ghrelin receptor in a subject. Accordingly, in another embodiment the invention provides a method of treating a disease that is mediated by the ghrelin receptor, comprising administering to said subject a therapeutically effective amount of a compound of Formula I-IV, or a pharmaceutically acceptable salt thereof.

Also disclosed are pharmaceutical compositions for preventing and/or treating diseases which are pathophysiologically related to ghrelin receptor in a subject, comprising a therapeutically effective amount of a compound of Formulae I-IV, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

DETAILED DESCRIPTION

Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods or specific treatment methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

In a first principal embodiment, the present invention provides compounds of Formula I:



I,

or a pharmaceutically acceptable salt thereof, wherein:

a dashed line indicates an optional bond;

W is C, N, or O;

X is a bond, CO, or CR^7R^8;

k is 0-2;

R is C_{1-6} alkyl or Cy^1 wherein said C_{1-6} alkyl or Cy^1 is optionally substituted with 1-3 substituents selected from halo, heteroaryl, C_{1-6} alkoxy, C_{1-6} alkyl, heterocycloalkyl, $CO_2(C_{1-6}$ alkyl), and $CO(C_{1-6}$ alkyl);

R^1 and R^2 are each, independently, H, C_{1-3} alkyl, methoxy, halo, or OH;

or R^1 and R^2 taken together with the atoms to which they are attached form a 5-6 membered ring;

or R^1 and X taken together with the atoms to which they are attached form a 5-6 membered ring;

or R^1, X and R taken together with the atoms to which they are attached form a bicyclic structure;

R^3 is H, C_{1-3} alkyl, methoxy, halo, or –OH, -$COOR^{12}$, -$CR^{13}R^{14}OH$, -$CONHR^{15}$, cycloalkyl, heteroaryl;

R^4 is a bond, NR^6 or CR^9R^{10};

or R^3 and R^4 taken together with the atoms to which they are attached form a 3-6-membered ring;

R^5 is Cy^2, $CO(C_{1-6}$ alkyl), C_{1-6} alkyl, cycloalkyl, or heterocycloalkyl, wherein said Cy^2, $CO(C_{1-6}$ alkyl), C_{1-6} alkyl, cycloalkyl, or heterocycloalkyl is optionally substituted with 1-3 substituents selected from halo, C_{1-6} alkylamine, COR^{11}, SO_2R^{11}, heterocycloalkyl, CO_2R^{11}, C_{1-6} hydroxyalkyl, heteroaryl, $CH_2CO_2R^{11}$, C_{1-6} alkoxy, OH, CN, R^{11}, CH_2OSO_3H, benzyl, CH_2SO_3H, CH_2CN, and $NHCH_2$ cycloalkyl;

R^6 is a bond, H, or CH_3;

R^7 and R^8 are each, independently, H, C_{1-3} alkyl, or $CONH_2$, wherein said C_{1-3} alkyl is optionally substituted with halo;

R^9 and R^{10} are each, independently, H or C_{1-3} alkyl, wherein said C_{1-3} alkyl is optionally substituted with halo;


R^{11} is H, NH_2, or optionally substituted C_{1-6} alkyl;

R^{12} is H or C_{1-3} alkyl;

R^{13} and R^{14} are each independently H or C_{1-3} alkyl; and

R^{15} is H or C_{1-3} alkyl.

In a second principal embodiment, the present invention provides compounds of Formula II:



II,


or a pharmaceutically acceptable salt thereof, wherein:

X, W, R^1 – R^4, and k are as defined above;

Cy^1 is a cyclic moiety selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, wherein said cyclic moiety is optionally substituted with 1-3 substituents selected from halo, heteroaryl, C_{1-6} alkoxy, C_{1-6} alkyl, heterocycloalkyl, $CO_2(C_{1-6}$ alkyl), and $CO(C_{1-6}$ alkyl); and

Cy^2 is a cyclic moiety selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, wherein said cyclic moiety is optionally substituted with 1-3 substituents selected from halo, C_{1-6} alkylamine, COR^{11}, SO_2R^{11}, heterocycloalkyl, CO_2R^{11}, C_{1-6} hydroxyalkyl, heteroaryl, $CH_2CO_2R^{11}$, C_{1-6} alkoxy, OH, CN, R^{11}, CH_2OSO_3H, benzyl, CH_2SO_3H, CH_2CN, and $NHCH_2$ cycloalkyl.

In a third principal embodiment, the compounds have the structure of Formula III:



III,

or a pharmaceutically acceptable salt thereof, wherein:

X, $R^1 - R^4$, and k are as defined above;

a dashed line indicates an optional bond;

U is C, N, S, or O

B is 5-7-membered ring or a bicyclic structure, wherein said 5-7-membered ring or a bicyclic structure is optionally substituted with COR^{11}, SO_2R^{11}, heterocycloalkyl, CO_2R^{11}, C_{1-6} hydroxyalkyl, heteroaryl, $CH_2CO_2R^{11}$, C_{1-6} alkoxy, OH, CN, R^{11}, CH_2OSO_3H, benzyl, CH_2SO_3H, or CH_2CN;

Y is each, independently, a C or N;

Z is halo, methoxy, or C_{1-3} alkyl optionally substituted with halo;

R' is a halo, heteroaryl, C_{1-6} alkoxy, C_{1-6} alkyl, heterocycloalkyl, CN cycloalkyl, $CO_2(C_{1-6}$ alkyl), or $CO(C_{1-6}$ alkyl);


or two R' taken together with the atoms to which they are attached form a 5-6-membered ring;

l is 0-3;

m is 0-3; and

n is 0-3.

In a fourth principal embodiment, the compounds have the structure of Formula IV:



IV,

or a pharmaceutically acceptable salt thereof, wherein X, $R^1 - R^4$, k, U, Z, R', k, l, m, and n are defined as above; R^{16} is H, C_{1-3} alkyl; R^{17} is H, halo or C_{1-3} alkyl; and p is 1-3.

In the first, second, third and fourth principal embodiments, in one subembodiment, X is CO.

In the first, second, third and fourth principal embodiments, in one subembodiment, X is a bond.

In the first, second, third and fourth principal embodiments, in one subembodiment, X is C_{1-3} alkyl.

In the first principal embodiment, as well as the second, third and fourth principal embodiments discussed below, in one subembodiment X is $CHCH_3$.

In some embodiments, X is not $CHCH_3$.

In the first, second, third and fourth principal embodiments, in one subembodiment, X is CH_2.

In some embodiments, X is not CH_2.

In the first, second, third and fourth principal embodiments, in one subembodiment, X is $C(CH_3)_2$.

In the first, second, third and fourth principal embodiments, in one subembodiment, X is $CHCF_3$.


In the first, second, third and fourth principal embodiments, in one subembodiment, X is $CH(CH_2CH_3)$.

In the first principal embodiment, in one subembodiment, R is Cy^1.

In the first and second principal embodiments, in one subembodiment, Cy^1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.

In the first and second principal embodiments, in one subembodiment, Cy^1 is substituted and unsubstituted.

In the first and second principal embodiments, in one subembodiment, said Cy^1 is



In the first and second principal embodiments, in one subembodiment, said Cy^1 is phenyl.

In some embodiments, R is not naphthalene.

In the first embodiment, in one subembodiment, R is C_{1-6} alkyl.

In the first principal embodiment, in one subembodiment, R is CH_3, $C(CH_3)_3$, or $CH(CH_3)_2$.

In the first principal embodiment, in one subembodiment, R is cycloalkane.

In the first principal embodiment, in one subembodiment, R is cyclopropane.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^1 is H, OH, or CH_3.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^1 is H.

In some embodiments, R^1 is not H.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^1 is OH.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^1 is CH_3.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^1 and X come together to form a 5-6 membered ring.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^1, X and R come together to form a bicyclic structure.

In the first, second, third, and fourth principal embodiments, in one embodiment, R^2 is H, OH or CH_3.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^2 is H.

In some embodiments R_2 is not H.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^2 is CH_3.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^2 and R^1 come together to form a 5-6 membered ring.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is H, C_{1-3} alkyl, methoxy, halo, or –OH, -$COOR^{12}$, -$CR^{13}R^{14}OH$, -$CONHR^{15}$, cycloalkyl, heteroaryl.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is H.

In some embodiments, R_3 is not H.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is halo.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is F.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is Cl.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is methoxy.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is C_{1-3} alkyl.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is methyl.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is $COOR^{12}$.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is COOH.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is $COOCH_3$.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is $CONHR^{15}$.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is $CONH_2$.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is cycloalkyl.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is cyclopropane.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is heteroaryl.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^3 is heteroaryl, optionally substituted with C_{1-3} alkyl.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^4 is a bond.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^4 is CH_2.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^4 is $CHCH_3$.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^4 is $C(CH_3)_2$.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^4 is NH.

In some embodiments, R^4 is not NH.






In the first, second, third, and fourth principal embodiments, in one subembodiment, R^4 is NCH_3.

In the first, second, third, and fourth principal embodiments, in one subembodiment, R^4 and R^3 come together to form a 5-membered heterocyclic ring.



In the first principal embodiment, in one subembodiment, R^5 is Cy^2.



















In the first, and second principal embodiments, in one subembodiment, said Cy^2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkly.


In the first and second principal embodiments, in one subembodiment, said Cy^2 is isoindoline.













In the first and second principal embodiments, in one subembodiment, said isoindoline is optionally substituted with 1-3 substituents selected from the group consisting of CH_3, , , CH_2CH_3, , , $CH_2CH_2OCH_3$, CH_2CN, , and fluoro.


In the first and second principal embodiments, in one subembodiment, said Cy^2 is tetrahydroisoquinoline.

In the first, second and third principal embodiments, in one subembodiment, said tetrahydroisoquinoline is optionally substituted with 1-3 substituents selected from the group consisting of CH_3, CH_2CH_3, $COCH_3$, SO_2CH_3, $CO_2CH_2CH_3$, , , F, and methoxy.

In the first principal embodiment, in one subembodiment, R^5 is phenyl, wherein said phenyl is optionally substituted with 1-3 substituents from the group consisting of , , , CH_3, , CH_2NH_2, CO_2CH_3, CO_2H, CH_2OH, , $CONH_2$, $C(CH_3)_2NH_2$, $CH_2CO_2CH_3$, , methoxy, OH, CH_2OCH_3, CH_2CH_2OH, CN, , , CH_2OSO_3H, , , , , , , , , , and .
















In some embodiments, R^5 is not phenyl substituted with .

In the first principal embodiment, in one subembodiment, R^5 is , , , , , , , , , , , .



In the first principal embodiment, in one subembodiment, R^5 is cycloalkyl or heterocycloalkyl.



In the first principal embodiment, in one subembodiment, R^5 is cyclopropane.

In the first principal embodiment, in one subembodiment, R^5 is , , , , , , , , , , , , , , or .



In the first principal embodiment, in one subembodiment, R^5 is $CO(C_{1-6}$ alkyl).









In the first principal embodiment, in one subembodiment, R^5 is $COCH_3$.









In the first principal embodiment, in one subembodiment, R^5 is C_{1-6} alkyl.










In the first principal embodiment, in one subembodiment, R^5 is  or .








In some forms, the compounds as presently disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein the compound of Formula I is a compound selected from the group consisting of:









	Chemical Structure	Chemical Name
H0906		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)benzenesulfonamide
H0907		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichloro-4-(cyclopropylethynyl)phenyl)ethyl)ureido)benzenesulfonamide









H0937		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)benzenesulfonamide
H0941		(*S*)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)-*N*-(4-(2-methyl-2-(methylamino)propyl)phenyl)benzenesulfonamide
H0942		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)-1-methylureido)benzenesulfonamide
H0943		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H0944		(*S*)-*N*-((4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)phenyl)sulfonyl)acetamide
H0950		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-phenylbenzenesulfonamide
H0951		(*S*)-*N*-(4-(2-aminoethyl)phenyl)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)benzenesulfonamide
H0953		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(*p*-tolyl)benzenesulfonamide










H0954		(*S*)-*N*-((4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)phenyl)sulfonyl)-*N*-methylacetamide
H0963		(*S*)-1-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)-3-(4-((4-methylbenzyl)sulfonyl)phenyl)urea
H0964		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-methylbenzyl)sulfonyl)phenyl)urea
H0965		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-phenylbenzenesulfonamide
H0966		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(*p*-tolyl)benzenesulfonamide
H0967		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(4-(2-(dimethylamino)-2-methylpropyl)phenyl)benzenesulfonamide
H0968		*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(2,3-dichlorobenzyl)ureido)benzenesulfonamide
H0969		(*S*)-1-(4-((4-(2-amino-2-methylpropyl)benzyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea









H0971		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-methylbenzenesulfonamide
H0975		*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(2-(2,3-dichloro-4-methoxyphenyl)propan-2-yl)ureido)benzenesulfonamide
H0981		1-(2,3-dichlorobenzyl)-3-(4-((4-(2-(dimethylamino)-2-methylpropyl)benzyl)sulfonyl)phenyl)urea
H0990		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(1*H*-indol-5-yl)benzenesulfonamide
H0991		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1*H*-indol-5-yl)benzenesulfonamide
H0993		*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-benzylureido)benzenesulfonamide
H0994		*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-ethylureido)benzenesulfonamide
H0995		4-(3-(2,3-dichlorobenzyl)ureido)-*N*-(4-(2-(dimethylamino)-2-methylpropyl)phenyl)benzenesulfonamide
H0996		1-(4-((4-(2-amino-2-methylpropyl)benzyl)sulfonyl)phenyl)-3-(2,3-dichlorobenzyl)urea









H0997		(*S*)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)-*N*-(1*H*-indol-5-yl)benzenesulfonamide
H1003		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroquinolin-6-yl)benzenesulfonamide
H1004		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1005		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1006		(*S*)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1008		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroquinolin-6-yl)benzenesulfonamide
H1009		4-(3-benzylureido)-*N*-(4-(2-(dimethylamino)-2-methylpropyl)phenyl)benzenesulfonamide









H1010		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(2-(dimethylamino)-2-methylpropyl)benzyl)sulfonyl)phenyl)urea
H1017		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1018		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(2-ethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1024		(*S*)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1025		(*S*)-1-(4-(((2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)urea
H1026		(*S*)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(4-(((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1027		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1028		(*S*)-1-(1-phenylethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea









H1029		1-benzyl-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1033		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1034		(*S*)-*N*-(2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)benzenesulfonamide
H1038		1-(3-chlorobenzyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1039		1-(2-chlorobenzyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1040		1-(2,3-dichlorobenzyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1041		1-(1-(2-chlorophenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1042		1-(1-(3-chlorophenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea









H1043		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)sulfonyl)phenyl)urea
H1044		1-(2,3-dichlorobenzyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)sulfonyl)phenyl)urea
H1045		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((indolin-6-ylmethyl)sulfonyl)phenyl)urea
H1046		1-(2,3-dichlorobenzyl)-3-(4-((indolin-6-ylmethyl)sulfonyl)phenyl)urea
H1047		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((indolin-5-ylmethyl)sulfonyl)phenyl)urea
H1048		1-(2,3-dichlorobenzyl)-3-(4-((indolin-5-ylmethyl)sulfonyl)phenyl)urea
H1049		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroisoquinolin-7-yl)benzenesulfonamide
H1050		(*S*)-*N*-(4-(aminomethyl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1051		(*S*)-1-(4-((4-(aminomethyl)benzyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea









H1052		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(2-(piperidin-4-yl)ethyl)benzenesulfonamide
H1054		ethyl (*S*)-6-((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl) sulfonamido)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate
H1055		ethyl (*S*)-6-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl) sulfonyl)methyl)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate
H1056		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1057		1-(2,3-dichlorobenzyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1058		methyl (*S*)-4-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl) sulfonyl)methyl)benzoate
H1059		(*S*)-4-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl) sulfonyl)methyl)benzoic acid
H1060		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)urea









H1061		methyl (*S*)-4-((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl) sulfonamido)benzoate
H1062		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(4-(hydroxymethyl)phenyl)benzenesulfonamide
H1067		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1068		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(2-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1070		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(pyridin-3-yl)benzyl)sulfonyl)phenyl)urea
H1071		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1072		(*S*)-1-(4-(((2-benzyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1073		(*S*)-4-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl) sulfonyl)methyl)benzamide









H1074		(*S*)-N-(4-(2-aminopropan-2-yl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1075		methyl (*S*)-2-(4-((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonamido)phenyl)acetate
H1076		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(4-(2-hydroxy-2-methylpropyl)phenyl)benzenesulfonamide
H1078		(*S*)-1-(4-((cyclopropylmethyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1080		1-((*S*)-1-(2,3-dichlorophenyl)ethyl)-3-(4-((1-(1,2,3,4-tetrahydroisoquinolin-6-yl)ethyl)sulfonyl)phenyl)urea
H1081		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((2-(1,2,3,4-tetrahydroisoquinolin-6-yl)propan-2-yl)sulfonyl)phenyl)urea
H1082		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((3-methoxybenzyl)sulfonyl)phenyl)urea
H1083		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-methoxybenzyl)sulfonyl)phenyl)urea









H1084		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((3-hydroxybenzyl)sulfonyl)phenyl)urea
H1087		methyl (*S*)-3-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonyl)methyl)benzoate
H1088		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((3-(hydroxymethyl)benzyl)sulfonyl)phenyl)urea
H1092		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((isochroman-6-ylmethyl)sulfonyl)phenyl)urea
H1093		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(methoxymethyl)benzyl)sulfonyl)phenyl)urea
H1094		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(4-(2-hydroxyethyl)phenyl)benzenesulfonamide
H1095		(*S*)-4-(3-(1-(2-chlorophenyl)ethyl)ureido)-*N*-(4-(2-hydroxyethyl)phenyl)benzenesulfonamide
H1096		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((2-morpholinoethyl)sulfonyl)phenyl)urea










H1097		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((isochroman-7-ylmethyl)sulfonyl)phenyl)urea
H1098		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1,3-dihydroisobenzofuran-5-yl)methyl)sulfonyl)phenyl)urea
H1099		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-hydroxybenzyl)sulfonyl)phenyl)urea
H1101		(*S*)-1-(4-((4-cyanobenzyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1102		1-((*S*)-1-(2,3-dichlorophenyl)ethyl)-3-(4-((1-(1,2,3,4-tetrahydroisoquinolin-6-yl)ethyl)sulfonyl)phenyl)urea hydrochloride
H1103		1-((*S*)-1-(2,3-dichlorophenyl)ethyl)-3-(4-((1-(1,2,3,4-tetrahydroisoquinolin-6-yl)ethyl)sulfonyl)phenyl)urea hydrochloride
H1106		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1H-indazol-5-yl)benzenesulfonamide
H1108		(*S*)-*N*-(2-aminopyrimidin-5-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide









H1109		(*S*)-*N*-(4-(1*H*-imidazol-5-yl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1110		(*S*)-*N*-(4-(1H-imidazol-2-yl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1111		(*S*)-*N*-(1*H*-benzo[d]imidazol-5-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1125		(*S*)-*N*-(2-aminopyrimidin-4-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1126		(*S*)-*N*-(6-aminopyridin-3-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1127		(*S*)-*N*-(5-aminopyridin-2-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1129		(*S*)-*N*-(6-aminopyridazin-3-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1130		(*S*)-1-(4-(((2-aminopyrimidin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea









H1131		1-benzyl-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)urea
H1132		1-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1133		*N*-(4-(hydroxymethyl)phenyl)-4-(3-(1-(naphthalen-1-yl)ethyl)ureido)benzenesulfonamide
H1140		1-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)-3-(1-(4-methoxynaphthalen-1-yl)ethyl)urea
H1141		*N*-(4-(hydroxymethyl)phenyl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1142		(*S*)-1-(4-(((1*H*-indol-5-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1145		*N*-(4-(hydroxymethyl)phenyl)-4-(3-(1-(4-methoxynaphthalen-1-yl)ethyl)ureido)benzenesulfonamide
H1148		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea







H1149		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1154		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(4-methoxynaphthalen-1-yl)ethyl)urea
H1155		*N*-(isoindolin-5-yl)-4-(3-(1-(naphthalen-1-yl)ethyl)ureido)benzenesulfonamide
H1156		*N*-(isoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1166		4-(1-hydroxy-3-(1-(naphthalen-1-yl)ethyl)ureido)-*N*-(isoindolin-5-yl)benzenesulfonamide
H1178		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-isopropylurea
H1179		1-benzyl-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1180		1-ethyl-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea







H1181		(*S*)-4-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonyl)methyl)benzyl hydrogen sulfate
H1188		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxyureido)-*N*-(isoindolin-5-yl)benzenesulfonamide
H1190		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-phenylurea
H1193		1-benzyl-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1194		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1199		4-(1-hydroxy-3-(1-phenylethyl)ureido)-*N*-(isoindolin-5-yl)benzenesulfonamide
H1203		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(4-methoxybenzyl)urea
H1204		1-benzyl-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methylurea









H1205		1-(*tert*-butyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1206		3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1208		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(thiazol-5-ylmethyl)urea
H1212		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-((5-methoxypyridin-2-yl)methyl)urea
H1213		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-3-(1-phenylethyl)urea
H1214		(*R*)-1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1215		(*S*)-1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1216		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(thiazol-4-ylmethyl)urea
H1217		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(thiophen-3-ylmethyl)urea









H1219		1-(4-(((2-benzylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1220		1-(4-(((2-(cyclopropylmethyl)isoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1221		1-(4-(((2-ethylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1222		(*S*)-1-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1225		(*S*)-1-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1227		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(2,2,2-trifluoro-1-phenylethyl)urea
H1228		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-neopentylurea
H1229		1-(3-methylbutan-2-yl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea








H1230		1-(cyclopropylmethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1231		1-(4-((2-(2-benzylisoindolin-5-yl)propan-2-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1232		1-(4-((2-(2-ethylisoindolin-5-yl)propan-2-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1233		1-(4-((1-(2-benzylisoindolin-5-yl)ethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1234		1-(4-((1-(2-ethylisoindolin-5-yl)ethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1235		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylpropyl)urea
H1236		1-isobutyl-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1237		(*S*)-1-(4-((1-methylpiperidin-4-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea








H1238		(*S*)-1-(4-(((1-methylpiperidin-4-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1239		(*S*)-*N*-(1-methylpiperidin-4-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1244		1-(1-cyclopropylethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1248		2-chloro-5-ethyl-*N*-((4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)carbamoyl)benzamide
H1249		2-chloro-*N*-((4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)carbamoyl)-5-morpholinobenzamide
H1250		2-chloro-*N*-((4-(*N*-(isoindolin-5-yl)sulfamoyl)phenyl)carbamoyl)-5-morpholinobenzamide









H1251		2-chloro-5-ethoxy-*N*-((4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)carbamoyl)benzamide
H1252		2-chloro-5-ethoxy-*N*-((4-(*N*-(isoindolin-5-yl)sulfamoyl)phenyl)carbamoyl)benzamide
H1253		*N*-((4-((4-(2-amino-2-methylpropyl)benzyl)sulfonyl)phenyl)carbamoyl)-2-chloro-5-ethylbenzamide
H1254		*N*-((4-(*N*-(4-(2-amino-2-methylpropyl)phenyl)sulfamoyl)phenyl)carbamoyl)-2-chloro-5-ethylbenzamide
H1255		2-chloro-5-ethyl-*N*-((4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)carbamoyl)benzamide
H1256		(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(((4-(3-(1-phenylethyl)ureido)phenyl)sulfonyl)methyl)isoindoline-2-carboxylate










H1259		2-chloro-5-ethyl-*N*-((4-(*N*-(isoindolin-5-yl)sulfamoyl)phenyl)carbamoyl)benzamide
H1260		1-(1-(3-chlorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1261		1-(1-(2-chlorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1262		1-(1-(4-fluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1263		2-chloro-5-ethyl-*N*-((4-(*N*-(1,2,3,4-tetrahydroisoquinolin-7-yl)sulfamoyl)phenyl)carbamoyl)benzamide
H1264		1-(2-(isoindolin-5-yl)-1,1-dioxido-2,3-dihydrobenzo[*b*]thiophen-5-yl)-3-((*S*)-1-phenylethyl)urea
H1266		1-(1-(3-chlorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1267		1-(1-(2-chlorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea









H1268		1-(1-(4-fluorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1269		1-(1-(3-fluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1270		(*S*)-1-(2-(isoindolin-5-yl)-1,1-dioxidobenzo[*b*]thiophen-5-yl)-3-(1-phenylethyl)urea
H1271		1-benzyl-3-(2-(isoindolin-5-yl)-1,1-dioxido-2,3-dihydrobenzo[*b*]thiophen-5-yl)urea
H1272		1-(1-(2-fluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1273		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(pyridin-3-yl)ethyl)urea
H1274		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(pyridin-4-yl)ethyl)urea
H1275		1-(4-((4-(morpholinomethyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea









H1276		1-(1-phenylethyl)-3-(4-((4-(pyrrolidin-1-ylmethyl)benzyl)sulfonyl)phenyl)urea
H1277		1-(4-((hexahydropyrrolo[3,4-c]pyrrol-2(1*H*)-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1280		1-(1-phenylethyl)-3-(4-((pyridin-4-ylmethyl)sulfonyl)phenyl)urea
H1281		1-(1-(2-chloro-5-ethylphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1283		1-(1-(2-chloro-5-morpholinophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1284		1-(1-(2-chloro-5-morpholinophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1285		1-(2-(2-methylisoindolin-5-yl)-1,1-dioxido-2,3-dihydrobenzo[*b*]thiophen-5-yl)-3-((*S*)-1-phenylethyl)urea










H1286		1-(1-(2-chloro-5-ethylphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1289		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(pyridin-2-yl)ethyl)urea
H1290		1-(4-((3-(aminomethyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1291		1-(4-(((3-oxoisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1292		1-(4-(((1-oxoisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1293		1-(4-(((3-hydroxy-2,3-dihydro-1*H*-inden-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1294		1-(1-phenylethyl)-3-(4-(((3-(pyrrolidin-1-yl)-2,3-dihydro-1*H*-inden-5-yl)methyl)sulfonyl)phenyl)urea









H1296		1-(2-(2-benzylisoindolin-5-yl)-1,1-dioxidobenzo[*b*]thiophen-5-yl)-3-(1-(4-methoxyphenyl)ethyl)urea
H1297		1-(2-(isoindolin-5-yl)-1,1-dioxido-2,3-dihydrobenzo[*b*]thiophen-5-yl)-3-(1-(4-methoxyphenyl)ethyl)urea
H1298		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(4-methoxyphenyl)ethyl)urea
H1299		(*S*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1300		(*R*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1301		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea
H1302		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1303		(*S*)-1-(1-phenylethyl)-3-(4-((piperidin-4-ylmethyl)sulfonyl)phenyl)urea









H1304		1-(4-((4-((diethylamino)methyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1305		1-(4-((4-((dimethylamino)methyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1306		(*S*)-1-(1-phenylethyl)-3-(4-(((2,3,4,5-tetrahydro-1H-benzo[*d*]azepin-7-yl)methyl)sulfonyl)phenyl)urea
H1307		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(pyridin-2-yl)ethyl)urea
H1308		*N*-(2-methylisoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1309		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(pyrimidin-5-yl)ethyl)urea
H1310		4-(1-(3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)ureido)ethyl)phenyl acetate
H1311		(*S*)-1-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1312		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1,2,3,4-tetrahydronaphthalen-1-yl)urea









H1313		1-(4-((4-((3-hydroxypyrrolidin-1-yl)methyl)benzyl)sulfonyl)phenyl)-3-((*S*)-1-phenylethyl)urea
H1314		1-(4-((4-((3-(hydroxymethyl)pyrrolidin-1-yl)methyl)benzyl)sulfonyl)phenyl)-3-((*S*)-1-phenylethyl)urea
H1315		(*S*)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1316		1-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1317		1-(2-fluoro-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1318		1-(1-phenylethyl)-3-(4-((3-(pyrrolidin-1-ylmethyl)benzyl)sulfonyl)phenyl)urea
H1319		1-(4-(((2-(oxetan-3-yl)isoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1320		1-(4-(((5,6-dihydro-4*H*-thieno[2,3-*c*]pyrrol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea









H1321		1-(4-(((5-methyl-5,6-dihydro-4*H*-thieno[2,3-*c*]pyrrol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1322		(*S*)-1-(4-(((3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1323		1-(4-(((6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-3-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1324		1-((*S*)-1-phenylethyl)-3-(4-(((1,2,3,4-tetrahydro-1,4-epiminonaphthalen-6-yl)methyl)sulfonyl)phenyl)urea
H1325		1-(4-(((9-methyl-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-6-yl)methyl)sulfonyl)phenyl)-3-((S)-1-phenylethyl)urea
H1326		1-(1-(3-methoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1327		1-(1-(3-methoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1328		1-((*S*)-1-phenylethyl)-3-(4-((4-(pyrrolidin-2-yl)benzyl)sulfonyl)phenyl)urea









H1329		1-(4-(((2-methyl-2*H*-indazol-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1330		1-(2,3-dihydrobenzofuran-3-yl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1331		1-(2,3-dihydrobenzofuran-3-yl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1332		1-((*R*)-1-phenylethyl)-3-(4-((4-(pyrrolidin-2-yl)benzyl)sulfonyl)phenyl)urea
H1333		4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1334		4-(3-(1-(2-chlorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1335		(*S*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1,2,3,4-tetrahydronaphthalen-1-yl)urea
H1336		(*R*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1,2,3,4-tetrahydronaphthalen-1-yl)urea
H1337		(*R*)-*N*-(2-methylisoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide








H1338		1-(4-(((2-(2-methoxyethyl)isoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1339		1-(4-(((2-(cyanomethyl)isoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1340		1-(1-phenylethyl)-3-(4-(((2-(tetrahydrofuran-3-yl)isoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1341		1-(1-phenylethyl)-3-(4-(((2-((tetrahydrofuran-2-yl)methyl)isoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1342		1-(1-(2-fluorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1343		(*R*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1344		1-(1-(2-chlorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1345		1-(1-(2,3-difluorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea








H1346		4-(3-(1-(2,3-difluorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1347		4-(3-(1-(2-fluorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1348		(*R*)-1-(4-(((5-methyl-5,6-dihydro-4*H*-thieno[2,3-c]pyrrol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1349		1-(2,3-dichlorobenzyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1350		2-methyl-5-(((4-(3-(1-phenylethyl)ureido)phenyl)sulfonyl)methyl)isoindoline 2-oxide
H1351		(*R*)-1-(4-(((5-methyl-5,6-dihydro-4*H*-thieno[2,3-c]pyrrol-3-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1352		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1353		1-(1-acetylindolin-3-yl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea









H1354		1-(1-acetylindolin-3-yl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1355		(*R*)-1-(4-(((7-fluoro-2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1356		(*R*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1357		(*R*)-1-(1-phenylethyl)-3-(4-(((1,1,2-trimethylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1358		1-(indolin-3-yl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1359		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((5-methyl-4,5,6,7-tetrahydrothieno[3,2-*c*]pyridin-2-yl)methyl)sulfonyl)phenyl)urea
H1360		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(diethylamino)benzyl)sulfonyl)phenyl)urea
H1361		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((3-(diethylamino)propyl)sulfonyl)phenyl)urea









H1362		4-(3-((*R*)-1-(2,3-dichlorophenyl)ethyl)ureido)-N-(4-((*cis*)-3,5-dimethylpiperazin-1-yl)-2-methoxyphenyl)benzenesulfonamide
H1363		(*R*)-1-(4-(((4-fluoro-2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1364		(*R*)-*N*-(2-aminopyrimidin-4-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1366		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1367		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((5-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1368		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1369		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((5-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1371		1-(4-(((4-((cyclopropylmethyl)amino)cyclohexyl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea








H1372		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-(diethylamino)cyclohexyl)methyl)sulfonyl)phenyl)urea
H1373		1-(4-(((4-aminocyclohexyl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1374		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((piperidin-3-ylmethyl)sulfonyl)phenyl)urea
H1375		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1-((tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)sulfonyl)phenyl)urea
H1376		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1-isopropylpiperidin-3-yl)methyl)sulfonyl)phenyl)urea
H1377		1-methyl-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1378		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((8-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1379		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-*c*]pyridin-2-yl)methyl)sulfonyl)phenyl)urea








H1380		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1381		1-methyl-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1382		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(2-methoxyphenyl)ethyl)urea
H1383		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-3-(1-phenylethyl)urea
H1384		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)methyl)sulfonyl)phenyl)urea
H1385		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1386		1-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea









H1387		1-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1388		1-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1389		1-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(2-fluorophenyl)ethyl)urea
H1390		1-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(2-methoxyphenyl)ethyl)urea
H1391		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1392		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1393		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-3-(1-(2-methoxyphenyl)ethyl)urea









H1394		(R)-1-(4-(((7-fluoroisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1395		6-((isoindolin-5-ylmethyl)sulfonyl)-3-(1-phenylethyl)-3,4-dihydroquinazolin-2(1H)-one
H1396		(R)-1-(4-(((4-fluoroisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1397		N-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-3,4-dihydroisoquinoline-2(1H)-carboxamide
H1398		3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-1-methyl-1-(1-phenylethyl)urea
H1399		3-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1400		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-fluoro-4-(((8-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1401		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-fluoro-4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea









H1402		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-fluoro-4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-methylurea
H1403		1-((S)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1404		1-(2,6-difluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1405		1-(4-(((7-chloroisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1406		1-(4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1407		1-(4-(((2,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1408		1-(5-((isoindolin-5-ylmethyl)sulfonyl)pyridin-2-yl)-3-(1-phenylethyl)urea
H1409		3-(4-(((4-fluoroisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea









H1410		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-(((4-fluoroisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1411		1-(1-(2,6-difluorophenyl)ethyl)-3-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1412		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)urea
H1413		3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1414		3-(2-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1415		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1416		1-benzyl-1-methyl-3-(4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea









H1417		(R)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1418		1-methyl-N-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3,4-dihydroisoquinoline-2(1H)-carboxamide
H1419		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1420		1-(1-(2-fluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)urea
H1421		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)urea
H1422		(R)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1423		(R)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(2-fluoro-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea









H1424		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea
H1425		1-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1426		1-(1-(2-fluorophenyl)ethyl)-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1427		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1428		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1429		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1430		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)urea
H1431		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea









H1432		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)-2-methoxyphenyl)urea
H1433		1-(4-((4-(hydroxymethyl)benzyl)sulfonyl)-2-methoxyphenyl)-3-(1-phenylethyl)urea
H1434		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)-2-methoxyphenyl)urea
H1435		1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)-2-methoxyphenyl)urea
H1436		1-(1-(2,6-difluorophenyl)ethyl)-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1437		1-(1-(2,6-difluorophenyl)ethyl)-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1438		1-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(2-methoxyphenyl)ethyl)urea
H1439		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea









H1440		1-(4-(((2,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)-3-(1-phenylethyl)urea
H1441		1-(2-methoxy-4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1442		1-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-(4-methoxyphenyl)ethyl)urea
H1443		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-methylurea
H1444		1-(1-(3,4-dimethoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1445		1-(1-(3,5-difluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1446		1-(1-(3,5-difluorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1447		1-(2-methyl-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea








H1448		1-(2-hydroxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1449		1-(1-(3,4-dimethoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1450		1-(1-(2,6-dimethoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1451		1-(1-(2,6-dimethoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1452		1-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1453		1-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1454		1-(1-(2-fluoro-6-methoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1455		1-(1-(2-fluoro-6-methoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea





H1456		1-(2-chloro-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1457		2-(3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)ureido)-2-phenylacetamide
H1458		1-hydroxy-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1459		methyl 5-((isoindolin-5-ylmethyl)sulfonyl)-2-(3-(1-phenylethyl)ureido)benzoate
H1460		3-(2-hydroxy-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1461		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-methoxyphenyl)-3-(1-phenylethyl)urea
H1462		1-(3-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1463		(S)-1-(4-(((5,6-dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl)methyl)sulfonyl)-2-methoxyphenyl)-3-(1-phenylethyl)urea








H1464		(S)-1-(2-methoxy-4-(((5-methyl-5,6-dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1465		(S)-1-(4-(((5,6-dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1466		methyl 5-(((2-methylisoindolin-5-yl)methyl)sulfonyl)-2-(3-(1-phenylethyl)ureido)benzoate
H1467		1-(2-(hydroxymethyl)-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1468		1-(2-(hydroxymethyl)-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1469		6-((isoindolin-5-ylmethyl)sulfonyl)-3-(1-phenylethyl)quinazoline-2,4(1H,3H)-dione
H1470		6-(((2-methylisoindolin-5-yl)methyl)sulfonyl)-3-(1-phenylethyl)quinazoline-2,4(1H,3H)-dione
H1471		1-hydroxy-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea








H1472		1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1473		1-hydroxy-1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1474		3-(2-hydroxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1475		1-(1-(3-chloro-4-methoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1476		1-(1-(3-chloro-4-methoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1477		1-(1-(3-chloro-4-methoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1478		1-(3-chloro-4-methoxybenzyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1479		N-(isoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzamide







H1480		N-(2-methylisoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzamide
H1481		(R)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1482		(S)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1483		1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1484		1-(2-cyclopropyl-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1485		1-(2-bromo-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1486		5-((isoindolin-5-ylmethyl)sulfonyl)-2-(3-(1-phenylethyl)ureido)benzoic acid
H1487		1-(3-hydroxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea







H1488		1-(4-(((8-azabicyclo[3.2.1]oct-2-en-3-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1489		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((8-methyl-8-azabicyclo[3.2.1]oct-2-en-3-yl)methyl)sulfonyl)phenyl)urea
H1490		1-(1-(2-fluorophenyl)ethyl)-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1491		1-(1-(2-fluorophenyl)ethyl)-1-hydroxy-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1492		1-(3-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1493		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-methylphenyl)-3-(1-phenylethyl)urea
H1494		1-(3-chloro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea








H1495		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)urea
H1496		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1497		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1498		1-hydroxy-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea







H1499		5-((isoindolin-5-ylmethyl)sulfonyl)-N-methyl-2-(3-(1-phenylethyl)ureido)benzamide
H1500		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(oxazol-2-yl)phenyl)-3-(1-phenylethyl)urea
H1501		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)-2-(oxazol-2-yl)phenyl)-3-(1-phenylethyl)urea
H1502		1-benzyl-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1503		1-benzyl-1-hydroxy-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1504		1-(3-bromo-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1505		methyl 2-((isoindolin-5-ylmethyl)sulfonyl)-5-(3-(1-phenylethyl)ureido)benzoate








H1506		1-(3-cyclopropyl-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1507		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-(oxazol-2-yl)phenyl)-3-(1-phenylethyl)urea
H1508		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)-3-(oxazol-2-yl)phenyl)-3-(1-phenylethyl)urea
H1509		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1510		1-(1-(2-fluorophenyl)ethyl)-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-methoxyphenyl)urea
H1511		1-(1-(2-fluorophenyl)ethyl)-1-hydroxy-3-(3-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1512		1-(2-(2-hydroxypropan-2-yl)-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea





H1513		1-(4-(((8-acetyl-8-azabicyclo[3.2.1]oct-2-en-2-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1514		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((8-isopropyl-8-azabicyclo[3.2.1]oct-2-en-2-yl)methyl)sulfonyl)phenyl)urea
H1515		1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-methoxyphenyl)-1-(1-phenylethyl)urea
H1516		1-hydroxy-3-(3-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1517		1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-1-(1-phenylethyl)urea
H1518		1-hydroxy-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea

H1519		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(1H-pyrazol-3-yl)phenyl)-3-(1-phenylethyl)urea
H1520		1-(3-(hydroxymethyl)-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1521		1-(1-(3-(difluoromethyl)-4-methylphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1522		1-(2-(isoindolin-5-yl)-1,1-dioxido-3-oxo-2,3-dihydrobenzo[b]thiophen-6-yl)-3-(1-phenylethyl)urea
H1523		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1524		1-hydroxy-3-(2-methoxy-4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea

H1525		1-hydroxy-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1526		1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1527		1-hydroxy-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1528		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-3-(1-phenylethyl)urea
H1529		2-((isoindolin-5-ylmethyl)sulfonyl)-N-methyl-5-(3-(1-phenylethyl)ureido)benzamide
H1530		2-((isoindolin-5-ylmethyl)sulfonyl)-5-(3-(1-phenylethyl)ureido)benzoic acid
H1531		2-((isoindolin-5-ylmethyl)sulfonyl)-5-(3-(1-phenylethyl)ureido)benzamide

H1532		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(1H-pyrazol-4-yl)phenyl)-3-(1-phenylethyl)urea
H1533		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(pyridin-3-yl)phenyl)-3-(1-phenylethyl)urea
H1534		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(pyridin-4-yl)phenyl)-3-(1-phenylethyl)urea
H1535		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-(1-phenylethyl)urea
H1537		1-((R)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1538		1-((R)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea

H1539		1-(4-(((4-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-((R)-1-phenylethyl)urea
H1540		1-(4-(((4-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-((R)-1-phenylethyl)urea
H1541		2-(3-(1-phenylethyl)ureido)-5-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)benzoic acid
H1542		2-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-5-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)benzoic acid
H1543		1-((R)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea
H1544		1-((R)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea
H1545		1-(4-(((4,4-difluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea

H1546		1-(4-(((4,4-difluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1547		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4,4-difluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1548		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4,4-difluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1549		2-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-5-((isoindolin-5-ylmethyl)sulfonyl)benzoic acid

At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term "C_{1-6} alkyl" is specifically intended to individually disclose methyl, ethyl, C_3 alkyl, C_4 alkyl, C_5 alkyl, and C_6 alkyl.

For compounds of the invention in which a variable appears more than once, each variable can be a different moiety selected from the Markush group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound; the two R groups can represent different moieties selected from the Markush group defined for R.

It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity,

described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

As used herein, the term "alkyl" is meant to refer to a saturated hydrocarbon group which is straight-chained or branched. Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), and the like. An alkyl group can contain from 1 to about 20, from 2 to about 20, from 1 to about 10, from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms.

As used herein, "alkenyl" refers to an alkyl group having one or more double carbon-carbon bonds. Example alkenyl groups include ethenyl, propenyl, cyclohexenyl, and the like.

As used herein, "alkynyl" refers to an alkyl group having one or more triple carbon-carbon bonds. Example alkynyl groups include ethynyl, propynyl, and the like.

As used herein, "haloalkyl" refers to an alkyl group having one or more halogen substituents. Example haloalkyl groups include CF_3, C_2F_5, CHF_2, CCl_3, $CHCI_2$, C_2CI_5, and the like.

As used herein, “hydroxylalkyl” refers to an alkyl group having one or more OH substituents. Example hydroxyalkyl groups include CH_2OH, C_2H_4OH, C_3H_6OH, and the like.

As used herein, "aryl" refers to monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, aryl groups have from 6 to about 20 carbon atoms.

As used herein, "cycloalkyl" refers to non-aromatic carbocycles including cyclized alkyl, alkenyl, and alkynyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems as well as spiro ring systems. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of pentane, pentene, hexane, and the like. In some embodiments, cycloalkyl groups can have from about 3 to about 10, or about 3 to about 7 ring-forming carbon atoms.

As used herein, "heterocyclyl" or "heterocycle" refers to a saturated or unsaturated cyclic hydrocarbon wherein one or more of the ring-forming carbon atoms of the cyclic hydrocarbon is replaced by a heteroatom such as O, S, or N. Heterocyclyl groups can be aromatic (e.g., "heteroaryl") or non-aromatic (e.g., "heterocycloalkyl"). Heterocyclyl groups can also correspond to hydrogenated and partially hydrogenated heteroaryl groups. Heterocyclyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems. Heterocyclyl groups can be characterized as having 3-14 or 3-7 ring-forming atoms. In some embodiments, heterocyclyl groups can contain, in addition to at least one heteroatom, from about 1 to about 13, about 2 to about 10, or about 2 to about 7 carbon atoms and can be attached through a carbon atom or heteroatom. In further embodiments, the heteroatom can be oxidized (e.g., have an oxo substituent) or a nitrogen atom can be quaternized. Examples of heterocyclyl groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo-l,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like, as well as any of the groups listed below for "heteroaryl" and "heterocycloalkyl." Further example heterocycles include pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, 3,6-dihydropyridyl, 1,2,3,6-tetrahydropyridyl, 1,2,5,6-tetrahydropyridyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2*H*-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6*H*-l,2,5-thia-diazinyl, 1,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl, octahydro-isoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, quinazolinyl, quinolinyl, 4*H*-quinolizinyl, quinoxalinyl, quinuclidinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzo-thiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, deca-hydroquinolinyl, 2H,6H-l,5,2dithiazinyl, dihydrofuro[2,3-*b*]tetrahydrofuran, furanyl, furazanyl, carbazolyl, 4aH-

carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, imidazolidinyl, imidazolinyl, imidazolyl, l*H*-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3*H*-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl and isoxazolyl. Further examples of heterocycles include azetidin-1-yl, 2,5-dihydro-l*H*-pyrrol-l-yl, piperindin-lyl, piperazin-1-yl, pyrrolidin-1-yl, isoquinol-2-yl, pyridin-1-yl, 3,6-dihydropyridin-l-yl, 2,3-dihydroindol-l-yl, l,3,4,9-tetrahydrocarbolin-2-yl, thieno[2,3-*c*]pyridin-6-yl, 3,4,10,10a-tetrahydro-l*H*-pyrazino[l,2-a]indol-2-yl, l,2,4,4a,5,6-hexahydro-pyrazino[l,2-a]quinolin-3-yl, pyrazino[l,2-*a*]quinolin-3-yl, diazepan-1 -yl, 1 ,4,5,6-tetrahydro-2*H*-benzo[fJisoquinolin-3-yl, 1 ,4,4a,5,6, 10b-hexahydro-2H-benzo[f]isoquinolin-3-yl, 3,3a,8,8a-tetrahydro- 1*H*-2-aza-cyclopenta[a]inden-2-yl, and 2,3,4,7-tetrahydro- 1*H*-azepin- 1 -yl, azepan- 1 -yl.

As used herein, "heteroaryl" groups refer to an aromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroaryl groups include without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl (furanyl), quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like. In some embodiments, the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms.

As used herein, "heterocycloalkyl" refers to non-aromatic heterocycles including cyclized alkyl, alkenyl, and alkynyl groups where one or more of the ring-forming carbon atoms is replaced by a heteroatom such as an O, N, or S atom. Example "heterocycloalkyl" groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo- 1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles such as indolene and isoindolene groups. In some embodiments, the heterocycloalkyl group has from 1

to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heterocycloalkyl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 triple bonds.

As used herein, "halo" or "halogen" includes fluoro, chloro, bromo, and iodo.

As used herein, "alkoxy" refers to an -O-alkyl group. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like.

As used herein, "thioalkoxy" refers to an -S-alkyl group.

As used here, "haloalkoxy" refers to an -O-haloalkyl group. An example haloalkoxy group is OCF .

As used herein, "cycloalkyloxy" refers to -O-cycloalkyl.

As used herein, "aralkyl" refres to an alkyl group substituted by an aryl group.

As used herein, "cycloalkylalkyl" refers to an alkyl group substituted by an cycloalkyl group.

As used herein, "heterocyclylalkyl" refers to an alkyl moiety substituted by a heterocarbocyclyl group. Example heterocyclylalkyl groups include "heteroarylalkyl" (alkyl substituted by heteroaryl) and "heterocycloalkylalkyl" (alkyl substituted by heterocycloalkyl). In some embodiments, heterocyclylalkyl groups have from 3 to 24 carbon atoms in addition to at least one ring-forming heteroatom.

As used herein "oxo" refers to =O.

The compounds described herein can be asymmetric (e.g., having one or more stereocenters). The description of a compound without specifying its stereochemistry is intended to capture mixtures of stereoisomers as well as each of the individual stereoisomer encompassed within the genus.

Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals

without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.

Synthesis

The compounds of the formulae (I), (II), (III) (IV) (and other disclosed compounds), or their pharmaceutically acceptable salts or adducts, can be prepared by the methods as illustrated by examples described in the "Examples" section, together with synthetic methods known in the art of organic chemistry, or modifications and derivatisations that are familiar to those of ordinary skill in the art.

The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one

solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.

Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Green and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.

Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectrometry (e.g., ^{1}H or ^{13}C) infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

Pharmaceutical Compositions

Pharmaceutical compositions for preventing and/or treating a subject are further provided comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

A "pharmaceutically acceptable" excipient is one that is not biologically or otherwise undesirable, i.e., the material can be administered to a subject without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier can be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art. The carrier can be a solid, a liquid, or both.

The disclosed compounds can be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment or prevention intended. The active compounds and compositions, for example, can be administered orally, rectally, parenterally, ocularly, inhalationaly, or topically. In particular, administration can be epicutaneous, inhalational, enema, conjunctival, eye drops, ear drops, alveolar, nasal, intranasal, vaginal, intravaginal, transvaginal, ocular, intraocular, transocular,

enteral, oral, intraoral, transoral, intestinal, rectal, intrarectal, transrectal, injection, infusion, intravenous, intraarterial, intramuscular, intracerebral, intraventricular, intracerebroventricular, intracardiac, subcutaneous, intraosseous, intradermal, intrathecal, intraperitoneal, intravesical, intracavernosal, intramedullar, intraocular, intracranial, transdermal, transmucosal, transnasal, inhalational, intracisternal, epidural, peridural, intravitreal, etc.

Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, Pa., 1995. Oral administration of a solid dose form can be, for example, presented in discrete units, such as hard or soft capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of at least one of the disclosed compound or compositions. In some forms, the oral administration can be in a powder or granule form. In some forms, the oral dose form is sub-lingual, such as, for example, a lozenge. In such solid dosage forms, the compounds of Formula I are ordinarily combined with one or more adjuvants. Such capsules or tablets can contain a controlled-release formulation. In the case of capsules, tablets, and pills, the dosage forms also can comprise buffering agents or can be prepared with enteric coatings.

In some forms, oral administration can be in a liquid dose form. Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art (e.g., water). Such compositions also can comprise adjuvants, such as wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents.

In some forms, the disclosed compositions can comprise a parenteral dose form. "Parenteral administration" includes, for example, subcutaneous injections, intravenous injections, intraperitoneally, intramuscular injections, intrasternal injections, and infusion. Injectable preparations (e.g., sterile injectable aqueous or oleaginous suspensions) can be formulated according to the known art using suitable dispersing, wetting agents, and/or suspending agents. Typically, an appropriate amount of a pharmaceutically acceptable carrier is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution. Other acceptable excipients include, but are not limited to, thickeners, diluents, buffers, preservatives, surface active agents and the like.

In some forms, the disclosed compositions can comprise a topical dose form. "Topical administration" includes, for example, transdermal administration, such as via transdermal patches or iontophoresis devices, intraocular administration, or intranasal or inhalation administration. Compositions for topical administration also include, for example, topical gels, sprays, ointments, and creams. A topical formulation can include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. When the compounds and compositions are administered by a transdermal device, administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes can also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers can be incorporated--see, for example, J Pharm Sci, 88 (10), 955-958, by Finnin and Morgan (October 1999).

Formulations suitable for topical administration to the eye include, for example, eye drops wherein the disclosed compound or composition is dissolved or suspended in suitable carrier. A typical formulation suitable for ocular or aural administration can be in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, can be incorporated together with a preservative, such as benzalkonium chloride. Such formulations can also be delivered by iontophoresis.

Other carrier materials and modes of administration known in the pharmaceutical art can also be used. The disclosed pharmaceutical compositions can be prepared by any of the well-known techniques of pharmacy, such as effective formulation and administration procedures. The above considerations in regard to effective formulations and administration procedures are well known in the art and are described in standard textbooks. Formulation of drugs is discussed

in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1975; Liberman, et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Kibbe, et al., Eds., Handbook of Pharmaceutical Excipients (3.sup.rd Ed.), American Pharmaceutical Association, Washington, 1999.

The disclosed compounds can be used, alone or in combination with other therapeutic agents, in the treatment or prevention of various conditions or disease states. The administration of two or more compounds "in combination" means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other. The two or more compounds can be administered simultaneously, concurrently or sequentially.

Disclosed are pharmaceutical compositions comprising an effective amount of a compound of the invention or a pharmaceutically accepted salt thereof; and a pharmaceutically acceptable carrier or vehicle. These compositions may further comprise additional agents. These compositions are useful for modulating the activity of ghrelin receptor, thus to improve the prevention and treatment of ghrelin receptor associated human diseases such as obesity and/or metabolic disorders.

Methods

All of the methods of the invention may be practiced with a compound of the invention alone, or in combination with other agents.

The above-described compounds and compositions are useful for the inhibition, reduction, prevention, and/or treatment of diseases which are pathophysiologically modulated by the ghrelin receptor. Accordingly, in some forms, disclosed are methods of preventing and/or treating diseases which are pathophysiologically modulated by the ghrelin receptor, comprising administering to a subject a therapeutically effective amount of a compound of Formula I as disclosed above, or a pharmaceutically acceptable salt thereof.

Suitable subjects can include mammalian subjects. Mammals include, but are not limited to, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. In some forms, humans are the subjects. Human subjects can be of either gender and at any stage of development.

Diseases modulated by the ghrelin receptor, and potentially treatable by the methods disclosed herein, include obesity, diabetes and substance abuse. A therapeutically effective

amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. Therapeutically effective amounts of compounds of Formula I, II, III, and IV may range from approximately 0.01 microgram per Kg (μg/Kg) body weight per day to about 100 mg/Kg body weight per day.

Definitions of Terms

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.

1. A, an, the

As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.

2. Abbreviations

Abbreviations, which are well known to one of ordinary skill in the art, may be used (e.g., "h" or "hr" for hour or hours, "g" or "gm" for gram(s), "mL" for milliliters, and "rt" for room temperature, "nm" for nanometers, "M" for molar, and like abbreviations).

3. About

The term "about," when used to modify the quantity of an ingredient in a composition, concentrations, volumes, process temperature, process time, yields, flow rates, pressures, and like values, and ranges thereof, employed in describing the embodiments of the disclosure, refers to variation in the numerical quantity that can occur, for example, through typical measuring and handling procedures used for making compounds, compositions, concentrates or use formulations; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of starting materials or ingredients used to carry out the methods; and like considerations. The term "about" also encompasses amounts that differ due to aging of a composition or formulation with a particular initial concentration or mixture, and amounts that differ due to mixing or processing a composition or formulation with a particular initial

concentration or mixture. Whether modified by the term "about" the claims appended hereto include equivalents to these quantities.

4. Comprise

Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises," means "including but not limited to," and is not intended to exclude, for example, other additives, components, integers or steps.

5. Ghrelin Receptor Agonist

A ghrelin receptor agonist is any molecule that binds to and activates the Ghrelin receptor in the cells.

6. Ghrelin Receptor Antagonist

A ghrelin receptor antagonist is any molecule that binds to and inhibits the activity of Ghrelin receptor.

7. Ghrelin Receptor Inverse Agonist

A ghrelin receptor inverse agonist is any molecule that binds to and decreases the activity of Ghrelin receptor to below the basal or constitutive level.

8. Pathophysiologically Mediated by Ghrelin Receptor

Something is "pathophysiologically mediated by the ghrelin receptor" if the ghrelin receptor is involved in the functional changes in body associated with or resulting from disease or injury.

9. Agonism Action

Agonism action refers to the binding of a molecule to a receptor that leads to the activation of the receptor, thus triggering a cellular response similar to the cellular response for a known agonist for the receptor.

10. Antagonism Action

Antagonism action refers to the binding of a molecule to a receptor that leads to the inhibition of the receptor.

11. Inverse Agonism Action

Inverse agonism action refers to the binding of a molecule to a receptor that leads to the decrease in the basal activity of the receptor.

12. Modulate

To modulate, or forms thereof, means either increasing, decreasing, or maintaining a cellular activity mediated through a cellular target. It is understood that wherever one of these words is used it is also disclosed that it could be 1%, 5%, 10%, 20%, 50%, 100%, 500%, or 1000% increased from a control, or it could be 1%, 5%, 10%, 20%, 50%, or 100% decreased from a control.

13. Optional

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

14. Or

The word "or" or like terms as used herein means any one member of a particular list and also includes any combination of members of that list.

15. Publications

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.

16. Subject

As used throughout, by a "subject" is meant an individual. Thus, the "subject" can include, for example, domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.) mammals, non-human mammals, primates, non-human primates, rodents, birds, reptiles, amphibians, fish, and any other animal. The subject can be a mammal such as a primate or a human. The subject can also be a non-human.

17. Treating

By "treating" or "treatment" is meant the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. These terms include active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition,

or disorder. These terms can mean that the symptoms of the underlying disease are reduced, and/or that one or more of the underlying cellular, physiological, or biochemical causes or mechanisms causing the symptoms are reduced. It is understood that reduced, as used in this context, means relative to the state of the disease, including the molecular state of the disease, not just the physiological state of the disease. In certain situations a treatment can inadvertently cause harm. In addition, these terms include palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. These terms mean both treatment having a curing or alleviating purpose and treatment having a preventive purpose. The treatment can be made either acutely or chronically. It is understood that treatment can mean a reduction or one or more symptoms or characteristics by at least 5% 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99%, 100%, relative to a control. In the context of these terms, preventing refers to the ability of a compound or composition (such as the disclosed compounds and compositions) to prevent a disease identified herein in patients diagnosed as having the disease or who are at risk of developing such disease. In this context, preventing includes the delaying the onset of the disease relative to a control. These terms do not require that the treatment in fact be effective to produce any of the intended results. It is enough that the results are intended.

18. Therapeutically Effective

The term "therapeutically effective" means that the amount of the composition used is of sufficient quantity to treat a subject as defined herein.

19. Toxicity

Toxicity is the degree to which a substance, molecule, is able to damage something, such as a cell, a tissue, an organ, or a whole organism, that has been exposed to the substance or molecule. For example, the liver, or cells in the liver, hepatocytes, can be damaged by certain substances. The methods of the present invention are preferably non-toxic.

The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the

invention in any manner. Those of skill in the art will readily recongnize a variety of noncritical parameters which can be changed or modified to yield essentially the same results.


EXAMPLES

The following are examples of preparation of compounds of formulae (I), (II), (III) and (IV). These examples are intended to be purely exemplary and are not intended to limit the disclosure.

General Synthetic Schemes


Scheme A

Scheme A constitutes a representative scheme for synthesizing the compounds of the present invention (where R, R^4 and R^5 are defined herein and where where R^4 is CH_2) from the sodium 4-acetamidobenzenesulfinate intermediate.




Scheme B

Scheme B constitutes a representative scheme for synthesizing the compounds of the present invention (where R, R^4 and R^5 are defined herein and where R^4 is NH) from the 4-nitrobenzenesulfonyl chloride intermediate.



Example 1:

Synthesis of H0937



Synthesis of 1c: To a solution of sodium methanolate (2.16 g, 40 mmol) in MeOH (70 mL) were added 2-nitropropane (1b) (18.7 g, 210 mmol) and benzaldehyde (1a) (21.2 g, 200 mmol). The resulting mixture was stirred at room temperature overnight. The solvent was then evaporated under reduced pressure and the residue was dissolved in a mixture of water and ether (100 mL/100 mL). The ether layer was separated and washed with aqueous sodium hydrogen sulphite solution (100 mL x 4), and then dried over anhydrous Na_2SO_4 and evaporated. The residue was purified by silica column chromatography (ethyl acetate: petroleum ether=1:5, v:v) to provide compound 1c (14.95 g, 38% yield).

Synthesis of 1d: To a solution of 1c (2.0 g, 10.25 mmol) in a mixture of EtOH (170 mL) and water (85 mL) was added 17 mL of con. HCl at room temperature, followed by Zinc powder (4.02 g, 61.15 mmol) in small portions. The resulting mixture was stirred at 70 ^{0}C for 4 hours, then cooled to room temperature and filtered. The filtrate was evaporated and the residue was purified by silica column chromatography (DCM:MeOH=20:1, v:v) to provide 1d (880 mg, 52% yield).

Synthesis of 1e: P (677 mg, 22 mmol) was slowly added to the solution of 1d (1.5 g, 9.1 mmol) in HI (22mL 45% in water) at room temperature. The mixture was stirred at 135 ^{0}C overnight, and then cooled to room temperature. Water (100 mL) was added to the above mixture, which was filtered. Saturated aqueous $Na_2S_2O_3$ solution (100 mL) was added to the filtrate and was made basic with 40% NaOH (20 mL). The resulting mixture was extracted with ethyl acetate (100 mL x 3). The combined ethyl acetate layer was washed with water and dried over anhydrous Na_2SO_4 and evaporated. The residue was purified by silica column chromatography (DCM : MeOH=30:1, v:v) to provide 1e (0.55 g, 41% yield).

Synthesis of 1f: 1e (7.0 g, 47 mmol) was added to con. H_2SO_4 (70 mL) and the mixture was cooled to -5 ^{0}C. KNO_3 (4.7 g, 47mmol) was added in small portions to the above mixture and stirred for 1 hour at -5 ^{0}C. The mixture was then poured into ice-water and was adjusted to pH=10 with 40% NaOH aqueous solution. The resulting mixture was extracted with ethyl acetate (150 mL x 3). The combined ethyl acetate layer was washed with brine, dried over anhydrous Na_2SO_4 and evaporated to provide 1f (6.5 g, 71% yield).

Synthesis of 1g: To a solution of 1f (6.4 g,33 mmol) in THF(150 mL) was added aq. Na_2CO_3 solution (60 mL) and Boc_2O (10.7 g, 49.5 mmol). The mixture was stirred at 50°C overnight, and then cooled to room temperature. The solvent was evaporated under reduced pressure and the residue was partitioned between ethyl acetate and water (150 mL/150 mL). The organic layer was separated, dried over anhydrous Na_2SO_4 and evaporated. The residue was purified by silica column chromatography (ethyl acetate:petroleum ether=1:20, v:v) to provide 1g (9.5 g, 98% yield).

Synthesis of 1h: A mixture of 1g (2.0 g, 6.8 mmol) and 10% Pd/C (100 mg) in methanol (60 mL) was stirred under 1 atm hydrogen atmosphere at room temperature for 2 hours and then filtered. The filtrate was evaporated under reduced pressure and the residue was purified by silica

column chromatography (ethyl acetate:petroleum ether=1:10, v:v) to provide 1h (1.0 g, 57 % yield).

Synthesis of 1j: To a solution of 1h (250 mg, 0.95 mmol) in DCM (10mL) was added pyridine (0.2 mL) and 1i (230 mg, 1.04 mmol). The mixture was stirred at room temperature overnight and evaporated under reduced pressure. The residue was purified by silica column chromatography (ethyl acetate:petroleum ether=1:5, v:v) to provide 1j (320 mg, 75% yield).

Synthesis of 1k: A mixture of 1j (320 mg, 0.71 mmol) and 10% Pd/C (50 mg) in methanol (20 mL) was stirred under 1 atm hydrogen atmosphere at room temperature for 2 hours and then filtered. The filtrate was evaporated under reduced pressure to provide crude 1k (298 mg, ca.100% yield).


Synthesis of 1l: To a solution of 1k (82 mg, 0.2 mmol) in DCM (10mL) was added saturated aqueous $NaHCO_3$ solution (5 mL) at room temperature. Triphosgene (58 mg, 0.2 mmol) dissolved in DCM (1 mL) was added to the above mixture. The resulting mixture was stirred for 2 hours. DCM (20 ml) was then added to the mixture. The two layers were separated and the organic phase was washed by brine, dried over anhydrous Na_2SO_4 and evaporated under reduced pressure to give crude 1l（90 mg， ca.100% yield）.


Synthesis of 1n: To a solution of 1l in THF (10 mL) was added 1m (36 mg, 0.16 mmol). The mixture was stirred at 70 °C overnight, then cooled and evaporated. The residue was purified by Prep-TLC (DCM:MeOH= 10:1, v:v) to provide 1n (38 mg, 35 % yield). LC-MS: 667.2 $[M+1]^+$

Synthesis of H0937: To a solution of 1n (38 mg, 0.06 mmol) in MeOH (1 mL) was added HCl/methanol solution (4 N, 1 mL). The mixture was stirred at room temperature overnight, then evaporated under reduced pressure to give H0937 (25 mg, 74% yield). ^{1}H-NMR (CD_3OD, 400 MHz): 7.52 (d, 1H), 7.34 (d, 1H), 7.26 (d, 1H), 6.99-7.01 (m, 4H), 6.94 (d, 1H), 5.10-5.12 (m, 1H), 378 (s, 3H), 3.56 (t, 1H), 3.21 (s ,6H), 2.71 (s, 2H), 1.33 (d, 3H). LC-MS: 567.2$[M+1]^+$.

Example 2:

Synthesis of H1027 & H1071





Synthesis of 2b: 2a (1.42 g, 5.7 mmol) was added to a mixture of amyl nitrate (1.42 g, 12.1 mmol) and $CuBr_2$ (2.16 g, 9.67 mmol) in CH_3CN (20 mL). The mixture was heated at 80 °C for 2 hours, then cooled and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA=10:1, *v:v*) to provide 2b (1.96 g, 78% yield) as a yellow oil. LC-MS: 312 $[M+1]^+$.

Synthesis of 2c: To a solution of 2b (1.96 g, 6.3 mmol) in dry DMF (40 mL) were added $Pd(dppf)Cl_2$ (1.03g, 1.26 mmol), TEA (3.18g, 31.5 mmol) and TES (2.92g, 25.2 mmol). The mixture was heated at 80 °C overnight under CO atmosphere, then cooled and added ethyl acetate (100 mL). The mixture was filtered and the filtrate was washed with water and brine, dried over anhydrous Na_2SO_4, and then evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA=10:1, *v:v*) to provide 2c (1.1 g, 70% yield). LC-MS: 262 $[M+1]^+$.


Synthesis of 2d: To a solution of 2c (1.14 g, 4.4 mmol) in MeOH (20 mL) was added $NaBH_4$ (332 mg, 8.74 mmol) in portions at 0 °C. After the addition was complete, the mixture was stirred for 1 hour at room temperature. Ethyl acetate (20 mL) was then added to the mixture. The mixture was washed with brine, dried over anhydrous Na_2SO_4 and evaporated to provide crude 2d (1.1 g, 96% yield). LC-MS: 264 $[M+1]^+$.

Synthesis of 2e: NBS (2.98 g, 16.7 mmol) was added in portions to a solution of 2d (1.1 g, 4.18 mmol) and PPh_3 (3.3 g, 12.6 mmol) in THF (20 mL) cooled to 0 °C. After the addition was complete, the mixture was stirred for 1 hour at room temperature, and ethyl acetate (30 mL) was added to the mixture. The mixture was washed with water and brine, dried over anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA =10:1, *v:v*) to provide 2e (1.1 g, 83% yield). LC-MS: 326 $[M+1]^+$.

Synthesis of 2g: To a solution of 2e (1.1 g, 3.48 mmol) in EtOH (20 mL) was added 2f (1.0 g, 4.52 mmol) at room temperature. The mixture was then heated under reflux for 2 hours, cooled and evaporated under reduced pressure. Ethyl acetate (30 mL) was added to the residue. The mixture was washed with water and brine, dried over anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA =10:1, *v:v*) to provide 2g (1.5 g, 98% yield). LC-MS: 445 $[M+1]^+$.

Synthesis of 2h: A solution of 2g (1.51 g, 3.4 mmol) in a mixture of 6 N HCl (30 mL) and MeOH (30 mL) was heated at 80 °C for 2 hours, cooled and evaporated under reduced pressure. The residue was adjusted to pH=7 with saturated Na_2CO_3 solution. THF (30 mL) was added, followed by Boc_2O (1.3 g, 4.1 mmol). The mixture was stirred at room temperature overnight. Ethyl acetate (30 mL) and water (30 mL) were added. The organic phase was separated and washed with water and brine and dried over anhydrous Na_2SO_4. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM:MeOH =20:1, *v:v*) to provide 2h (1. 1 g, 80.3% yield). LC-MS: 403 $[M+1]^+$.

Synthesis of 2j: To a solution of compound 2h (100 mg, 0.25 mmol) in a mixture of sat. $NaHCO_3$ (2.5 ml) and DCM (10 mL) was added a solution of triphosgene (74 mg, 0.25 mmol) in DCM (2 mL) at 0 °C. After the addition was complete, the mixture was stirred at room temperature for 2 hours, and then DCM (20 mL) was added to the mixture. The DCM phase was separated and washed with water and brine and dried over anhydrous Na_2SO_4. The solvent was evaporated under reduced pressure, and the residue was then re-dissolved in dry THF (5 ml). 2i (39.2 mg, 0.21 mmol) and DMAP (5 mg) were added to the above mixture and the resulting mixture was stirred for another 1 hour. The solution was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (DCM:MeOH =20:1, *v:v*) to provide 2j (60 mg, 39% yield). LC-MS: 618 $[M+1]^+$.




Synthesis of H1027: To a solution of 2j (60 mg, 0.1 mmol) in DCM (2 mL) was added HCl/MeOH (4 N, 5 mL) at room temperature. The mixture was stirred for 2 hours and then evaporated under reduced pressure. The residue was purified by Pre-HPLC to provide H1027

(28.4 mg, 57% yield). ^{1}H-NMR ($CDCl_3$, 400 MHz): δ= 7.39-7.41 (m, 2H), 7.27-7.31 (m, 4H), 7.07-7.11 (m, 1H), 6.79-6.95 (m, 1H), 6.72-6.81 (m, 1H), 5.59 (m,1H), 5.22-5.26 (m, 1H), 4.23 (s, 1H), 4.15 (s, 1H), 3.87 (s, 2H),3.67 (s, 1H), 2.92-3.00 (m, 2H), 2.52-2.62 (m, 2H), 1.41 (d, J=6.8Hz, 3H). LC-MS: 518 [M+1]+.

Synthesis of H1071: To a solution of H1027 (25 mg, 0.05 mmol) in MeOH (5 mL) were added aqueous formaldehyde solution (40%, 0.1 mL), acetic acid (0.1 mL) and sodium acetate (20 mg), followed by $NaBH_3CN$ (7 mg, 0.1 mmol). The mixture was stirred at room temperature for 2 hours and then evaporated. The residue was washed with aqueous $NaHCO_3$ solution and the mixture was extracted with CH_2Cl_2 (25 mL x 3). The combined organic phase was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by pre-HPLC to provide H1071 (20 mg, 75% yield) as light yellow solid. ^{1}H-NMR (CD_3OD, 300 MHz): δ= 7.41-7.59 (m, 6H), 7.29-7.32 (m, 1H), 7.17-7.20 (m, 1H), 6.98-7.09 (m, 2H), 5.30-5.33 (m,1H), 4.54 (s, 1H), 4.42 (s, 1H), 4.27 (s, 2H),3.59 (s, 1H),3.02-3.08 (m,3H), 2.87 (s, 3H), 1.48 (d, J=7.2Hz, 3H) LC-MS: 532 $[M+1]^+$.

Example 3:

Synthesis of H1060



Synthesis of 3c: To a solution of 3a (1.5 g, 6.6 mmol) in EtOH (50 mL) was added 3b (1.74g, 7.9 mmol) at room temperature. The resulting mixture was heated under reflux for 2 hours, cooled and filtered to provide crude 3c (1.8 g, 81% yield) which was directly used in the next step. LC-MS: 348$[M+1]^+$.

Synthesis of 3d: To a suspension of 3c (1.8 g, 5.18 mmol) in MeOH (15 mL) was added HCl (6 N, 15mL). The resulting mixture was heated under reflux for 16 hours, then cooled and filtered to provide 3d (1.2 g, 73% yield). LC-MS: 306 $[M+1]^+$.


Synthesis of 3f: To a solution of 3d (1.2 g, 3.71 mmol) in pyridine (15 mL) was added 3e (868 mg, 5.56 mmol) at room temperature. The resulting mixture was stirred for 3 hours and then evaporated under reduced pressure. The residue was partitioned between ethyl acetate and brine (50 mL/50mL). The organic phase was separated, dried with anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica column chromatography to provide 3f (1.1 g, 70% yield). LC-MS: 426 $[M+1]^+$.

Synthesis of 3h: To a solution of 3f (500 mg, 1.2 mmol) and 3g (265 mg, 1.4 mmol) in dry THF (15 mL) were added DMAP (15 mg, 0.12 mmol) and DIEA (301 mg, 2.3 mmol). The resulting mixture was heated under reflux for 16 hours, cooled to room temperature and evaporated under reduced pressure. The residue was partitioned between ethyl acetate and brine (50 mL/50 mL). The organic phase was separated, dried with anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica column chromatography to provide 3h (414 mg, 68% yield). LC-MS: 521 $[M+1]^+$.

Synthesis of H1060: To a solution of 3h (414 mg, 0.80 mmol) in dry THF (15 mL) was added LAH (46 mg, 1.20 mmol) in portions at 0 °C. After the addition was complete, the mixture was stirred for 2 hours and then quenched by aqueous $NaHCO_3$ solution (15 mL). The mixture was extracted with ethyl acetate (15 mL x 3). The combined organic layer was washed with brine, dried over anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica column chromatography to provide H1060 (278 mg, 71% yield). ^{1}H-NMR (CD_3OD, 400 MHz): δ= 7.39-7.47 (m, 6H), 7.29-7.31 (m, 1H), 7.24 (d, *J*=8 Hz, 2H), 7.08 (d, *J*=8 Hz, 2H), 5.29 (q, 1H), 4.56 (s, 2H), 4.42 (s, 2H), 1.46 (d, *J*=6.8Hz, 3H). LC-MS: 493[M+1]+.

Example 4:

Synthesis of H1148 & H1194



Synthesis of 4b: To a solution of 4a (10 g, 44.4 mmol) in THF (200 mL) was added $NaBH_4$ (17.6 g, 464.8 mmol), followed by $BF_3.Et_2O$ (170 ml, 519.2 mmol) dropwise at room temperature. The mixture was then heated at 80 °C overnight, cooled to 0 °C and adjusted to pH 13 with aqueous NaOH solution. The mixture was extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with water, brine and dried over anhydrous Na_2SO_4. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (DCM:MeOH =10:1, *v:v*) to provide 4b (7.3 g, 83% yield). LC-MS: 198 $[M+1]^+$.

Synthesis of 4c: To a solution of 4b (6 g, 30 mmol) in THF (100 mL) was added saturated Na_2CO_3 solution (25 mL), followed by Boc_2O (33 g, 151 mmol). The mixture was stirred at room temperature for 2 hours and evaporated under reduced pressure. The residue was extracted with ethyl acetate (50 mL x 3). The combined organic phase was washed with brine, dried over anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA =10:1, *v:v*) to provide 4c (9 g, ca. 100% yield). LC-MS: 298 $[M+1]^+$.

Synthesis of 4d: To a solution of 4c (9 g, 30.3 mmol) in a mixture of MeOH (30 mL) and DMF (30 mL) were added $Pd(dppf)Cl_2$ (1.6 g, 2 mmol) and TEA (6.12 g, 60.6 mmol). The mixture was heated at 80 °C overnight under CO atmosphere, cooled and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA =10:1, *v:v*) to provide 4d (5.8 g, 69% yield). LC-MS: 278 $[M+1]^+$.

Synthesis of 4e: To a solution of 4d (5.8 g, 21 mmol) in THF (100 ml) was slowly added LAH (1.6 g, 42 mmol) at 0 °C. After the addition was complete, the mixture was stirred for 2 hours at room temperature. Water (1.6 mL) and aqueous NaOH (10%, 1.6 mL) were slowly added, and the mixture was filtered. The filtrate was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (PE:EA =3:1, *v:v*) to provide 4e (3.23 g, 62% yield). LC-MS: 250 $[M+1]^+$.

Synthesis of 4f: NBS (4.6 g, 26 mmol) was added in portions to a solution of 4e (3.23 g, 130 mmol) and PPh_3 (6.8 g, 26 mmol) in THF (150 mL) cooled to 0 °C. After the addition was complete, the mixture was stirred for 3 hours at room temperature and then evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA =3:1, *v:v*) to provide 4f (2 g, 50% yield). LC-MS: 312 $[M+1]^+$.


Synthesis of 4h: To a solution of 4f (2 g, 6.4 mmol) in EtOH (50 mL) was added 4g (2.8 g, 12.7 mmol) at room temperature. The mixture was heated at 80 °C overnight, cooled and evaporated under reduced pressure. The residue was dissolved in ethyl acetate (50 mL), washed with water and brine, dried over anhydrous Na_2SO_4, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA =1:1, *v:v*) to provide 4h (1.9 g, 72% yield) as a white solid. LC-MS: 431 $[M+1]^+$.

Synthesis of 4i: A solution of 4h (1.9 g, 4.5 mmol) in 6 N HCl (20 mL) and MeOH (40 mL) was heated at 80 °C overnight, cooled and evaporated under reduced pressure. The residue was dissolved in a mixture of saturated Na_2CO_3 (20 ml) and THF (40 mL), and Boc_2O (1.45 g, 5.0 mmol) was then added. The mixture was stirred at room temperature overnight. Ethyl acetate (40 mL) and water (40 mL) were added to the above mixture. The organic phase was separated, washed with water and brine, dried over anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA =1:1, *v:v*) to provide 4i (1.36 g, 70% yield). LC-MS: 389 $[M+1]^+$.

Synthesis of 4k: To a solution of 4i (1.36 g, 3.50 mmol) in pyridine (20 mL) was added 4j (821 mg, 5.25 mmol) at room temperature. The mixture was stirred for 3 hours and then evaporated under reduced pressure. The residue was partitioned between ethyl acetate (20 mL) and brine (20 mL). The organic phase was separated, washed with brine, dried with anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA =1:1, *v:v*) to provide 4k (1.24 g, 70% yield). LC-MS: 509 $[M+1]^+$.

Synthesis of 4m: To a solution of 4k (6.0 g, 11.8 mmol) and 4l (1.57 g, 13.0 mmol) in dry THF (150 mL) were added DMAP (100 mg, 0.008 mmol) and DIEA (10 mL, 60 mmol) at room temperature. The resulting mixture was heated at 80 °C overnight and evaporated under reduced pressure. The residue was partitioned between ethyl acetate (200 mL) and brine (200 mL). The organic phase was separated, dried with anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (DCM:HCl =20:1, *v:v*) to provide 4m (4.0 g, 63.3% yield). LC-MS: 536 $[M+1]^+$.

Synthesis of H1148: To a solution of 4m (4.0 g, 7.5 mmol) in DCM (10 mL) was added HCl/MeOH (4 N, 50 mL) at room temperature. The solution was stirred for 2 hours and then filtered to provide H1148 (3.34 g, 94.4% yield). ^1H NMR (CD_3OD, 400 MHz): δ= 7.41 (s, 3H), 7.23-7.25 (m, 5H), 7.15 (s, 1H), 7.05 (d, *J*=7.6 Hz, 1H), 4.81 (q, 1H), 4.49 (s, 2H), 4.45 (s, 2H), 4.40 (s, 2H), 1.38 (d, *J*=6.8Hz, 3H). LC-MS: 436 $[M+1]^+$.



Synthesis of H1194: To a solution of H1148 (3.34 g, 7.1 mmol) in a mixture of THF (47 mL) and MeOH (47 mL) were added aqueous formaldehyde solution (40%, 9.5 mL), AcOH (1.0 mL) and NaOAc (1.0 g), followed by $NaBH_3CN$ (895 mg, 14.2 mmol). The mixture was stirred for 3 hours at room temperature and evaporated under reduced pressure. Aqueous Na_2CO_3 solution (100 mL) was added and the mixture was extracted with DCM (100 mL x 3). The combined organic phase was dried with anhydrous Na_2SO_4 and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (DCM:HCl =20:1, *v:v*) to provide H1194 (2.3 g, 75% yield). ^1H-NMR (CD_3OD, 400 MHz): δ= 7.38-7.39 (m, 4H), 7.20-7.25 (m, 3H), 7.09-7.14 (m, 1H), 6.94-6.97(m, 1H), 4.80 (q, 1H), 4.34 (s, 2H), 4.14 (s, 2H), 4.10 (s, 2H), 1.37 (d, *J*=7.2Hz, 3H). LC-MS: 450[M+1]+.

Evaluation of Inverse Agonist on Food Intake Test in Mouse:

Male C57BL/6J mice, 18-22 g body weight, were fasted overnight (16 h before compound administration) and placed in a regular light dark cycle (6:00-18:00 light/18:00-6:00 dark). After 1 wk acclimation, animals were sorted into two groups (n=6 each, 2 per cage) based

on body weight. Animals in group one were be treated with vehicle and animals in group 2 were treated with the test agent (n=6 for each group). The cumulative food intake was evaluated at 1, 2, 4, 8 and 24 hrs after drug or vehicle treatment. Food intake was measured by subtracting uneaten food from the initial premeasured food.

The following table presents representative compounds of Formula I with biological data including the ghrelin antagonist/agonist activity in vitro (Example A) and mouse food intake results (Example B). The data clearly demonstrates that compounds of Formula I are ghrelin receptor modulators and are useful in preventing and/or treating diseases associated with ghrelin receptor, for example, obesity.

Evaluation of Ghrelin Inverse Agonist Potency (EC_{50}) with IP-1 Assay:

HEK293 cells stably expressing recombinant human ghrelin receptor (HEK293/GRLN) were used in the IP-One HTRF assay. One day before the test, cells were seeded at a density of 1.5×10^4/well in a Matrigel® coated 384-well plate with 30 µL of complete Dulbecco's Modified Eagle's Medium and incubated at 37 °C in 5 % CO_2 for 18–22 hours. On the test day, the medium was removed by centrifugation at 600 rpm for 30 seconds, and 20 µL of stimulation buffer containing 1x tested compound was added with Bravo (Agilent technologies). The plate was then incubated at 37 °C 5 % CO_2 for 1 hour. After the incubation, 5 µL of IP1-d2 and 5 µL of Tb-Cryp were added to all wells using multidrop Combi(Thermo). After additional incubation at room temperature for 1 hour, the plates were read on Envision with 620 and 665(Perkin Elmer).

Evaluation of Ghrelin Agonist (EC_{50}) and Antagonist Potency (IC_{50}) with Calcium FLIPR Assay:

The intracellular calcium assay was carried out in a 384-well format FLIPRTM (Molecular Device) HEK293/GHSR1a cell line. Cells were seeded 24 hr prior to the experiments at an optimal density per well. Preincubation with selected calcium dye lasted for 30-60 min at room temperature or 37° C. Test compounds, dissolved in DMSO, were added at the appropriate time and incubated for 15 min followed by the addition of ghrelin with FlexStation or FLIPR. Relative fluorescence was monitored by the FLIPRTM Molecular Device. EC_{50} and IC_{50} values were estimated from dose-response data using GraphPad Prism software. To check for GHSR-1a agonism, the compound was added at t = 20 sec. and the calcium response was followed for 2

minutes. To check for GHSR-1a antagonism, the compound and Ghrelin (10 nM) were added to the cells at t = 20 sec. and the calcium response was measured for 2 minutes. The potency of the antagonist was calculated by its ability to reduce the ghrelin response. Dose-response curves were made for relevant antagonists.

Metabolic Stability Study

The metabolic stability of compounds in human, dog, rat and mouse liver microsomes was performed according the experimental conditions reported below:

Substrate (μM)	Protein (mg/ml)	Sample replicate	NADPH (mM)
1	0.5	N=2	1.3

a) Prepare the following 5 stock solutions:

1. Test compound stock solutions: dilute 10 mM solution of dextromethorphan (Dtr) in DMSO, 10 mM solution of diphenhydramine (DPA) in DMSO, 10 mM solution of omeprazole (Ome) in DMSO, 10 mM solution of verapamil (Ver) in DMSO, and 10 mM of an inverse agonist compound in DMSO to 0.25 mM solution each with acetonitrile/water (70/30).

2. Buffer: 100 mM potassium phosphate Buffer (PBS) at pH 7.4

3. Liver microsomes (20 mg/ml): Thaw in 37 °C water bath quickly

4. 2000 μL of NADPH regenerating system (1.3 mM). Place this system on ice before use:

330 μl	100mM G6P
1300 μl	10mM NADP
5 μl	1200 U/ml G6PD
365 μl	PBS buffer

5. Quench solution: acetonitrile with IS for LC-MS/MS analysis

b) Dilute the 20 mg/mL stock liver microsomes to 0.628 mg/mL of protein with 100 mM PBS.

c) Aliquot 398 µL of microsomes protein mixture (0.628 mg/mL) into the incubation plate and place the plate on ice.

d) Spike 2µL of a substrate stock solution into the incubation wells filled with 398 µL of the protein mixture in order to obtain a test compound concentration of 1.25 µM in each well.

e) Pipette 80 µL of the test compound and microsomes protein mixture into the wells of a stop plate pre-filled with 300 µL of cold quench solution and 20 µL of NADPH regenerating system. The test compound concentration in the wells, measured by LC-MS/MS, represents the concentration at time = 0.

f) To determine the test compound concentration when $t \neq 0$, pre-incubate the NADPH regenerating system and the incubation plate containing the remaining 320 µL of incubation mixture (microsomes protein and test compound) for 5 minutes at 37 °C.

g) Start the incubation reaction by adding 80 µL NADPH regenerating system to each well containing the remaining 320 µL incubation mixture.

h) After 10 min., 30 min., and 90 min. of incubation at 37 °C, transfer 100 µL of the incubation mixture (microsomes protein, test compound, and NADPH) into the wells of a stop plate pre-filled with 300 µL of the cold quench solution. Shake well.

i) Centrifuge the stop plate at 5000×g for 10 minutes. Collect and dilute the supernatant 3 times with distilled water. Sample and analyze the test compound concentration for all the wells by LC-MS/MS.

Animal PK Studies via i.v. (intravenous), p.o. (orally) and s.c. (subcutaneous) administrations

All treated animals received a single dose of a test compound (either through i.v., p.o., or s.c. administration) according to the regimen shown in the following table:

Route of	Number	Dose	Dose

Dose	of Animals	Level (mg/kg)	volume (mL/kg)
i.v., s.c.	3 male	5	5
p.o.	3 male	10	10







For oral dose groups, appropriate amount of test compound was prepared in the following formulation carrier: 1% DMSO (increase to 5% maximum if necessary) and 0.5% Methycellulose. Each mouse or rat received by oral gavage 10 mL/kg of the formulation mixture.

For i.v. and s.c dose groups, appropriate amount of test compound was dissolved in 1% DMSO (increase to 5% maximum if necessary), 99% of 20% HP-β-Cyclodextron (w/v). The pH wasadjusted accordingly. Each mouse or rat received 5mL/kg of the formulation mixture. i.v. dose was administered by tail vein injection. Subcutaneous injection was administered over the shoulders, into the loose skin over the neck. At designated time points (e.g., i.v. and s.c.: 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hrs; p.o.: 0.25, 0.5, 1, 2, 4, 8 and 24 hrs), systemic samples of blood (50μL in mouse or 500 μL in rat) were collected by puncture (submandibular vein in mouse or jugular vein in rat) into vacutainers containing EDTA-K2 as anti-coagulant. The blood was centrifuged at 6000 rpm for 8 min at 4 °C to obtain plasma. All plasma samples were stored at -20 °C. All plasma samples were added to acetonitrile for protein precipitation and quantitatively analyzed by LC-MS/MS.









Food Intake Study - Evaluation of GHSR1a inverse agonists on Food Intake Test in Mouse:










Twelve male C57BL/6J mice, weighing 18-22 g each, were fasted overnight (16 h before compound administration) and placed in a regular light dark cycle (6:00-18:00 light/18:00-6:00 dark). After 1 week acclimation, animals were sorted into two groups (n=6 each, 2 per cage) based on body weight. Animals in group one were treated with carrier minus the test compound (control group) and animals in group 2 were treated with carrier with the test compound (experimental group). The cumulative food intake was evaluated at 1, 2, 4, 8 and 24 hrs after experimental or control treatment. Food intake was measured by subtracting uneaten food from the initial premeasured food.










TABLE 1









Compound No.	Chemical Structure	Activity (μM)	Metabolic Stability Study (H = human; M = mouse; R = rat; D = dog) [μL/min/mg]	PK[1] CL (L/h/kg) Vd (L/Kg) $t_{1/2}$ (h) F (%)	Food Intake Study
H0906		IC_{50} = 0.0189 EC_{50}/E_{Max} = 30 EC_{50} = 0.0068 PPB = 99.84(H) PPB = 99.96(M)	H = 19.9 M = 24.4 R = 13.6 D = 4904	CL_{iv} = 0.18 CL_{po} = 239.47 Vd_{iv} = 0.27 Vd_{po} = 479.77 $t_{1/2\ iv}$ = 1.03 $t_{1/2po}$ = 1.39 F = 0.1	Not performed
H0907		IC_{50} = 0.0235 EC_{50}/E_{Max} = 30 EC_{50} = 1.61	Not performed	Not performed	Not performed
H0937		IC_{50} = 0.084 EC_{50}/E_{Max} = 30 EC_{50} = 0.0127	H = <10 M = <10 R = <10 D = <10	Not performed	Not performed
H0941		IC_{50} = 0.0077 EC_{50}/E_{Max} = 30 EC_{50} = 0.0028 PPB = 99.98(H) PPB = 99.95(M)	H = 47.7 M = 66.2 R = 36.2 D = 48.2	Not performed	Not performed
H0942		IC_{50} = 2.04 EC_{50}/E_{Max} = 30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0943		IC_{50} = 0.0078 EC_{50}/E_{Max} = 30 EC_{50} = 0.0025	H = 10.6 M = <10 R = 11.7 D = <10	Not performed	Not performed







[1] Unless indicated otherwise, the PK values reported in this table are the PK's for mouse. If indicated, (R) = rat; (M) = mouse; and (D) = dog.










H0944		IC_{50} = 30 EC_{50}/E_{Max} = 30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0950		IC_{50} = 20.8 EC_{50}/E_{Max} = 30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0951		IC_{50} = 0.0838 EC_{50}/E_{Max} = >30 EC_{50} = 0.0327	Not performed	Not performed	Not performed
H0953		IC_{50} = >30 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0954		IC_{50} = >30 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0963		IC_{50} = >30 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0964		IC_{50} = 4.17 EC_{50}/E_{Max} = 13.05/1346 EC_{50} = 2.477	Not performed	Not performed	Not performed
H0965		IC_{50} = >30 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed










H0966		IC_{50} = 6.58 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0967		IC_{50} = 0.016 EC_{50}/E_{Max} = >30 EC_{50} = 0.0047	H = 38.2 M = 58 R = not reported D = not reported	CL_{iv} = 2.34 CL_{po} = 697.4 Vd_{iv} = 8.62 Vd_{po} = 2326.2 $t_{1/2iv}$ = 2.56 $t_{1/2po}$ = 2.31 F = 0.2	30mg/kg po fasted – inh 5mg/kg sc fasted - inh
H0968		IC_{50} = 0.044 EC_{50}/E_{Max} >30 EC_{50} = 0.0057	H = 32.5 M = 27.4 R = not reported D = not reported	Not performed	30mg/kg po fasted - inh
H0969		IC_{50} = 0.053 EC_{50}/E_{Max} >30 EC_{50} = 0.0189	H = 19.5 M = 74.4 R = not reported D = not reported	CL_{iv} = 0.46 CL_{po} = 27.01 Vd_{iv} = 1.97 Vd_{po} = 168.2 $t_{1/2iv}$ = 2.96 $t_{1/2po}$ = 4.32 F = 1.3	30mg/kg po fasted = inh
H0971		IC_{50} = 0.417 EC_{50}/E_{Max} >30 EC_{50} = 0.135	H = 31.9 M = 24.8 R = not reported D = not reported	Not performed	Not performed
H0975		IC_{50} = 0.0095 EC_{50}/E_{Max} = 30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0981		IC_{50} = 0.0095 EC_{50}/E_{Max} = 30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0990		IC_{50} = 0.823 EC_{50}/E_{Max} = 30 EC_{50} = not reported	Not performed	Not performed	Not performed
H0991		IC_{50} = 0.1455 EC_{50}/E_{Max} = 30 EC_{50} = 0.06677	Not performed	Not performed	Not performed







H0993		IC_{50} = 0.2878 EC_{50}/E_{Max} = 30 EC_{50} = 0.021	H = 18.5 M = 14.3 R = 15.1 D <10	CL_{iv} = 2.15 CL_{po} = 438.1 Vd_{iv} = 4.31 Vd_{po} = 2550 $t_{1/2iv}$ = 1.39 $t_{1/2po}$ = 4.03 F = 0.4	Not performed
H0994		IC_{50} = 30 EC_{50}/E_{Max} = 30 EC_{50} = 1.434	Not performed	Not performed	Not performed
H0995		IC_{50} = 0.0321 EC_{50}/E_{Max} = 30 EC_{50} = 0.00252	H = 54.5 M = 194.6 R = 92.4 D = 52.7	Not performed	Not performed
H0996		IC_{50} = 0.461 EC_{50}/E_{Max} = 30 EC_{50} = 0.064	H = 27.5 M = 125.4 R = 77.8 D = <10	Not performed	Not performed
H0997		IC_{50} = 30 EC_{50}/E_{Max} = 30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1003		IC_{50} = 2.02 EC_{50}/E_{Max} = 14.36/2228 EC_{50} = not reported	Not performed	Not performed	Not performed
H1004		IC_{50} = 0.0037 EC_{50}/E_{Max} = >30 EC_{50} = 0.00397	Not performed	CL_{iv} = 35.5 CL_{po} = 223.9 Vd_{iv} = 37.7 Vd_{po} = 479.2 $t_{1/2iv}$ = 0.74 $t_{1/2po}$ = 1.48 F = 13	Not performed
H1005		IC_{50} = 0.0198 EC_{50}/E_{Max} = >30 EC_{50} = 0.00888	Not performed	CL_{iv} = 0.44 CL_{po} = 33.33 Vd_{iv} = 1.46 Vd_{po} = 112.3 $t_{1/2iv}$ = 2.3 $t_{1/2po}$ = 2.33 F = 1.3	Not performed
H1006		IC_{50} = 0.072 EC_{50}/E_{Max} = >30 EC_{50} = 0.0369	Not performed	Not performed	Not performed









H1008		IC_{50} = 6.38 EC_{50}/E_{Max} = 12.68/2021 EC_{50} = not reported	Not performed	Not performed	Not performed
H1009		IC_{50} = 0.252 EC_{50}/E_{Max} = 30 EC_{50} = 0.0328	H = 13.2 M = 33.8 R = not reported D = not reported	Not performed	Not performed
H1010		IC_{50} = 0.042 EC_{50}/E_{Max} = 30 EC_{50} = 0.015	H = 40.5 M = 40.5 R = not reported D = not reported	CL_{iv} = 3.34 CL_{po} = 108.2 Vd_{iv} = 1.39 Vd_{po} = 169 $t_{1/2iv}$ = 1.39 $t_{1/2po}$ = 1.08 F = 3.09	Not performed
H1017		IC_{50} = 0.072 EC_{50}/E_{Max} = 30 EC_{50} = 0.0098 PPB(H) = 99.9 PPB(M) = 99.97	H = 11.5 M = 30.5 R = not reported D = not reported	Not performed	Not performed
H1018		IC_{50} = 0.0998 EC_{50}/E_{Max} = 30 EC_{50} = 0.01367	H = <10 M = 46.3 R = not reported D = not reported	Not performed	Not performed
H1024		IC_{50} = 0.0347 EC_{50}/E_{Max} = >30 EC_{50} = 0.0257	H = <10 M = <10 R = not reported D = not reported	CL_{iv} = 11.17 CL_{po} = 132.3 Vd_{iv} = 16.35 Vd_{po} = 349.6 $t_{1/2iv}$ = 1.01 $t_{1/2po}$ = 1.83 F = 7.91	Not performed
H1025		IC_{50} = 21.45 EC_{50}/E_{Max} = >30 EC_{50} = not reported	H = 92.4 M = 159.5 R = not reported D = not reported	CL_{iv} = 1.84 CL_{po} = 30.89 Vd_{iv} = 2.86 Vd_{po} = 94.83 $t_{1/2iv}$ = 1.08 $t_{1/2po}$ = 1.45 F = 5.92	Not performed
H1026		IC_{50} = 14.9 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed










H1027		IC_{50} = 0.0025 EC_{50}/E_{Max} = >30 EC_{50} = 0.001616	H = <10 M = <10 R = not reported D = not reported	CL_{iv} = 0.71(M); 12.34(R) CL_{po} = 85.67(M); 24.98(R) Vd_{iv} = 1.64(M); 168.2(R) Vd_{po} = 345(M); 80.4(R) $t_{1/2iv}$ = 1.61(M); 10.2(R) $t_{1/2po}$ = 2.79(M); 2.21(R) F = 0.72(M); 57.14(R)	Not performed
H1028		IC_{50} = 0.414 EC_{50}/E_{Max} = >30 EC_{50} = 0.2335	Not performed	Not performed	Not performed
H1029		IC_{50} = 0.3323 EC_{50}/E_{Max} = >30 EC_{50} = 0.1878	Not performed	Not performed	Not performed
H1033		IC_{50} = 3.02 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1034		IC_{50} = 1.258 EC_{50}/E_{Max} = >30 EC_{50} = 1.606	Not performed	Not performed	Not performed
H1038		IC_{50} = 0.3761 EC_{50}/E_{Max} = >30 EC_{50} = 0.1234	Not performed	Not performed	Not performed










H1039		IC_{50} = 0.1129 EC_{50}/E_{Max} = >30 EC_{50} = 0.0333	H = <10 M = 13.5 R = not reported D = not reported	CL_{iv} = 2.55 CL_{po} = 334.4 Vd_{iv} = 11.7 Vd_{po} = 898 $t_{1/2iv}$ = 3.18 $t_{1/2po}$ = 1.86 F = 0.6	Not performed
H1040		IC_{50} = 0.0318 EC_{50}/E_{Max} = >30 EC_{50} = 0.1639	Not performed	Not performed	Not performed
H1041		IC_{50} = 0.0174 EC_{50}/E_{Max} = >30 EC_{50} = 0.0555	Not performed	Not performed	Not performed
H1042		IC_{50} = 0.0366 EC_{50}/E_{Max} = >30 EC_{50} = 0.1222	Not performed	Not performed	Not performed
H1043		IC_{50} = 0.0041 EC_{50}/E_{Max} = >30 EC_{50} = 0.0184	Not performed	Not performed	Not performed
H1044		IC_{50} = 0.0531 EC_{50}/E_{Max} = >30 EC_{50} = 0.1434	Not performed	Not performed	Not performed
H1045		IC_{50} = 2.743 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1046		IC_{50} = 1.993 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1047		IC_{50} = 0.865 EC_{50}/E_{Max} = >30 EC_{50} = 1.165	Not performed	Not performed	Not performed











H1048		IC_{50} = 16.765 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1049		IC_{50} = 0.0163 EC_{50}/E_{Max} = >30 EC_{50} = 0.0296	Not performed	Not performed	Not performed
H1050		IC_{50} = 0.0574 EC_{50}/E_{Max} = >30 EC_{50} = 0.1086	Not performed	Not performed	Not performed
H1051		IC_{50} = 0.0537 EC_{50}/E_{Max} = >30 EC_{50} = 0.116	Not performed	Not performed	Not performed
H1052		IC_{50} = 0.4675 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1054		IC_{50} = 10.09 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	CL_{iv} = 1.62 CL_{po} = 53.9 Vd_{iv} = 4.32 Vd_{po} = 96.2 $t_{1/2iv}$ = 1.85 $t_{1/2po}$ = 1.24 F = 3.0	Not performed
H1055		IC_{50} = 4.47 EC_{50}/E_{Max} = >30 EC_{50} = 0.516	Not performed	Not performed	Not performed
H1056		IC_{50} = 0.0058 EC_{50}/E_{Max} = >30 EC_{50} = 0.0026	H = 16.4 M = 13.5 R = not reported D = not reported	Not performed	Not performed
H1057		IC_{50} = 0.0193 EC_{50}/E_{Max} = >30 EC_{50} = 0.0069 PPB =	H = 12.6 M = 10.8 R = not reported D = not reported	CL_{iv} = 1.57 CL_{po} = 82.24 Vd_{iv} = 2.18 Vd_{po} = 368.9 $t_{1/2iv}$ = 0.96 $t_{1/2po}$ = 3.11 F = 1.6	Not performed










		99.5(H) PPB = 99.5(M)			
H1058		IC_{50} = 20 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1059		IC_{50} = >30 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1060		IC_{50} = 0.28 EC_{50}/E_{Max} = >30 EC_{50} = 0.0408 PPB = 99.87(H) PPB = 99.81(M) PPB = 99.82(R) PPB = 99.88(D)	H = 40 M = 108.7 R = not reported D = not reported	CL_{iv} = 4.13 CL_{po} = 22.1 Vd_{iv} = 8.25 Vd_{po} = 22.4 $t_{1/2iv}$ = 1.37 $t_{1/2po}$ = 0.7 F = 18.8	Not performed
H1061		IC_{50} = 2.87 EC_{50}/E_{Max} = >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1062		IC_{50} = 0.2225 EC_{50}/E_{Max} = >30 EC_{50} = 0.058 PPB = 99.88(H) PPB = 99.81(M) PPB = 99.88(R) PPB = 99.83(D)	H = 32.4 M = 67.2 R = not reported D = not reported	Not performed	Not performed
H1067		IC_{50} = 0.014 EC_{50}/E_{Max} = >30 EC_{50} = 0.0045	H = 326.2 M = 289 R = not reported D = not reported	Not performed	Not performed






H1068		IC_{50} = 0.0263 EC_{50}/E_{Max} = >30 EC_{50} = 0.0084	H = 199.7 M = 196.4 R = not reported D = not reported	Not performed	Not performed
H1070		IC_{50} = 5.29 EC_{50}/E_{Max} = 7.27 EC_{50} = not reported	Not performed	Not performed	Not performed
H1071		IC_{50} = 0.005 EC_{50}/E_{Max} = >30 EC_{50} = 0.0017 PPB = 99.11(H) PPB = 99.02(M) PPB = 99.13(R) PPB = 99.18(D)	H = 49.9/100.3 M = 80.7/152.5 R = 274/188 D = 172.6/160.7	CL_{iv} = 1.71 CL_{po} = 8.28 Vd_{iv} = 2.83 Vd_{po} = 21.1 $t_{1/2iv}$ = 1.15 $t_{1/2po}$ = 1.77 F = 19.9	Not performed
H1072		IC_{50} = 0.1225 EC_{50}/E_{Max} = >30 EC_{50} = 0.0219	Not performed	Not performed	Not performed
H1073		IC_{50} = >30 EC_{50}/E_{Max} = 7.27 EC_{50} = not reported	Not performed	Not performed	Not performed
H1074		IC_{50} = 3.25 EC_{50}/E_{Max} = >30 EC_{50} = 0.6568	Not performed	Not performed	Not performed
H1075		IC_{50} = 3.018 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1076		IC_{50} = 0.515 EC_{50}/E_{Max} = >30 EC_{50} = 0.0577	H = 91.4 M = 73.9 R = not reported D = not reported	Not performed	Not performed









H1078		IC_{50} = 3.576 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1080		IC_{50} = 0.0226 EC_{50}/E_{Max} >30 EC_{50} = 0.0111/0.0412 hERG inh = 3.57	H <10 M <10 R = not reported D = not reported	Not performed	Not performed
H1081		IC_{50} = 1.238 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1082		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1083		IC_{50} = 30 EC_{50}/E_{Max} >30 EC_{50} = 1.18	Not performed	Not performed	Not performed
H1084		IC_{50} = 3.5 EC_{50}/E_{Max} = 10.8 EC_{50} = not reported	Not performed	Not performed	Not performed
H1087		IC_{50} = 8.18 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1088		IC_{50} = 7.97 EC_{50}/E_{Max} >30 EC_{50} = 0.367	Not performed	Not performed	Not performed
H1092		IC_{50} = 30 EC_{50}/E_{Max} >30 EC_{50} = 0.578	Not performed	Not performed	Not performed








H1093		IC_{50} = 2.382 EC_{50}/E_{Max} >30 EC_{50} = 0.327	Not performed	Not performed	Not performed
H1094		IC_{50} = 0.488 EC_{50}/E_{Max} >30 EC_{50} = 0.118	H = 55.1 M = 100.8 R = not reported D = not reported	Not performed	Not performed
H1095		IC_{50} = 1.43 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1096		IC_{50} = 30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1097		IC_{50} = 1.969 EC_{50}/E_{Max} >30 EC_{50} = 0.363	Not performed	Not performed	Not performed
H1098		IC_{50} = 12.06 EC_{50}/E_{Max} >30 EC_{50} = 0.649	Not performed	Not performed	Not performed
H1099		IC_{50} = 8.673 EC_{50}/E_{Max} >30 EC_{50} = 1.139	Not performed	Not performed	Not performed
H1101		IC_{50} = 30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1102		IC_{50} = 0.0739 EC_{50}/E_{Max} >30 EC_{50} = 0.0583/0.036/0.0216	Not performed	Not performed	Not performed








H1103		IC_{50} = 0.487 EC_{50}/E_{Max} >30 EC_{50} = 0.066/0.055 72	Not performed	Not performed	Not performed
H1106		IC_{50} = 1.426 EC_{50}/E_{Max} >30 EC_{50} = 0.862	Not performed	Not performed	Not performed
H1108		IC_{50} = 0.422 EC_{50}/E_{Max} >30 EC_{50} = 0.1166	H = 38.7 M = 47.5 R = not reported D = not reported	Not performed	Not performed
H1109		IC_{50} = 0.427 EC_{50}/E_{Max} >30 EC_{50} = 0.136	Not performed	Not performed	Not performed
H1110		IC_{50} = 0.95 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1111		IC_{50} = 2.251 EC_{50}/E_{Max} >30 EC_{50} = 1.233	Not performed	Not performed	Not performed
H1125		IC_{50} = 0.893 EC_{50}/E_{Max} >30 EC_{50} = 0.0933	H = 10.7 M = 14.9 R = not reported D = not reported	Not performed	Not performed
H1126		IC_{50} = 0.183 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1127		IC_{50} = 0.861 EC_{50}/E_{Max} >30 EC_{50} = 0.0947	H = 41 M = 59.5 R = not reported D = not reported	Not performed	Not performed
H1129		IC_{50} = 3.33 EC_{50}/E_{Max} >30 EC_{50} = 2.461	Not performed	Not performed	Not performed









H1130		IC_{50} = 3.38 EC_{50}/E_{Max} >30 EC_{50} = 1.28	Not performed	Not performed	Not performed
H1131		IC_{50} = 30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1132		IC_{50} = 0.574 EC_{50}/E_{Max} >30 EC_{50} = 0.219	Not performed	Not performed	Not performed
H1133		IC_{50} = 0.419 EC_{50}/E_{Max} >30 EC_{50} = 0.17	Not performed	Not performed	Not performed
H1140		IC_{50} = 30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1141		IC_{50} = 2.61 EC_{50}/E_{Max} >30 EC_{50} = 0.562	Not performed	Not performed	Not performed
H1142		IC_{50} = 30 EC_{50}/E_{Max} >30 EC_{50} = 0.44	H = 114.9 M = 151.4 R = 209.6 D = not reported	Not performed	Not performed
H1145		IC_{50} = 30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1148		IC_{50} = 0.01 EC_{50}/E_{Max} >30 EC_{50} = 0.0029 & 0.00313 PPB = 91.2(H) PPB = 94.5(R)	H = 22.2 M = 21.1 R = not reported D = not reported	CL_{iv} = 1.23/61.9(M); 145.3(R); 0.7(D) CL_{po} = 96.7/164.5(M); 4.82(D) Vd_{iv} = 2.43/190.5(M);	Not performed









		PPB = 92.3(M) hERG inh = 12.52		104.5(R); 2.35(D) Vd_{po} = 176.8/617.4(M); 14.74(D) $t_{1/2iv}$ = 1.37/2.13(M); 0.51(R); 2.32(D) $t_{1/2po}$ = 1.27/2.6(M); 2.34(D) F = 1.3/36.23(M); 15.7(D)	
H1149		IC_{50} = 0.0048 EC_{50}/E_{Max} >30 EC_{50} = 0.00169 & 0.00241	H = 21.1 M = 24.3 R = not reported D = not reported	CL_{iv} = 0.98 CL_{po} = 107.5 Vd_{iv} = 1.22 Vd_{po} = 272 $t_{1/2iv}$ = 0.87 $t_{1/2po}$ = 1.75 F = 0.86	Not performed
H1154		IC_{50} = 0.12648 EC_{50}/E_{Max} >30 EC_{50} = 0.0298 & 0.02677	H = 19.2 M = 22.9 R = not reported D = not reported	Not performed	Not performed
H1155		IC_{50} = 0.0043 EC_{50}/E_{Max} >30 EC_{50} = 0.00503 (partial)	Not performed	Not performed	Not performed
H1156		IC_{50} = 0.0103 EC_{50}/E_{Max} >30 EC_{50} = 0.00426	H = 18.1 M = 12.9 R = not reported D = not reported	Not performed	Not performed
H1166		IC_{50} = 0.009 EC_{50}/E_{Max} >30 EC_{50} = 0.0071	H = 19.9 M = 14.5 R = not reported D = not reported	Not performed	Not performed








H1178		IC_{50} = 4.89 EC_{50}/E_{Max} >30 EC_{50} = 1.017	Not performed	Not performed	Not performed
H1179		IC_{50} = 0.143 EC_{50}/E_{Max} >30 EC_{50} = 0.03743	H = 14.9 M <10 R = not reported D = not reported	Not performed	Not performed
H1180		IC_{50} = 14.66 EC_{50}/E_{Max} >30 EC_{50} = 0.315	Not performed	Not performed	Not performed
H1181		IC_{50} = 3.31 EC_{50}/E_{Max} >30 EC_{50} = 0.957	Not performed	Not performed	Not performed
H1188		IC_{50} = 0.539 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1190		IC_{50} = 0.264 EC_{50}/E_{Max} >30 EC_{50} = 0.317	Not performed	Not performed	Not performed
H1193		IC_{50} = 0.324 EC_{50}/E_{Max} >30 EC_{50} = 0.064	H = 49.8 M = 43.7 R = not reported D = not reported	Not performed	Not performed
H1194		IC_{50} = 0.0383 EC_{50}/E_{Max} >30 EC_{50} = 0.0168 PPB = 92.4(H) PPB = 94(M) hERG inh = 22.6	H = 111.6 M = 64.2 R = 56 D = 14	CL_{iv} = 3.61(M); 5.68(R); 1.00(D) CL_{po} = 22.8(M); 50.9(R); 1.84(D) Vd_{iv} = 6.33(M); 8.86(R); 2.11(D) Vd_{po} = 53.3(M); 232.2(R); 4.05(D) $t_{1/2iv}$ =	Not performed








				1.21(M); 1.08(R); 1.44(D) $t_{1/2po}$ = 1.62(M); 4.54(R); 1.5(D) F = 15.56(M); 11.9(R); 54.07(D)	
H1199		IC_{50} = 0.0757 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1203		IC_{50} = 0.447 EC_{50}/E_{Max} >30 EC_{50} = 0.161	Not performed	Not performed	Not performed
H1204		IC_{50} = 0.692 EC_{50}/E_{Max} >30 EC_{50} = 0.624	Not performed	Not performed	Not performed
H1205		IC_{50} = 9.87 EC_{50}/E_{Max} >30 EC_{50} = 5.335	Not performed	Not performed	Not performed
H1206		IC_{50} = 0.262 EC_{50}/E_{Max} >30 EC_{50} = 0.252	Not performed	Not performed	Not performed
H1208		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1212		IC_{50} = 3.099 EC_{50}/E_{Max} >30 EC_{50} = 1.775	Not performed	Not performed	Not performed








H1213		IC_{50} = 4.35 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1214		IC_{50} = 0.278 EC_{50}/E_{Max} >30 EC_{50} = 0.147	H = 16.6 M = 21.4 R = 18 D <10	Not performed	Not performed
H1215		IC_{50} = 0.0124 EC_{50}/E_{Max} >30 EC_{50} = 0.0046 PPB = 90.3(H) PPB = 90.7(M) PPB = 93.5(R)	H = 21 M = 13.7 R = 18.5 D = 16.6	Not performed	Not performed
H1216		IC_{50} = 8.447 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1217		IC_{50} = 1.4475 EC_{50}/E_{Max} >30 EC_{50} = 1.147	Not performed	Not performed	Not performed
H1219		IC_{50} = 0.00777 EC_{50}/E_{Max} >30 EC_{50} = 0.163	H >500 M >500 R = not reported D = not reported	Not performed	Not performed
H1220		IC_{50} = 0.00361 EC_{50}/E_{Max} >30 EC_{50} = 0.0304	H = 183.8 M = 248 R = not reported D = not reported	CL_{iv} = 3.05 CL_{po} = 61.6 Vd_{iv} = 3.08 Vd_{po} = 78.7 $t_{1/2iv}$ = 0.7 $t_{1/2po}$ = 0.89 F = 4.71	Not performed










H1221		IC_{50} = 0.0081 EC_{50}/E_{Max} >30 EC_{50} = 0.0387	H = 111.2 M = 107.7 R = not reported D = not reported	Not performed	Not performed
H1222		IC_{50} = 3.16 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1225		IC_{50} = 5.9 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1227		IC_{50} = 0.0384 EC_{50}/E_{Max} >30 EC_{50} = 0.175	H = 99.4 M = 79.9 R = not reported D = not reported	Not performed	Not performed
H1228		IC_{50} = 0.766 EC_{50}/E_{Max} >30 EC_{50} = 1.263	Not performed	Not performed	Not performed
H1229		IC_{50} = 0.291 EC_{50}/E_{Max} >30 EC_{50} = 0.369	Not performed	Not performed	Not performed
H1230		IC_{50} = 6.4 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1231		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed









H1232		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = 0.3095	Not performed	Not performed	Not performed
H1233		IC_{50} = 0.2246 EC_{50}/E_{Max} >30 EC_{50} = 0.1702	Not performed	Not performed	Not performed
H1234		IC_{50} = 0.0426 EC_{50}/E_{Max} >30 EC_{50} = 0.0154	H = 149.8 M = 122.7 R = not reported D = not reported	Not performed	Not performed
H1235		IC_{50} = 0.032 EC_{50}/E_{Max} >30 EC_{50} = 0.0061	H = 102.4 M = 87.1 R = not reported D = not reported	Not performed	Not performed
H1236		IC_{50} = 1.641 EC_{50}/E_{Max} >30 EC_{50} = 0.5066	Not performed	Not performed	Not performed
H1237		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1238		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1239		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed










H1244		IC_{50} = 1.285 EC_{50}/E_{Max} >30 EC_{50} = 0.356	Not performed	Not performed	Not performed
H1248		IC_{50} = 0.283 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1249		IC_{50} = 3.29 EC_{50}/E_{Max} >30 EC_{50} = 1.63	Not performed	Not performed	Not performed
H1250		IC_{50} = 1.373 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1251		IC_{50} = 0.0896 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1252		IC_{50} = 0.44 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1253		IC_{50} = 0.0868 EC_{50}/E_{Max} = 0.036/1485 EC_{50} = not reported	Not performed	Not performed	Not performed










H1254		IC_{50} = 0.0172 EC_{50}/E_{Max} = 0.01754/3141 EC_{50} = not reported	Not performed	Not performed	Not performed
H1255		IC_{50} = 2.33 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1256		IC_{50} = 0.09 EC_{50}/E_{Max} >30 EC_{50} = 0.1237	H = 268.4 M = 272.6	Not performed	Not performed
H1259		IC_{50} = 0.272 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1260		IC_{50} = 0.0037 EC_{50}/E_{Max} >30 EC_{50} = 0.0044	H = 38.9 M = 24.7	Not performed	Not performed
H1261		IC_{50} = 0.00157 EC_{50}/E_{Max} >30 EC_{50} = 0.0022 PPB = 95.5(H) PPB = 98.1(M)	H = 48.8 M = 23	Not performed	Not performed
H1262		IC_{50} = 0.0106 EC_{50}/E_{Max} >30 EC_{50} = 0.0075 PPB = 90.1(H)	H = 18.2 M = 11.2 R = not reported D = not reported	CL_{iv} = 1.31 CL_{po} = 110.8 Vd_{iv} = 1.69 Vd_{po} = 307 $t_{1/2iv}$ = 0.89 $t_{1/2po}$ = 1.92 F = 1.13	Not performed










		PPB = 95.0(M)			
H1263		IC_{50} = 0.246 EC_{50}/E_{Max} = 0.329/1540 EC_{50} = not reported	Not performed	Not performed	Not performed
H1264		IC_{50} = 0.0044 EC_{50}/E_{Max} =0.0047/4728 EC_{50} = not reported PPB = 77.9(H) PPB = 81.5(M)	H <10 M <10 R = not reported D = not reported	CL_{iv} = 2.89 CL_{po} = 682.6 Vd_{iv} = 4.83 Vd_{po} = 627.9 $t_{1/2iv}$ = 1.16 $t_{1/2po}$ = 0.64 F = 0.36	Not performed
H1266		IC_{50} = 0.0242 EC_{50}/E_{Max} >30 EC_{50} = 0.0191	H = 169.4 M = 106.1 R = not reported D = not reported	Not performed	Not performed
H1267		IC_{50} = 0.0092 EC_{50}/E_{Max} >30 EC_{50} = 0.0047	H = 109.8 M = 147.8 R = not reported D = not reported	Not performed	Not performed
H1268		IC_{50} = 0.0832 EC_{50}/E_{Max} >30 EC_{50} = 0.0299	H = 108.7 M = 60.5 R = not reported D = not reported	Not performed	Not performed
H1269		IC_{50} = 0.024 EC_{50}/E_{Max} >30 EC_{50} = 0.0088	H = 25.7 M = 23.6 R = not reported D = not reported	Not performed	Not performed
H1270		IC_{50} = 0.0251 EC_{50}/E_{Max} = 0.0341/5442 EC_{50} = not reported	Not performed	Not performed	Not performed










H1271		IC_{50} = 0.005 EC_{50}/E_{Max} = 0.0096/5006 EC_{50} = not reported	H <10 M <10 R = not reported D = not reported	Not performed	Not performed
H1272		IC_{50} = 0.0235 EC_{50}/E_{Max} >30 EC_{50} = 0.0053	H = 18.4 M = 18.6 R = not reported D = not reported	Not performed	Not performed
H1273		IC_{50} = 1.03 EC_{50}/E_{Max} >30 EC_{50} = 0.192	Not performed	Not performed	Not performed
H1274		IC_{50} = 1.582 EC_{50}/E_{Max} >30 EC_{50} = 0.685	Not performed	Not performed	Not performed
H1275		IC_{50} = 1.02 EC_{50}/E_{Max} >30 EC_{50} = 0.31	Not performed	Not performed	Not performed
H1276		IC_{50} = 0.076 EC_{50}/E_{Max} >30 EC_{50} = 0.0234	H = 109.7 M = 247 R = not reported D = not reported	Not performed	Not performed
H1277		IC_{50} = 8.76 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1280		IC_{50} = 0.905 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1281		IC_{50} = 0.039 EC_{50}/E_{Max} >30 EC_{50} = 0.0153	H = 63.8 M = 47.8 R = not reported D = not reported	Not performed	Not performed









H1283		IC_{50} = 0.379 EC_{50}/E_{Max} >30 EC_{50} = 0.201	Not performed	Not performed	Not performed
H1284		IC_{50} = 1.896 EC_{50}/E_{Max} >30 EC_{50} = 0.371	Not performed	Not performed	Not performed
H1285		IC_{50} = 0.065 EC_{50}/E_{Max} = 0.147 EC_{50} = not reported	Not performed	Not performed	Not performed
H1286		IC_{50} = 0.0395 EC_{50}/E_{Max} >30 EC_{50} = 0.0243	H = 251.8 M = 162.4 R = not reported D = not reported	Not performed	Not performed
H1289		IC_{50} = 0.542 EC_{50}/E_{Max} = 0.147 EC_{50} = 0.161	Not performed	Not performed	Not performed
H1290		IC_{50} = 3.41 EC_{50}/E_{Max} >30 EC_{50} = 0.722	Not performed	Not performed	Not performed
H1291		IC_{50} = 1.2 EC_{50}/E_{Max} >30 EC_{50} = 0.468	Not performed	Not performed	Not performed
H1292		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed









H1293		IC_{50} = 5.68 EC_{50}/E_{Max} >30 EC_{50} = 0.93	Not performed	Not performed	Not performed
H1294		IC_{50} = 3.32 EC_{50}/E_{Max} = 12.87 EC_{50} = not reported	Not performed	Not performed	Not performed
H1296		IC_{50} >30 EC_{50}/E_{Max} = 13.24 EC_{50} = 4.92	Not performed	Not performed	Not performed
H1297		IC_{50} = 0.0231 EC_{50}/E_{Max} = 0.0158/4623 EC_{50} = not reported	Not performed	Not performed	Not performed
H1298		IC_{50} = 0.506 EC_{50}/E_{Max} >30 EC_{50} = 0.1152	Not performed	Not performed	Not performed
H1299		IC_{50} = 0.1925 EC_{50}/E_{Max} >30 EC_{50} = 0.102	H = 71.5 M = 50.9 R = not reported D = not reported	Not performed	Not performed
H1300		IC_{50} = 0.0083 EC_{50}/E_{Max} >30 EC_{50} = 0.0047	H = 124.3 M = 42.1 R = not reported D = not reported	Not performed	Not performed
H1301		IC_{50} = 4.45 EC_{50}/E_{Max} >30 EC_{50} = 1.14	Not performed	Not performed	Not performed
H1302		IC_{50} = 0.0057 EC_{50}/E_{Max} >30 EC_{50} = 0.0047	H = 201.7 M = 164.1 R = not reported D = not reported	Not performed	Not performed









H1303		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} >30	Not performed	Not performed	Not performed
H1304		IC_{50} = 0.145 EC_{50}/E_{Max} >30 EC_{50} = 0.1823	Not performed	Not performed	Not performed
H1305		IC_{50} = 0.298 EC_{50}/E_{Max} >30 EC_{50} = 0.282	Not performed	Not performed	Not performed
H1306		IC_{50} = 0.062 EC_{50}/E_{Max} >30 EC_{50} = 0.0746	H = 31.2 M = 19.6 R = not reported D = not reported	Not performed	Not performed
H1307		IC_{50} = 2.299 EC_{50}/E_{Max} >30 EC_{50} = 0.935	Not performed	Not performed	Not performed
H1308		IC_{50} = 0.0235 EC_{50}/E_{Max} >30 EC_{50} = 0.0312	H = 49.4 M = 38.5 R = not reported D = not reported	Not performed	Not performed
H1309		IC_{50} = 4.497 EC_{50}/E_{Max} >30 EC_{50} = 1.845	Not performed	Not performed	Not performed
H1310		IC_{50} = 0.262 EC_{50}/E_{Max} >30 EC_{50} = 0.184	Not performed	Not performed	Not performed
H1311		IC_{50} = 0.108 EC_{50}/E_{Max} >30 EC_{50} = 0.08464	H = 95.9 M = 123.8 R = not reported D = not reported	Not performed	Not performed









H1312		IC_{50} = 0.069 EC_{50}/E_{Max} >30 EC_{50} = 0.0858	H = 93.5 M = 117.5 R = not reported D = not reported	Not performed	Not performed
H1313		IC_{50} = 1.459 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1314		IC_{50} = 3.1 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1315		IC_{50} = 0.301 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1316		IC_{50} = 0.0309 EC_{50}/E_{Max} >30 EC_{50} = 0.0116	Not performed	Not performed	Not performed
H1317		IC_{50} = 0.0484 EC_{50}/E_{Max} >30 EC_{50} = 0.0182	H = 96.7 M = 102.8 R = not reported D = not reported	Not performed	Not performed
H1318		IC_{50} = 5.31 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1319		IC_{50} = 0.041 EC_{50}/E_{Max} >30 EC_{50} = 0.0125	H = 195.6 M >500 R = not reported D = not reported	Not performed	Not performed
H1320		IC_{50} = 0.0584 EC_{50}/E_{Max} >30 EC_{50} = 0.0433	Not performed	Not performed	Not performed









H1321		IC_{50} = 0.0475 EC_{50}/E_{Max} >30 EC_{50} = 0.0232	H = 85.3 M = 81.9 R = not reported D = not reported	Not performed	Not performed
H1322		IC_{50} = 0.1117 EC_{50}/E_{Max} >30 EC_{50} = 0.0815	H = 129 M = 171.1 R = not reported D = not reported	Not performed	Not performed
H1323		IC_{50} = 0.2432 EC_{50}/E_{Max} >30 EC_{50} = 0.102	H = 84.1 M = 58.5 R = not reported D = not reported	Not performed	Not performed
H1324		IC_{50} = 10.5 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1325		IC_{50} = 3.83 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1326		IC_{50} = 0.0098 EC_{50}/E_{Max} >30 EC_{50} = 0.0069	H = 129.5 M = 60.5 R = not reported D = not reported	Not performed	Not performed
H1327		IC_{50} = 0.0056 EC_{50}/E_{Max} >30 EC_{50} = 0.0055	H = 165.3 M = 144.8 R = not reported D = not reported	Not performed	Not performed
H1328		IC_{50} = 0.546 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1329		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed









H1330		IC_{50} = 0.147 EC_{50}/E_{Max} >30 EC_{50} = 0.142	Not performed	Not performed	Not performed
H1331		IC_{50} = 0.213 EC_{50}/E_{Max} >30 EC_{50} = 0.13	Not performed	Not performed	Not performed
H1332		IC_{50} = 0.0732 EC_{50}/E_{Max} >30 EC_{50} = 0.0421	Not performed	Not performed	Not performed
H1333		IC_{50} = 0.00224 EC_{50}/E_{Max} >30 EC_{50} = 0.0013 PPB = 99.89(H) PPB = 99.94(M) PPB = 99.9(R) PPB = 99.85(D)	H = 47.2 M = 54 R = not reported D = not reported	CL_{iv} = 1.78 CL_{po} = 84.3 Vd_{iv} = 3.26 Vd_{po} = 170 $t_{1/2iv}$ = 1.27 $t_{1/2po}$ = 1.4 F = 2.08	
H1334		IC_{50} = 0.00918 EC_{50}/E_{Max} >30 EC_{50} = 0.0082	H = 109.8 M = 97.9 R = not reported D = not reported	Not performed	Not performed
H1335		IC_{50} = 0.133 EC_{50}/E_{Max} >30 EC_{50} = 0.0699	Not performed	Not performed	Not performed
H1336		IC_{50} = 0.381 EC_{50}/E_{Max} >30 EC_{50} = 0.2626	Not performed	Not performed	Not performed
H1337		IC_{50} = 0.0241 EC_{50}/E_{Max} >30 EC_{50} = 0.0105	H = 58.6 M = 39.2 R = not reported D = not reported	Not performed	Not performed







H1338		IC_{50} = 0.0076 EC_{50}/E_{Max} >30 EC_{50} = 0.0065	H = 106.9 M = 242.1 R = not reported D = not reported	Not performed	Not performed
H1339		IC_{50} = 0.309 EC_{50}/E_{Max} >30 EC_{50} = 0.176	Not performed	Not performed	Not performed
H1340		IC_{50} = 0.0047 EC_{50}/E_{Max} >30 EC_{50} = 0.0033	H = 282.4 M >500 R = not reported D = not reported	Not performed	Not performed
H1341		IC_{50} = 0.0697 EC_{50}/E_{Max} >30 EC_{50} = 0.0209	Not performed	Not performed	Not performed
H1342		IC_{50} = 0.0174 EC_{50}/E_{Max} >30 EC_{50} = 0.0079	H = 80.1 M = 118.4 R = not reported D = not reported	Not performed	Not performed
H1343		IC_{50} = 0.0052 EC_{50}/E_{Max} >30 EC_{50} = 0.0021	H = 71.9 M = 252.4 R = not reported D = not reported	Not performed	Not performed
H1344		IC_{50} = 0.0044 EC_{50}/E_{Max} >30 EC_{50} = 0.0041	H = 53.5 M = 115.7 R = not reported D = not reported	Not performed	Not performed
H1345		IC_{50} = 0.0052 EC_{50}/E_{Max} >30 EC_{50} = 0.0042	H = 86.5 M = 166.2 R = not reported D = not reported	Not performed	Not performed







H1346		IC_{50} = 0.0191 EC_{50}/E_{Max} >30 EC_{50} = 0.00698	H = 72.9 M = 69.3 R = not reported D = not reported	Not performed	Not performed
H1347		IC_{50} = 0.0262 EC_{50}/E_{Max} >30 EC_{50} = 0.00795	H = 59.9 M = 58.1 R = not reported D = not reported	Not performed	Not performed
H1348		IC_{50} = 0.0650 EC_{50}/E_{Max} >30 EC_{50} = 0.0199	Not performed	Not performed	Not performed
H1349		IC_{50} = 0.0153 EC_{50}/E_{Max} >30 EC_{50} = 0.029	Not performed	Not performed	Not performed
H1350		IC_{50} = 18.2 EC_{50}/E_{Max} >30 EC_{50} = 7.46	Not performed	Not performed	Not performed
H1351		IC_{50} = 3.45 EC_{50}/E_{Max} >30 EC_{50} = 6.96	Not performed	Not performed	Not performed
H1352		IC_{50} = 0.0046 EC_{50}/E_{Max} >30 EC_{50} = 0.0077	Not performed	Not performed	Not performed
H1353		IC_{50} = 5.1 EC_{50}/E_{Max} >30 EC_{50} = 8.23	Not performed	Not performed	Not performed








H1354		IC_{50} = 8.899 EC_{50}/E_{Max} >30 EC_{50} = 8.61	Not performed	Not performed	Not performed
H1355		IC_{50} = 0.041 EC_{50}/E_{Max} >30 EC_{50} = 0.0129	H = 153.5 M = 304.3 R = not reported D = not reported	Not performed	Not performed
H1356		IC_{50} = 0.0739 EC_{50}/E_{Max} >30 EC_{50} = 0.029	H = 382.5 M = 126 R = not reported D = not reported	Not performed	Not performed
H1357		IC_{50} = 0.057 EC_{50}/E_{Max} >30 EC_{50} = 0.036	Not performed	Not performed	Not performed
H1358		IC_{50} = 1.876 EC_{50}/E_{Max} >30 EC_{50} = 1.821	Not performed	Not performed	Not performed
H1359		IC_{50} = 0.0015 EC_{50}/E_{Max} >30 EC_{50} = 0.004	H = 108.6 M = 108.6 R = not reported D = not reported	Not performed	Not performed
H1360		IC_{50} >30 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1361		IC_{50} = 1.614 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed










H1362		IC_{50} = 1.553 EC_{50}/E_{Max} >30 EC_{50} = not reported	Not performed	Not performed	Not performed
H1363		IC_{50} = 0.0084 EC_{50}/E_{Max} >30 EC_{50} = 0.00315	H = 140.1 M = 335.3 R = not reported D = not reported	Not performed	Not performed
H1364		IC_{50} = 0.0296 EC_{50}/E_{Max} >30 EC_{50} = 0.13	H <10 M = 36 R = not reported D = not reported	Not performed	Not performed
H1366		IC_{50} = 0.0215 EC_{50}/E_{Max} >30 EC_{50} = 0.0025	Not performed	Not performed	Not performed
H1367		IC_{50} = 0.0212 EC_{50}/E_{Max} >30 EC_{50} = 0.0033	Not performed	Not performed	Not performed
H1368		IC_{50} = 0.0203 EC_{50}/E_{Max} >30 EC_{50} = 0.0028	Not performed	Not performed	Not performed
H1369		IC_{50} = 0.00366 EC_{50}/E_{Max} >30 EC_{50} = 0.0011	Not performed	Not performed	Not performed
H1371		IC_{50} = 2.44 EC_{50}/E_{Max} >30 EC_{50} = 0.231	Not performed	Not performed	Not performed








H1372		IC_{50} = 18.2 EC_{50}/E_{Max}> 30 EC_{50} = 0.936	Not performed	Not performed	Not performed
H1373		Not performed	Not performed	Not performed	Not performed
H1374		Not performed	Not performed	Not performed	Not performed
H1375		IC_{50} = >30 EC_{50}/E_{Max} = >30	Not performed	Not performed	Not performed
H1376		IC_{50} = 6.89 EC_{50}/E_{Max} = >30 EC_{50} = 0.631	Not performed	Not performed	Not performed
H1377		IC_{50} = 5.52 EC_{50}/E_{Max} = >30 EC_{50} = 0.384	Not performed	Not performed	Not performed
H1378		IC_{50} = 0.019 EC_{50}/E_{Max} = >30 EC_{50} = 0.0013	H = 151.7 M = 245.9 D = 227.9	Not performed	Not performed
H1379		IC_{50} = 0.0443 EC_{50}/E_{Max} = >30 EC_{50} = 0.00143	H = 261.6 M = >500 D = >500	Not performed	Not performed






H1380		IC_{50} = 0.0023 EC_{50}/E_{Max} $_{Max}EC_{50}$ = 0.000367	H = 137 M = 66.5 D = 169.9	Not performed	Not performed
H1381		IC_{50} = 0.48/0.257 EC_{50}/E_{Max} = >30 EC_{50} = 0.0221/0.0331 PPB = 90.94 (H) PPB = 91.46 (M)	H = 60 M = 68.1 D = 88.7	$CL_{i.v.}$ = 3.83 $CL_{p.o.}$ = 17.7 $Vd_{i.v.}$ = 3.1 $Vd_{p.o.}$ = 42.87 $T_{1/2\ i.v.}$ = 0/56 $T_{1/2\ p.o.}$ = 1.68 F(%) = 20.64	Not performed
H1382		IC_{50} = 0.0343 EC_{50}/E_{Max}= >30 EC_{50} = 0.00268	H = 42.4 M = 43.4 D = 41.9	Not performed	Not performed
H1383		IC_{50} = 0.0119 EC_{50}/E_{Max} = >30 EC_{50} = 0.00201	H = 21 M = 91.9 R = 48.2 D = 27.8	Not performed	Not performed
H1384		IC_{50} = 0.00595 EC_{50}/E_{Max} = >30 EC_{50} = 0.0024	H = 95.1 M = 165.1	Not performed	Not performed
H1385		IC_{50} = 0.00398 EC_{50}/E_{Max} = >30 EC_{50} = 0.0065	H = <10 M = <10	Not performed	Not performed








H1386		IC_{50} = 0.0212 EC_{50}/E_{Max} = >30 EC_{50} = 0.0117	H = <10 M = 11	Not performed	Not performed
H1387		IC_{50} = 0.0074 EC_{50}/E_{Max} = >30 EC_{50} = 0.0037	H = 86.7 M = 167.5	Not performed	Not performed
H1388		IC_{50} = 0.0102 EC_{50}/E_{Max}= >30 EC_{50} = 0.0046 PPB = 96.9 (H) PPB = 92.1 (M)	H = 58.1 M = 42.4	$CL_{i.v.}$ = 4.66 $CL_{p.o.}$ = 40.5 $Vd_{i.v.}$ = 6.3 $Vd_{p.o.}$ = 86.8 $T_{1/2\ i.v.}$ = 0.93 $T_{1/2\ p.o.}$ = 1.49 F(%) = 11.3	Not performed
H1389		IC_{50} = 0.0276 EC_{50}/E_{Max} = >30 EC_{50} = 0.0151	H = 21.3 M = 21.2	Not performed	Not performed
H1390		IC_{50} = 0.0364 EC_{50}/E_{Max}= >30 EC_{50} = 0.0107	H = 34.6 M = 55.9	Not performed	Not performed
H1391		IC_{50} = 0.0105 EC_{50}/E_{Max} = >30 EC_{50} = 0.0072	H = 14.8 M = 11.8	Not performed	Not performed










H1392		IC_{50} = 0.0988 EC_{50}/E_{Max} = >30 EC_{50} = 0.0526	Not performed	Not performed	Not performed
H1393		IC_{50} = 0.0092 EC_{50}/E_{Max} = >30 EC_{50} = 0.00373	H = 55.5 M = 55.1	Not performed	Not performed
H1394		IC_{50} = 0.0519 EC_{50}/E_{Max} = >30 EC_{50} = 0.0078	H = 67.4 M = 182.5	Not performed	Not performed
H1395		IC_{50} = 0.0689 EC_{50}/E_{Max} = 0.0461/1904	Not performed	Not performed	Not performed
H1396		IC_{50} = 0.0108 EC_{50}/E_{Max} = >30 EC_{50} = 0.0013	H = 62.5 M = 330.4	not performed	Not performed
H1397		IC_{50} = 1.1 EC_{50}/E_{Max} = >30 EC_{50} = 0.0678	H = 35.1 M = 32	Not performed	Not performed
H1398		IC_{50} = 0.629 EC_{50}/E_{Max} = >30 EC_{50} = 0.0626	H = 52.9 M = 80.5	Not performed	Not performed









H1399		IC_{50} = 2.06 EC_{50}/E_{Max}= >30	Not performed	Not performed	Not performed
H1400		IC_{50} = 0.0705 EC_{50}/E_{Max}= >30 EC_{50} = 0.0154	Not performed	Not performed	Not performed
H1401		IC_{50} = 0.0034 EC_{50}/E_{Max}= >30	Not performed	Not performed	Not performed
H1402		IC_{50} = 0.075 EC_{50}/E_{Max} = >30	Not performed	Not performed	Not performed
H1403		IC_{50} = 0.0015 EC_{50}/E_{Max} = >30	Not performed	Not performed	Not performed
H1404		IC_{50} = 1.62 EC_{50}/E_{Max}= >30	H = 10 M = 19	Not performed	Not performed
H1405		IC_{50} = 1.86 EC_{50}/E_{Max} = >30 EC_{50} = 0.09	Not performed	Not performed	Not performed
H1406		IC_{50} = 0.0855 EC_{50}/E_{Max} = >30 EC_{50} = 0.00792	H = 15 M = 22.2	Not performed	Not performed
H1407		IC_{50} = 0.0127 EC_{50}/E_{Max} = >30 EC_{50} = 0.00145	H = 144.4 M = 84.1	Not performed	Not performed









H1408		IC_{50} = 0.162 EC_{50}/E_{Max} = >30 EC_{50} = 0.036	Not performed	Not performed	Not performed
H1409		IC_{50} = 0.282 EC_{50}/E_{Max}= >30 EC_{50} = 0.0745	Not performed	Not performed	Not performed
H1410		IC_{50} = 0.032 EC_{50}/E_{Max} = >30 EC_{50} = 0.0132	H = 73.3 M = 358.6	Not performed	Not performed
H1411		IC_{50} = 0.124 EC_{50}/E_{Max} = >30 EC_{50} = 0.0178	Not performed	Not performed	Not performed
H1412		IC_{50} = 0.0157 EC_{50}/E_{Max} = >30 EC_{50} = 0.0043	H = 22.5 M = 122.4	Not performed	Not performed
H1413		IC_{50} = 0.681 EC_{50}/E_{Max} = >30 EC_{50} = 0.2254	Not performed	Not performed	Not performed
H1414		IC_{50} = 2.09 EC_{50}/E_{Max} = >30 EC_{50} = 0.589	Not performed	Not performed	Not performed










H1415		IC_{50} = 0.0011 (0.01593) EC_{50}/E_{Max}= >30 EC_{50} = 0.0005733 (0.0004) PPB = 99.85 (H) PPB = 99.77 (R) PPB = 99.93 (M)	H = <10 M = 12.8 R = 28.3 D = 10.5	$CL_{i.v.}$ = 1.03(M); 2.12 (R) $CL_{p.o.}$ = 74.5 (M) $CL_{i.p.}$ = 2.76(R) $Vd_{i.v.}$ = 1.72(M); 39.67(R) $Vd_{p.o.}$ = 326.9(M) $Vd_{i.p.}$ = 61.91(R) $T_{1/2\ i.v.}$ = 1.16(M); 12.96(R) $T_{1/2\ p.o}$ = 3.04(M) $T_{1/2\ i.p.}$ = 17/23(R) F(%) = 1.12(M); 8.9 (R)	Not performed
H1416		IC_{50} = 1.037 EC_{50}/E_{Max} = >30 EC_{50} = 0.0266	Not performed	Not performed	Not performed
H1417		IC_{50} = 0.045 EC_{50}/E_{Max} = >30 EC_{50} = 0.00973 PPB = 99.85 (H) PPB = 99.88 (M)	H = 48.9 M = 53.4	$CL_{i.v.}$ = 1.57 $CL_{p.o.}$ = 13.61 $Vd_{i.v.}$ = 4.74 $Vd_{p.o.}$ = 24.97 $T1/2_{i.v.}$ = 2.09 $T_{1/2\ p.o.}$ = 1.27 F(%) = 11.80	Not performed
H1418		IC_{50} = 2.7 EC_{50}/E_{Max} = >30 EC_{50} = 0.0695	Not performed	Not performed	Not performed
H1419		IC_{50} = 0.0044 EC_{50}/E_{Max} = >30 EC_{50} = 0.0005 PPB = 99.59(H) PPB = 99.69(M)	H = 33.1 M = 45.1	Not performed	Not performed










H1420		IC_{50} = 0.022 EC_{50}/E_{Max}= >30 EC_{50} = 0.001 PPB = 97.2(H) PPB = 95.39(M)	H = 17.4 M = 50.6	Not performed	Not performed
H1421		IC_{50} = 0.0018 EC_{50}/E_{Max} = >50 EC_{50} = 0.0004 PPB = 99.63(H) PPB = 99.66(M)	H = 13.2 M = 38.8	$CL_{i.p.}$ = 1.96 (R) $Vd_{i.p.}$ = 54.56 (R) $T_{1/2\ i.p.}$ = 19.01 (R)	Not performed
H1422		IC_{50} = 0.0294 EC_{50}/E_{Max} = >30 EC_{50} = 0.0007	Not performed	Not performed	Not performed
H1423		IC_{50} = 0.1144 EC_{50}/E_{Max}= >30 EC_{50} = 0.00377	Not performed	Not performed	Not performed
H1424		IC_{50} = 0.0154 EC_{50}/E_{Max}= >30 EC_{50} = 0.0089	Not performed	Not performed	Not performed
H1425		IC_{50} = 0.0081 EC_{50}/E_{Max}= >30 EC_{50} = 0.0018	H = 310.0 M = 141.5	Not performed	Not performed
H1426		IC_{50} = 0.0529 EC_{50}/E_{Max} = >30 EC_{50} = 0.0034	H = 77.3 M = 80.6	Not performed	Not performed










H1427		IC_{50} = 0.0038 EC_{50}/E_{Max} = >30 EC_{50} = 0.0007	H = 58.8 M = 82.1	Not performed	Not performed
H1428		IC_{50} = 0.0033 EC_{50}/E_{Max} = >30 EC_{50} = 0.0005	H = 69.3 M = 194.8	Not performed	Not performed
H1429		IC_{50} = 0.16 EC_{50}/E_{Max} = >30 EC_{50} = 0.00731	H = 65.2 M = 63.6	Not performed	Not performed
H1430		IC_{50} = 2.473 EC_{50}/E_{Max} = >30 EC_{50} = 0.0564	Not performed	Not performed	Not performed
H1431		IC_{50} = 0.00454 EC_{50}/E_{Max}= >30 EC_{50} = 0.000657	H = 99.7 M = 135.7	Not performed	Not performed
H1432		IC_{50} = 5.5 EC_{50}/E_{Max} = >30 EC_{50} = 0.367	Not performed	Not performed	Not performed
H1433		IC_{50} = 3.1225 EC_{50}/E_{Max} = >30 EC_{50} = 0.4729	Not performed	Not performed	Not performed
H1434		IC_{50} = 0.8567 EC_{50}/E_{Max}= >30 EC_{50} = 0.0612	Not performed	Not performed	Not performed
H1435		IC_{50} = >30 EC_{50}/E_{Max} = >30 EC_{50} = >10	Not performed	Not performed	Not performed









H1436		IC_{50} = 0.01954 EC_{50}/E_{Max} = >30 EC_{50} = 0.0043	Not performed	Not performed	Not performed
H1437		IC_{50} = 0.02427 EC_{50}/E_{Max} = >30 EC_{50} = 0.01	Not performed	Not performed	Not performed
H1438		IC_{50} = 0.01261 EC_{50}/E_{Max} = >30 EC_{50} = 0.002758	Not performed	Not performed	Not performed
H1439		IC_{50} = 0.01245 EC_{50}/E_{Max}= >30 EC_{50} = 0.0141	Not performed	Not performed	Not performed
H1440		IC_{50} = 0.004401 EC_{50}/E_{Max} = >30 EC_{50} = 0.0029	Not performed	Not performed	Not performed
H1441		IC_{50} = 0.01494 (0.04043) EC_{50}/E_{Max} = >30 EC_{50} = 0.0043 (0.0033) PPB = 97.55(H) PPB = 95.5(M)	H = 17.3 M = 16.4	Not performed	Not performed
H1442		IC_{50} = 0.05809 EC_{50}/E_{Max} = >30 EC_{50} = 0.0164	Not performed	Not performed	Not performed
H1443		IC_{50} = 0.068 EC_{50}/E_{Max}= >30 EC_{50} = 0.0858	Not performed	Not performed	Not performed









H1444		IC_{50} = 2.8605 EC_{50}/E_{Max} = >30 EC_{50} = 0.185	Not performed	Not performed	Not performed
H1445		IC_{50} = 0.02383 EC_{50}/E_{Max} = >30 EC_{50} = 0.0039	H = 19.4 M = 17.3	Not performed	Not performed
H1446		IC_{50} = 0.09655 EC_{50}/E_{Max}= >30 EC_{50} = 0.009	H = 177.6 M = 58.5	Not performed	Not performed
H1447		IC_{50} = 0.10002 EC_{50}/E_{Max} = >30 EC_{50} = 0.0065	H = 72.5 M = 42.6	Not performed	Not performed
H1448		IC_{50} = 0.03029 EC_{50}/E_{Max} = >30 EC_{50} = 0.0033	H = 28 M = 20.8	$CL_{i.v.}$ = 4.83 $CL_{p.o.}$ = 254.6 $Vd_{i.v.}$ = 9.26 $Vd_{p.o.}$ = 242.2 $T_{1/2\ i.v.}$ = 1.33 $T_{1/2\ p.o.}$ 0.66 F(%) = 1.90	Not performed
H1449		IC_{50} = 4.1695 EC_{50}/E_{Max} = >30 EC_{50} = 0.9276	Not performed	Not performed	Not performed
H1450		IC_{50} = 0.2896 EC_{50}/E_{Max} = >30 EC_{50} = 0.1823	Not performed	Not performed	Not performed
H1451		IC_{50} = 0.06852 EC_{50}/E_{Max}= >30 EC_{50} = 0.03329	Not performed	Not performed	Not performed






H1452		IC_{50} = 0.08695 EC_{50}/E_{Max}= >30 EC_{50} = 0.03475	Not performed	Not performed	Not performed
H1453		IC_{50} = 0.1088 EC_{50}/E_{Max} = >30 EC_{50} = 0.04684	Not performed	Not performed	Not performed
H1454		IC_{50} = 0.03184 EC_{50}/E_{Max} = >30 EC_{50} = 0.0061	H = 259.9 M = 193.3	Not performed	Not performed
H1455		IC_{50} = 0.04255 EC_{50}/E_{Max} = >30 EC_{50} = 0.0052	H = 55.5 M = 56.9	Not performed	Not performed
H1456		IC_{50} = 0.10898 EC_{50}/E_{Max}= >30 EC_{50} = 0.0062	H = 160.6 M = 137.8	Not performed	Not performed
H1457		IC_{50} = 16.6185 EC_{50}/E_{Max} = >30 EC_{50} = 0.1225	Not performed	Not performed	Not performed
H1458		IC_{50} = 1.1681 EC_{50}/E_{Max} = >30 EC_{50} = 0.2879	Not performed	Not performed	Not performed
H1459		IC_{50} = 0.011537 EC_{50}/E_{Max}= >30 EC_{50} = 0.0084	H = 53.7 M = 49.3	Not performed	Not performed
H1460		IC_{50} = 0.536 EC_{50}/E_{Max}= >30 EC_{50} = 0.1635	Not performed	Not performed	Not performed









H1461		IC_{50} = 0.0078995 (1.721) EC_{50}/E_{Max} = >30 EC_{50} = 0.0035 (0.003)	H = 22.0 M = <10	CL $_{i.p.}$ 2.30 (R) $Vd_{i.p.}$ 8.64 (R) $T_{1/2\,i.p.}$ 2.61 (R)	Not performed
H1462		IC_{50} = 0.0138 EC_{50}/E_{Max}= >30 EC_{50} = 0.006238	H = 76.1 M = 15.8	Not performed	Not performed
H1463		IC_{50} = 1.1475 EC_{50}/E_{Max} = >30 EC_{50} = 0.2894	Not performed	Not performed	Not performed
H1464		IC_{50} = 2.959 EC_{50}/E_{Max} = >30 EC_{50} = 0.2904	Not performed	Not performed	Not performed
H1465		IC_{50} = 5.2895 EC_{50}/E_{Max} = >30 EC_{50} = 0.6776	Not performed	Not performed	Not performed
H1466		IC_{50} = 0.07241 EC_{50}/E_{Max} = >30 EC_{50} = 0.0168	Not performed	Not performed	Not performed
H1467		IC_{50} = 0.12124 EC_{50}/E_{Max} = >30 EC_{50} = 0.0197	Not performed	Not performed	Not performed
H1468		IC_{50} = 0.0806 EC_{50}/E_{Max} = >30 EC_{50} = 0.01817	Not performed	Not performed	Not performed
H1469		IC_{50} = 0.1104 EC_{50}/E_{Max} = 01101 EC_{50} = 0.026	Not performed	Not performed	Not performed









H1470		IC_{50} = 0.4833 EC_{50}/E_{Max} = 02273 EC_{50} = 0.02234	Not performed	Not performed	Not performed
H1471		IC_{50} = 0.0118 EC_{50}/E_{Max} = >30 EC_{50} = 0.003887	Not performed	Not performed	Not performed
H1472		IC_{50} = 0.006 EC_{50}/E_{Max} = >30 EC_{50} = 0.003252	CL i.p. = 2.19 (R) Vd i.p. = 7.71 (R) T1/2 i.p. 2.43 (R)	Not performed	Not performed
H1473		IC_{50} = 2.2385 EC_{50}/E_{Max} = >30 EC_{50} = 0.5146	Not performed	Not performed	Not performed
H1474		IC_{50} = 0.7001 EC_{50}/E_{Max} = >30 EC_{50} = 0.1332	Not performed	Not performed	Not performed
H1475		IC_{50} = 0.03223 EC_{50}/E_{Max} = >30 EC_{50} = 0.0189	Not performed	Not performed	Not performed
H1476		IC_{50} = 0.0426 EC_{50}/E_{Max} = >30 EC_{50} = 0.0241	Not performed	Not performed	Not performed
H1477		IC_{50} = 0.03689 EC_{50}/E_{Max}= >30 EC_{50} = 0.0174	Not performed	Not performed	Not performed
H1478		IC_{50} = 0.04028 EC_{50}/E_{Max} = >30 EC_{50} = 0.0196	Not performed	Not performed	Not performed









H1479		IC_{50} = 2.501 EC_{50}/E_{Max} = >30 EC_{50} = 1.955	Not performed	Not performed	Not performed
H1480		IC_{50} = 24.15 EC_{50}/E_{Max} = >30 EC_{50} = >10	Not performed	Not performed	Not performed
H1481		IC_{50} = <0.0003 (1.0765) EC_{50}/E_{Max} = >30 EC_{50} = 0.0002 (0.0004)	H = <10 M = 13.2	Not performed	Not performed
H1482		IC_{50} = 0.00028195 EC_{50}/E_{Max} = >30 EC_{50} = 0.0004	H = <10 M = 12.5	Not performed	Not performed
H1483		IC_{50} = 0.05382 EC_{50}/E_{Max} = >30 EC_{50} = 0.0241	Not performed	Not performed	Not performed
H1484		IC_{50} = 0.02165 EC_{50}/E_{Max} = >30 EC_{50} = 0.0071	H = 116.7 M = 149.3	Not performed	Not performed
H1485		IC_{50} = 0.01906 EC_{50}/E_{Max} = >30 EC_{50} = 0.0102	Not performed	Not performed	Not performed
H1486		IC_{50} = 0.009212 EC_{50}/E_{Max} = >30 EC_{50} = 0.0049 PPB = 94.81(H) PPB = 97.35(R)	H = <10 M = <10	Not performed	Not performed









H1487		IC_{50} = 0.018745 EC_{50}/E_{Max} = >30 EC_{50} = 0.0057	H = 26.1 M = 16.9	Not performed	Not performed
H1488		IC_{50} = 2.0525 EC_{50}/E_{Max} = >30 EC_{50} = 0.6682	Not performed	Not performed	Not performed
H1489		IC_{50} = 7.4695 EC_{50}/E_{Max} = >30 EC_{50} = 1.4110	Not performed	Not performed	Not performed
H1490		IC_{50} = 0.005427 EC_{50}/E_{Max} = >30 EC_{50} = 0.0036	H = 12.8	Not performed	Not performed
H1491		IC_{50} = 0.029695 EC_{50}/E_{Max} = >30 EC_{50} = 0.0046	H = 79.5	Not performed	Not performed
H1492		IC_{50} = 0.03627 EC_{50}/E_{Max}= >30 EC_{50} = 0.0051	H = 24.4	Not performed	Not performed
H1493		IC_{50} = 0.01528 EC_{50}/E_{Max} = >30 EC_{50} = 0.0042	H = 21.5	Not performed	Not performed
H1494		IC_{50} = 0.01061 EC_{50}/E_{Max} = >30 EC_{50} = 0.0040	H = 19.1	Not performed	Not performed







H1495		IC_{50} = 0.002159 EC_{50}/E_{Max} = >30 EC_{50} = 0.0012	H = 21.1	Not performed	Not performed
H1496		IC_{50} = 0.005906 EC_{50}/E_{Max} = >30 EC_{50} = 0.0025	H = 178.3	Not performed	Not performed
H1497		IC_{50} = 0.002814 EC_{50}/E_{Max}= >30 EC_{50} = 0.0033 PPB = 99.84(H) PPB = 99.8(R)	H = <10	Not performed	Not performed
H1498		IC_{50} = 0.02476 EC_{50}/E_{Max} = >30 EC_{50} = 0.0072 PPB = 98.77(H) PPB = 97.06(R)	H = 9.9	Not performed	Not performed
H1499		IC_{50} = 0.03798 EC_{50}/E_{Max} = >30 EC_{50} = 0.0071	H = 27.1	Not performed	Not performed








H1500		IC_{50} = 0.01637 EC_{50}/E_{Max} = >30 EC_{50} = 0.0062	H = 61.4	Not performed	Not performed
H1501		IC_{50} = 0.1188 EC_{50}/E_{Max} = >30 EC_{50} = 0.0181	H = 319.6	Not performed	Not performed
H1502		IC_{50}= 0.1642 EC_{50}/E_{Max} = >30 EC_{50} = 0.03508	Not performed	Not performed	Not performed
H1503		IC_{50} = 0.5117 EC_{50}/E_{Max} = >30 EC_{50} = 0.101	Not performed	Not performed	Not performed
H1504		IC_{50} = 0.006473 EC_{50}/E_{Max} = >30 EC_{50} = 0.005554	H = 19.3	Not performed	Not performed
H1505		IC_{50} = 0.008279 EC_{50}/E_{Max} = >30 EC_{50} = 0.0117	H = 37.3 M = 135.5	Not performed	Not performed
H1506		IC_{50} = 0.002277 EC_{50}/E_{Max} = >30 EC_{50}= 0.0042	H = 49.2 M = 132.5	Not performed	Not performed
H1507		IC_{50} = 0.01285 EC_{50}/E_{Max} = >30 EC_{50} = 0.0197	Not performed	Not performed	Not performed





H1508		IC_{50} = 0.06176 EC_{50}/E_{Max}= >30 EC_{50} = 0.03	Not performed	Not performed	Not performed
H1509		IC_{50} = 0.000336 (0.4564) EC_{50}/E_{Max} = >30 EC_{50} = 0.001 (0.0008)	H = 15.9 M = 16.0	Not performed	Not performed
H1510		IC_{50} = 0.005363 EC_{50}/E_{Max} = >30 EC_{50} = 0.0035	H = 23.8 M = 18.4	Not performed	Not performed
H1511		IC_{50} = 0.006043 EC_{50}/E_{Max} = >30 EC_{50} = 0.0052	H = 94.2 M = 44.5	Not performed	Not performed
H1512		IC_{50} = 0.5824 EC_{50}/E_{Max} = >30 EC_{50} = 0.2727	Not performed	Not performed	Not performed
H1513		IC_{50} = 14.579 EC_{50}/E_{Max}= >30 EC_{50} = 0.7073	Not performed	Not performed	Not performed
H1514		IC_{50} = 16.175 EC_{50}/E_{Max} = >30 EC_{50} = 0.0176	Not performed	Not performed	Not performed
H1515		IC_{50} = 0.01571 EC_{50}/E_{Max} = >30 EC_{50} = 0.0096	H = 15.2 M = 18.4	Not performed	Not performed

H1516		IC_{50} = 0.03352 EC_{50}/E_{Max} = >30 EC_{50} = 0.0113	H = 65.2 M = 35.1	Not performed	Not performed
H1517		IC_{50} = 0.01052 EC_{50}/E_{Max} = >30 EC_{50} = 0.0067	H = 25.6 M = 56.6	Not performed	Not performed
H1518		IC_{50} = 0.02739 EC_{50}/E_{Max} = >30 EC_{50} = 0.0078	H = 151.1 M = 154.7	Not performed	Not performed
H1519		IC_{50} = 0.01214 EC_{50}/E_{Max} = >30 EC_{50} = 0.0046	H = 47.3 M = 169.8	Not performed	Not performed
H1520		IC_{50} = 0.02617 EC_{50}/E_{Max} = >30 EC_{50} = 0.0127	Not performed	Not performed	Not performed
H1521		IC_{50} = 0.0523 EC_{50}/E_{Max}= >30 EC_{50} = 0.0178	Not performed	Not performed	Not performed
H1522		IC_{50} = 3.849 EC_{50}/E_{Max} = >30 EC_{50} = 1.889	Not performed	Not performed	Not performed
H1523		IC_{50} = 0.004917 EC_{50}/E_{Max} = >30 EC_{50} = 0.0021	H = 100.9 M = 155.5	Not performed	Not performed

H1524		IC_{50} = 0.009768 EC_{50}/E_{Max} = >30 EC_{50} = 0.0126	Not performed	Not performed	Not performed
H1525		IC_{50} = 0.03744 EC_{50}/E_{Max} = >30 EC_{50} = 0.02554	Not performed	Not performed	Not performed
H1526		IC_{50} = 0.03186 EC_{50}/E_{Max} = >30 EC_{50} = 0.02191	Not performed	Not performed	Not performed
H1527		IC_{50} = 0.1298 EC_{50}/E_{Max} = >30 EC_{50} = 0.03403	Not performed	Not performed	Not performed
H1528		IC_{50} = 0.5814 EC_{50}/E_{Max} = >30 EC_{50} = 0.08328	Not performed	Not performed	Not performed
H1529		IC_{50} = 0.04738 EC_{50}/E_{Max}= >30 EC_{50} = 0.02781	Not performed	Not performed	Not performed
H1530		IC_{50} = 0.6142 EC_{50}/E_{Max} = >30 EC_{50} = 0.7839	Not performed	Not performed	Not performed
H1531		IC_{50} = 0.4179 EC_{50}/E_{Max}= >30 EC_{50} = 0.4444	Not performed	Not performed	Not performed


H1532		IC_{50} = 1.6595 EC_{50}/E_{Max} = >30 EC_{50} = 0.0695	Not performed	Not performed	Not performed
H1533		IC_{50} = 1.6955 EC_{50}/E_{Max} = >30 EC_{50} = 0.0762	Not performed	Not performed	Not performed
H1534		IC_{50} = 1.6635 EC_{50}/E_{Max} = >30 EC_{50} = 0.0895	Not performed	Not performed	Not performed
H1535		IC_{50} = 0.4926 EC_{50}/E_{Max} = >30 EC_{50} = 0.0214	Not performed	Not performed	Not performed
H1537		IC_{50} = 0.06895 EC_{50}/E_{Max}= >30 EC_{50} = 0.0184	H = 43.2 M = 135.3	Not performed	Not performed
H1538		IC_{50} = 0.1718 EC_{50}/E_{Max} = >30 EC_{50} = 0.0086	H = 237.3 M = 354	Not performed	Not performed

H1539		IC_{50} = 8.0495 EC_{50}/E_{Max} = >30 EC_{50} = 0.2627	Not performed	Not performed	Not performed
H1540		IC_{50} = 7.4405 EC_{50}/E_{Max} = >30 EC_{50} = 0.2063	Not performed	Not performed	Not performed
H1541		IC_{50} = 0.07227 EC_{50}/E_{Max} = >30 EC_{50} = 0.0097	H = <10 R = <10	Not performed	Not performed
H1542		IC_{50} = 0.001685 EC_{50}/E_{Max} = >30 EC_{50} = 0.0019	H = <10 R = 13.3	Not performed	Not performed
H1543		IC_{50} = 0.01593 EC_{50}/E_{Max} = >30 EC_{50} = 0.0126	H = 46.8 R = 204.6	Not performed	Not performed
H1544		IC_{50} = 0.04043 EC_{50}/E_{Max} = >30 EC_{50} = 0.0097	H = 323.3 R = 427.2	Not performed	Not performed
H1545		IC_{50} = 1.721 EC_{50}/E_{Max}= >30 EC_{50} = 0.01912	Not performed	Not performed	Not performed

H1546		IC_{50} = 1.0765 EC_{50}/E_{Max} = >30 EC_{50} = 0.1265	Not performed	Not performed	Not performed
H1547		IC_{50} = 0.4564 EC_{50}/E_{Max} = >30 EC_{50} = 0.035	Not performed	Not performed	Not performed
H1548		IC_{50} = 0.6553 EC_{50}/E_{Max} = >30 EC_{50} = 0.1324	Not performed	Not performed	Not performed
H1549		IC_{50} = 0.001685 EC_{50}/E_{Max} = >30 EC_{50} = 0.0012	Not performed	Not performed	Not performed

What is claimed is:

1. A compound of Formula I:



I,

or a pharmaceutically acceptable salt thereof, wherein:

a dashed line indicates an optional bond;

W is C, N, or O;

X is a bond, CO, or CR^7R^8;

k is 0-2;

R is C_{1-6} alkyl or Cy^1 wherein said C_{1-6} alkyl or Cy^1 is optionally substituted with 1-3 substituents selected from halo, heteroaryl, C_{1-6} alkoxy, C_{1-6} alkyl, heterocycloalkyl, $CO_2(C_{1-6}$ alkyl), and $CO(C_{1-6}$ alkyl);

R^1 and R^2 are each independently, H, C_{1-3} alkyl, methoxy, halo or OH;

or R^1 and R^2 taken together with the atoms to which they are attached form a 5-6 membered ring;

or R^1 and X taken together with the atoms to which they are attached form a 5-6 membered ring;

or R^1, X and R taken together with the atoms to which they are attached form a bicyclic structure;

R^3 is H, C_{1-3} alkyl, methoxy, halo, OH, $COOR^{12}$, $CR^{13}R^{14}OH$, $COHNR^{15}$, cycloalkyl, or heteroaryl;

R^4 is a bond, NR^6 or CR^9R^{10};

or R^3 and R^4 taken together with the atoms to which they are attached form a 3-6-membered ring;

R^5 is Cy^2, $CO(C_{1-6}$ alkyl), or C_{1-6} alkyl, wherein said Cy^2, $CO(C_{1-6}$ alkyl), or C_{1-6} alkyl is optionally substituted with 1-3 substituents selected from halo, C_{1-6} alkylamine, COR^{11}, SO_2R^{11},

heterocycloalkyl, CO_2R^{11}, C_{1-6} hydroxyalkyl, heteroaryl, $CH_2CO_2R^{11}$, C_{1-6} alkoxy, OH, CN, R^{11}, CH_2OSO_3H, benzyl, CH_2SO_3H, CH_2CN, and $NHCH_2$ cycloalkyl;

R^6 is a bond, H, or CH_3;


R^7 and R^8 are each, independently, H or C_{1-3} alkyl, or $CONH_2$, wherein said C_{1-3} alkyl is optionally substituted with halo;

R^9 and R^{10} are each, independently, H or C_{1-3} alkyl, wherein said C_{1-3} alkyl is optionally substituted with halo;

R^{11} is H, NH_2, or optionally substituted C_{1-6} alkyl; and

R^{12}, R^{13}, R^{14} and R^{15} are each independently H or C_{1-3} alkyl.

2. A compound of Formula II:



II,


or a pharmaceutically acceptable salt thereof, wherein:

W, X, k, R^1, R^2, R^3, and R^4 are defined as in claim 1;

Cy^1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; and

Cy^2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.

3. A compound of Formula III:



III,

or a pharmaceutically acceptable salt thereof, wherein:

a dashed line indicates an optional bond;

W, X, k, R^1, R^2, R^3, and R^4 are defined as in claim 1;

U is C, N, S, or O;

Y is each, independently, a C or N;

Z is halo or methoxy;

B is 5-7-membered ring or a bicyclic structure, wherein said 5-7-membered ring or said bicyclic structure is optionally substituted with COR^{11}, SO_2R^{11}, heterocycloalkyl, CO_2R^{11}, C_{1-6} hydroxyalkyl, heteroaryl, $CH_2CO_2R^{11}$, C_{1-6} alkoxy, OH, CN, R^{11}, CH_2OSO_3H, benzyl, CH_2SO_3H, or CH_2CN;

R' is a halo, heteroaryl, C_{1-6} alkoxy, C_{1-6} alkyl, heterocycloalkyl, CN cycloalkyl, $CO_2(C_{1-6}$ alkyl), or $CO(C_{1-6}$ alkyl);


or two R' taken together with the atoms to which they are attached form a 5-6-membered ring;

l is 0-3;

m is 0-3; and

n is 0-3.

4. A compound of Formula IV:



IV,

or a pharmaceutically acceptable salt thereof, wherein:

a dashed line indicates an optional bond;

W, X, k, R^1, R^2, R^3, and R^4 are defined as in claim 1;

U is C, N, S, or O;

R' is a halo, heteroaryl, C_{1-6} alkoxy, C_{1-6} alkyl, heterocycloalkyl, CN cycloalkyl, $CO_2(C_{1-6}$ alkyl), or $CO(C_{1-6}$ alkyl);

or two R' taken together with the atoms to which they are attached form a 5-6-membered ring;

R^{16} is H or C_{1-3} alkyl;

R^{17} is H, halo, or C_{1-3} alkyl;

l, m, and n are as defined in claim 3; and

p is 1-3.

5. The compound of claim 1, wherein W is C.

6. The compound of claim 1, wherein X is CR^7R^8.

7. The compound of claim 1, wherein X is CO.

8. The compound of claim 1, wherein X is a bond.

9. The compound of claim 6, wherein said CR^7R^8 is C_{1-3} alkyl.

10. The compound of claim 6, wherein said CR^7R^8 is $CH(CH_3)$.

11. The compound of claim 6, wherein said CR^7R^8 is CH_2.

12. The compound of claim 6, wherein said CR^7R^8 is $C(CH_3)_2$.

13. The compound of claim 6, wherein said CR^7R^8 is $CHCF_3$.

14. The compound of claim 6, wherein said CR^7R^8 is $CH(CH_2CH_3)$.

15. The compound of claim 9, wherein said C_{1-3} alkyl is optionally substituted with halo.









16. The compound of claim 15, wherein said C_{1-3} alkyl is $CHCF_3$.


17. The compound of claim 1, wherein R is Cy^1.

18. The compound of claim 17, wherein said Cy^1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocycloalkly.

19. The compound of claim 18, wherein said Cy^1 is optionally substituted.

20. The compound of claim 17, wherein said Cy^1 is selected from the group consisting of



, and .

21. The compound of claim 17, wherein said Cy^1 is phenyl.

22. The compound of claim 17, wherein said Cy^1 is cyclopropane.

23. The compound of claim 1, wherein R is C_{1-6} alkyl.

24. The compound of claim 23, wherein said C_{1-6} alkyl is CH_3.

25. The compound of claim 23, wherein said C_{1-6} alkyl is $C(CH_3)_3$.

26. The compound of claim 23, wherein said C_{1-6} alkyl is $CH(CH_3)_2$.

27. The compound of claim 1, wherein R^1 is H.

28. The compound of claim 1, wherein R^1 is OH.

29. The compound of claim 1, wherein R^1 is CH_3.

30. The compound of claim 1, wherein R^2 is H.

31. The compound of claim 1, wherein R^2 is CH_3.

32. The compound of claim 1, wherein R^3 is H.

33. The compound of claim 1, wherein R^3 is F.

34. The compound of claim 1, wherein R^3 is Cl.

35. The compound of claim 1, wherein R^3 is methoxy.

36. The compound of claim 1, wherein R^4 is a bond.

37. The compound of claim 1, wherein R^4 is CR^9R^{10}.

38. The compound of claim 37, wherein said CR^9R^{10} is CH_2.

39. The compound of claim 37, wherein said CR^9R^{10} is $CHCH_3$.

40. The compound of claim 37, wherein said CR^9R^{10} is $C(CH_3)_2$.

41. The compound of claim 1, wherein R^4 is NR^6.

42. The compound of claim 41, wherein said NR^6 is NH.

43. The compound of claim 41, wherein said NR^6 is NCH_3.



















44. The compound of claim 1, wherein R^4 and R^3 come together to form a 5-membered heterocyclic ring.





45. The compound of claim 1, wherein R^5 is Cy^2.


46. The compound of claim 45, wherein said Cy^2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.







47. The compound of claim 45, wherein said Cy^2 is optionally substituted.

48. The compound of claim 45, wherein said Cy^2 is phenyl.



49. The compound of claim 46, wherein said phenyl is optionally substituted with 1-3 substituents from the group consisting of , , , CH_3, , CH_2NH_2, CO_2CH_3, CO_2H, CH_2OH, , $CONH_2$, $C(CH_3)_2NH_2$, $CH_2CO_2CH_3$, , methoxy, OH, CH_2OCH_3, CH_2CH_2OH, CN, , , CH_2OSO_3H, , , , , , , , , , and .


50. The compound of claim 44, wherein said Cy^2 is selected from the group consisting of  ,  ,  and  .


51. The compound of claim 44, wherein said Cy^2 is  .

52. The compound of claim 50, wherein  is optionally substituted with 1-3 substituents from the group consisting of CH_3,  ,  , CH_2CH_3,  ,  , $CH_2CH_2OCH_3$, CH_2CN,  , and F.

53. The compound of claim 44, wherein said Cy^2 is tetrahydroisoquinoline.


54. The compound of claim 52, wherein said tetrahydroisoquinoline is substituted with 1-3 substituents from the group consisting of CH_3, CH_2CH^3, $COCH_3$, SO_2CH_3, $CO_2CH_2CH_3$,  ,  , F, and methoxy.


55. The compound of claim 44, wherein said Cy^2 is selected from the group consisting of 




.

56. The compound of claim 44, wherein said Cy^2 is cyclopropane.

57. The compound of claim 1, wherein R^5 is selected from the group consisting of ,







58. The compound of claim 1, wherein R^5 is $CO(C_{1-6}$ alkyl).

59. The compound of claim 58, wherein said $CO(C_{1-6}$ alkyl) is $COCH_3$.

60. The compound of claim 1, wherein R^5 is C_{1-6} alkyl.

61. The compound of claim 1, wherein R^5 is  or .

62. The compound of claim 2, wherein Cy^1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.

63. The compound of claim 2, wherein Cy^1 is phenyl.

64. The compound of claim 2, wherein Cy^2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.

65. The compound of claim 2, wherein Cy^2 is isoindoline.

66. The compound of claim 2, wherein Cy^2 is tetrahydroisoquinoline.

67. The compound of claim 3, wherein B is selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.

68. The compound of claim 3, wherein B is a 5-membered heterocycloalkyl.

69. The compound of claim 3, wherein B is a 6-membered heterocycloalkyl.

70. The compound of claim 4, wherein p is 1.









71. The compound of claim 68, wherein n is 0.









72. The compound of claim 4, wherein p is 2.










73. The compound of claim 69, wherein n is 0.








74. A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:










Compound No.	Chemical Structure	Chemical Name









H0906		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)benzenesulfonamide
H0907		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichloro-4-(cyclopropylethynyl)phenyl)ethyl)ureido)benzenesulfonamide
H0937		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)benzenesulfonamide
H0941		(*S*)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)-*N*-(4-(2-methyl-2-(methylamino)propyl)phenyl)benzenesulfonamide
H0942		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)-1-methylureido)benzenesulfonamide
H0943		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H0944		(*S*)-*N*-((4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)phenyl)sulfonyl)acetamide
H0950		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-phenylbenzenesulfonamide










H0951		(*S*)-*N*-(4-(2-aminoethyl)phenyl)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)benzenesulfonamide
H0953		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(*p*-tolyl)benzenesulfonamide
H0954		(*S*)-*N*-((4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)phenyl)sulfonyl)-*N*-methylacetamide
H0963		(*S*)-1-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)-3-(4-((4-methylbenzyl)sulfonyl)phenyl)urea
H0964		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-methylbenzyl)sulfonyl)phenyl)urea
H0965		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-phenylbenzenesulfonamide
H0966		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(*p*-tolyl)benzenesulfonamide
H0967		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(4-(2-(dimethylamino)-2-methylpropyl)phenyl)benzenesulfonamide










H0968		*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(2,3-dichlorobenzyl)ureido)benzenesulfonamide
H0969		(*S*)-1-(4-((4-(2-amino-2-methylpropyl)benzyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H0971		(*S*)-*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-methylbenzenesulfonamide
H0975		*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-(2-(2,3-dichloro-4-methoxyphenyl)propan-2-yl)ureido)benzenesulfonamide
H0981		1-(2,3-dichlorobenzyl)-3-(4-((4-(2-(dimethylamino)-2-methylpropyl)benzyl)sulfonyl)phenyl)urea
H0990		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(1*H*-indol-5-yl)benzenesulfonamide
H0991		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1*H*-indol-5-yl)benzenesulfonamide
H0993		*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-benzylureido)benzenesulfonamide
H0994		*N*-(4-(2-amino-2-methylpropyl)phenyl)-4-(3-ethylureido)benzenesulfonamide









H0995		4-(3-(2,3-dichlorobenzyl)ureido)-*N*-(4-(2-(dimethylamino)-2-methylpropyl)phenyl)benzenesulfonamide
H0996		1-(4-((4-(2-amino-2-methylpropyl)benzyl)sulfonyl)phenyl)-3-(2,3-dichlorobenzyl)urea
H0997		(*S*)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)-*N*-(1*H*-indol-5-yl)benzenesulfonamide
H1003		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroquinolin-6-yl)benzenesulfonamide
H1004		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1005		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1006		(*S*)-4-(3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide









H1008		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroquinolin-6-yl)benzenesulfonamide
H1009		4-(3-benzylureido)-*N*-(4-(2-(dimethylamino)-2-methylpropyl)phenyl)benzenesulfonamide
H1010		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(2-(dimethylamino)-2-methylpropyl)benzyl)sulfonyl)phenyl)urea
H1017		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1018		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(2-ethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1024		(*S*)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1025		(*S*)-1-(4-(((2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)urea
H1026		(*S*)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(4-(((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1027		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea









H1028		(*S*)-1-(1-phenylethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1029		1-benzyl-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1033		(*S*)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)-*N*-(2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1034		(*S*)-*N*-(2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-4-(3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)ureido)benzenesulfonamide
H1038		1-(3-chlorobenzyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1039		1-(2-chlorobenzyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1040		1-(2,3-dichlorobenzyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1041		1-(1-(2-chlorophenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea









H1042		1-(1-(3-chlorophenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1043		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)sulfonyl)phenyl)urea
H1044		1-(2,3-dichlorobenzyl)-3-(4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)sulfonyl)phenyl)urea
H1045		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((indolin-6-ylmethyl)sulfonyl)phenyl)urea
H1046		1-(2,3-dichlorobenzyl)-3-(4-((indolin-6-ylmethyl)sulfonyl)phenyl)urea
H1047		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((indolin-5-ylmethyl)sulfonyl)phenyl)urea
H1048		1-(2,3-dichlorobenzyl)-3-(4-((indolin-5-ylmethyl)sulfonyl)phenyl)urea
H1049		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1,2,3,4-tetrahydroisoquinolin-7-yl)benzenesulfonamide
H1050		(*S*)-*N*-(4-(aminomethyl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide









H1051		(*S*)-1-(4-((4-(aminomethyl)benzyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1052		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(2-(piperidin-4-yl)ethyl)benzenesulfonamide
H1054		ethyl (*S*)-6-((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonamido)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate
H1055		ethyl (*S*)-6-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonyl)methyl)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate
H1056		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1057		1-(2,3-dichlorobenzyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1058		methyl (*S*)-4-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonyl)methyl)benzoate
H1059		(*S*)-4-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonyl)methyl)benzoic acid
H1060		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)urea









H1061		methyl (*S*)-4-((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl) sulfonamido)benzoate
H1062		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(4-(hydroxymethyl)phenyl)benzenesulfonamide
H1067		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1068		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(2-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1070		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(pyridin-3-yl)benzyl)sulfonyl)phenyl)urea
H1071		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1072		(*S*)-1-(4-(((2-benzyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1073		(*S*)-4-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl) sulfonyl)methyl)benzamide









H1074		(*S*)-N-(4-(2-aminopropan-2-yl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1075		methyl (*S*)-2-(4-((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonamido)phenyl)acetate
H1076		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(4-(2-hydroxy-2-methylpropyl)phenyl)benzenesulfonamide
H1078		(*S*)-1-(4-((cyclopropylmethyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1080		1-((*S*)-1-(2,3-dichlorophenyl)ethyl)-3-(4-((1-(1,2,3,4-tetrahydroisoquinolin-6-yl)ethyl)sulfonyl)phenyl)urea
H1081		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((2-(1,2,3,4-tetrahydroisoquinolin-6-yl)propan-2-yl)sulfonyl)phenyl)urea
H1082		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((3-methoxybenzyl)sulfonyl)phenyl)urea
H1083		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-methoxybenzyl)sulfonyl)phenyl)urea









H1084		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((3-hydroxybenzyl)sulfonyl)phenyl)urea
H1087		methyl (*S*)-3-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonyl)methyl)benzoate
H1088		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((3-(hydroxymethyl)benzyl)sulfonyl)phenyl)urea
H1092		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((isochroman-6-ylmethyl)sulfonyl)phenyl)urea
H1093		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(methoxymethyl)benzyl)sulfonyl)phenyl)urea
H1094		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(4-(2-hydroxyethyl)phenyl)benzenesulfonamide
H1095		(*S*)-4-(3-(1-(2-chlorophenyl)ethyl)ureido)-*N*-(4-(2-hydroxyethyl)phenyl)benzenesulfonamide
H1096		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((2-morpholinoethyl)sulfonyl)phenyl)urea










H1097		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((isochroman-7-ylmethyl)sulfonyl)phenyl)urea
H1098		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1,3-dihydroisobenzofuran-5-yl)methyl)sulfonyl)phenyl)urea
H1099		(*S*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-hydroxybenzyl)sulfonyl)phenyl)urea
H1101		(*S*)-1-(4-((4-cyanobenzyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1102		1-((*S*)-1-(2,3-dichlorophenyl)ethyl)-3-(4-((1-(1,2,3,4-tetrahydroisoquinolin-6-yl)ethyl)sulfonyl)phenyl)urea hydrochloride
H1103		1-((*S*)-1-(2,3-dichlorophenyl)ethyl)-3-(4-((1-(1,2,3,4-tetrahydroisoquinolin-6-yl)ethyl)sulfonyl)phenyl)urea hydrochloride
H1106		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(1H-indazol-5-yl)benzenesulfonamide
H1108		(*S*)-*N*-(2-aminopyrimidin-5-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide









H1109		(*S*)-*N*-(4-(1*H*-imidazol-5-yl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1110		(*S*)-*N*-(4-(1H-imidazol-2-yl)phenyl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1111		(*S*)-*N*-(1*H*-benzo[d]imidazol-5-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1125		(*S*)-*N*-(2-aminopyrimidin-4-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1126		(*S*)-*N*-(6-aminopyridin-3-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1127		(*S*)-*N*-(5-aminopyridin-2-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1129		(*S*)-*N*-(6-aminopyridazin-3-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1130		(*S*)-1-(4-(((2-aminopyrimidin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea









H1131		1-benzyl-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)urea
H1132		1-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1133		*N*-(4-(hydroxymethyl)phenyl)-4-(3-(1-(naphthalen-1-yl)ethyl)ureido)benzenesulfonamide
H1140		1-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)-3-(1-(4-methoxynaphthalen-1-yl)ethyl)urea
H1141		*N*-(4-(hydroxymethyl)phenyl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1142		(*S*)-1-(4-(((1*H*-indol-5-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1145		*N*-(4-(hydroxymethyl)phenyl)-4-(3-(1-(4-methoxynaphthalen-1-yl)ethyl)ureido)benzenesulfonamide
H1148		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea







H1149		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1154		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(4-methoxynaphthalen-1-yl)ethyl)urea
H1155		*N*-(isoindolin-5-yl)-4-(3-(1-(naphthalen-1-yl)ethyl)ureido)benzenesulfonamide
H1156		*N*-(isoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1166		4-(1-hydroxy-3-(1-(naphthalen-1-yl)ethyl)ureido)-*N*-(isoindolin-5-yl)benzenesulfonamide
H1178		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-isopropylurea
H1179		1-benzyl-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1180		1-ethyl-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea







H1181		(*S*)-4-(((4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)phenyl)sulfonyl)methyl)benzyl hydrogen sulfate
H1188		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxyureido)-*N*-(isoindolin-5-yl)benzenesulfonamide
H1190		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-phenylurea
H1193		1-benzyl-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1194		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1199		4-(1-hydroxy-3-(1-phenylethyl)ureido)-*N*-(isoindolin-5-yl)benzenesulfonamide
H1203		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(4-methoxybenzyl)urea
H1204		1-benzyl-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methylurea









H1205		1-(*tert*-butyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1206		3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1208		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(thiazol-5-ylmethyl)urea
H1212		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-((5-methoxypyridin-2-yl)methyl)urea
H1213		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-3-(1-phenylethyl)urea
H1214		(*R*)-1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1215		(*S*)-1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1216		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(thiazol-4-ylmethyl)urea
H1217		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(thiophen-3-ylmethyl)urea









H1219		1-(4-(((2-benzylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1220		1-(4-(((2-(cyclopropylmethyl)isoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1221		1-(4-(((2-ethylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1222		(*S*)-1-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1225		(*S*)-1-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1227		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(2,2,2-trifluoro-1-phenylethyl)urea
H1228		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-neopentylurea
H1229		1-(3-methylbutan-2-yl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea








H1230		1-(cyclopropylmethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1231		1-(4-((2-(2-benzylisoindolin-5-yl)propan-2-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1232		1-(4-((2-(2-ethylisoindolin-5-yl)propan-2-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1233		1-(4-((1-(2-benzylisoindolin-5-yl)ethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1234		1-(4-((1-(2-ethylisoindolin-5-yl)ethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1235		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylpropyl)urea
H1236		1-isobutyl-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1237		(*S*)-1-(4-((1-methylpiperidin-4-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea








H1238		(*S*)-1-(4-(((1-methylpiperidin-4-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1239		(*S*)-*N*-(1-methylpiperidin-4-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1244		1-(1-cyclopropylethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1248		2-chloro-5-ethyl-*N*-((4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)carbamoyl)benzamide
H1249		2-chloro-*N*-((4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)carbamoyl)-5-morpholinobenzamide
H1250		2-chloro-*N*-((4-(*N*-(isoindolin-5-yl)sulfamoyl)phenyl)carbamoyl)-5-morpholinobenzamide









H1251		2-chloro-5-ethoxy-*N*-((4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)carbamoyl)benzamide
H1252		2-chloro-5-ethoxy-*N*-((4-(*N*-(isoindolin-5-yl)sulfamoyl)phenyl)carbamoyl)benzamide
H1253		*N*-((4-((4-(2-amino-2-methylpropyl)benzyl)sulfonyl)phenyl)carbamoyl)-2-chloro-5-ethylbenzamide
H1254		*N*-((4-(*N*-(4-(2-amino-2-methylpropyl)phenyl)sulfamoyl)phenyl)carbamoyl)-2-chloro-5-ethylbenzamide
H1255		2-chloro-5-ethyl-*N*-((4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)carbamoyl)benzamide
H1256		(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(((4-(3-(1-phenylethyl)ureido)phenyl)sulfonyl)methyl)isoindoline-2-carboxylate










H1259		2-chloro-5-ethyl-*N*-((4-(*N*-(isoindolin-5-yl)sulfamoyl)phenyl)carbamoyl)benzamide
H1260		1-(1-(3-chlorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1261		1-(1-(2-chlorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1262		1-(1-(4-fluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1263		2-chloro-5-ethyl-*N*-((4-(*N*-(1,2,3,4-tetrahydroisoquinolin-7-yl)sulfamoyl)phenyl)carbamoyl)benzamide
H1264		1-(2-(isoindolin-5-yl)-1,1-dioxido-2,3-dihydrobenzo[*b*]thiophen-5-yl)-3-((*S*)-1-phenylethyl)urea
H1266		1-(1-(3-chlorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1267		1-(1-(2-chlorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea










H1268		1-(1-(4-fluorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1269		1-(1-(3-fluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1270		(*S*)-1-(2-(isoindolin-5-yl)-1,1-dioxidobenzo[*b*]thiophen-5-yl)-3-(1-phenylethyl)urea
H1271		1-benzyl-3-(2-(isoindolin-5-yl)-1,1-dioxido-2,3-dihydrobenzo[*b*]thiophen-5-yl)urea
H1272		1-(1-(2-fluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1273		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(pyridin-3-yl)ethyl)urea
H1274		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(pyridin-4-yl)ethyl)urea
H1275		1-(4-((4-(morpholinomethyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea










H1276		1-(1-phenylethyl)-3-(4-((4-(pyrrolidin-1-ylmethyl)benzyl)sulfonyl)phenyl)urea
H1277		1-(4-((hexahydropyrrolo[3,4-c]pyrrol-2(1*H*)-yl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1280		1-(1-phenylethyl)-3-(4-((pyridin-4-ylmethyl)sulfonyl)phenyl)urea
H1281		1-(1-(2-chloro-5-ethylphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1283		1-(1-(2-chloro-5-morpholinophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1284		1-(1-(2-chloro-5-morpholinophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1285		1-(2-(2-methylisoindolin-5-yl)-1,1-dioxido-2,3-dihydrobenzo[*b*]thiophen-5-yl)-3-((*S*)-1-phenylethyl)urea










H1286		1-(1-(2-chloro-5-ethylphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1289		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(pyridin-2-yl)ethyl)urea
H1290		1-(4-((3-(aminomethyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1291		1-(4-(((3-oxoisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1292		1-(4-(((1-oxoisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1293		1-(4-(((3-hydroxy-2,3-dihydro-1*H*-inden-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1294		1-(1-phenylethyl)-3-(4-(((3-(pyrrolidin-1-yl)-2,3-dihydro-1*H*-inden-5-yl)methyl)sulfonyl)phenyl)urea









H1296		1-(2-(2-benzylisoindolin-5-yl)-1,1-dioxidobenzo[*b*]thiophen-5-yl)-3-(1-(4-methoxyphenyl)ethyl)urea
H1297		1-(2-(isoindolin-5-yl)-1,1-dioxido-2,3-dihydrobenzo[*b*]thiophen-5-yl)-3-(1-(4-methoxyphenyl)ethyl)urea
H1298		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(4-methoxyphenyl)ethyl)urea
H1299		(*S*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1300		(*R*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1301		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea
H1302		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1303		(*S*)-1-(1-phenylethyl)-3-(4-((piperidin-4-ylmethyl)sulfonyl)phenyl)urea









H1304		1-(4-((4-((diethylamino)methyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1305		1-(4-((4-((dimethylamino)methyl)benzyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1306		(*S*)-1-(1-phenylethyl)-3-(4-(((2,3,4,5-tetrahydro-1H-benzo[*d*]azepin-7-yl)methyl)sulfonyl)phenyl)urea
H1307		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(pyridin-2-yl)ethyl)urea
H1308		*N*-(2-methylisoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1309		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(pyrimidin-5-yl)ethyl)urea
H1310		4-(1-(3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)ureido)ethyl)phenyl acetate
H1311		(*S*)-1-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1312		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1,2,3,4-tetrahydronaphthalen-1-yl)urea









H1313		1-(4-((4-((3-hydroxypyrrolidin-1-yl)methyl)benzyl)sulfonyl)phenyl)-3-((*S*)-1-phenylethyl)urea
H1314		1-(4-((4-((3-(hydroxymethyl)pyrrolidin-1-yl)methyl)benzyl)sulfonyl)phenyl)-3-((*S*)-1-phenylethyl)urea
H1315		(*S*)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1316		1-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1317		1-(2-fluoro-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1318		1-(1-phenylethyl)-3-(4-((3-(pyrrolidin-1-ylmethyl)benzyl)sulfonyl)phenyl)urea
H1319		1-(4-(((2-(oxetan-3-yl)isoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1320		1-(4-(((5,6-dihydro-4*H*-thieno[2,3-*c*]pyrrol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1321		1-(4-(((5-methyl-5,6-dihydro-4*H*-thieno[2,3-*c*]pyrrol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea









H1322		(*S*)-1-(4-(((3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1323		1-(4-(((6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-3-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1324		1-((*S*)-1-phenylethyl)-3-(4-(((1,2,3,4-tetrahydro-1,4-epiminonaphthalen-6-yl)methyl)sulfonyl)phenyl)urea
H1325		1-(4-(((9-methyl-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-6-yl)methyl)sulfonyl)phenyl)-3-((S)-1-phenylethyl)urea
H1326		1-(1-(3-methoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1327		1-(1-(3-methoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1328		1-((*S*)-1-phenylethyl)-3-(4-((4-(pyrrolidin-2-yl)benzyl)sulfonyl)phenyl)urea
H1329		1-(4-(((2-methyl-2*H*-indazol-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1330		1-(2,3-dihydrobenzofuran-3-yl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea









H1331		1-(2,3-dihydrobenzofuran-3-yl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1332		1-((*R*)-1-phenylethyl)-3-(4-((4-(pyrrolidin-2-yl)benzyl)sulfonyl)phenyl)urea
H1333		4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1334		4-(3-(1-(2-chlorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1335		(*S*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1,2,3,4-tetrahydronaphthalen-1-yl)urea
H1336		(*R*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1,2,3,4-tetrahydronaphthalen-1-yl)urea
H1337		(*R*)-*N*-(2-methylisoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzenesulfonamide
H1338		1-(4-(((2-(2-methoxyethyl)isoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1339		1-(4-(((2-(cyanomethyl)isoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea








H1340		1-(1-phenylethyl)-3-(4-(((2-(tetrahydrofuran-3-yl)isoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1341		1-(1-phenylethyl)-3-(4-(((2-((tetrahydrofuran-2-yl)methyl)isoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1342		1-(1-(2-fluorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1343		(*R*)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1344		1-(1-(2-chlorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1345		1-(1-(2,3-difluorophenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1346		4-(3-(1-(2,3-difluorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1347		4-(3-(1-(2-fluorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide








H1348		(*R*)-1-(4-(((5-methyl-5,6-dihydro-4*H*-thieno[2,3-c]pyrrol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1349		1-(2,3-dichlorobenzyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1350		2-methyl-5-(((4-(3-(1-phenylethyl)ureido)phenyl)sulfonyl)methyl)isoindoline 2-oxide
H1351		(*R*)-1-(4-(((5-methyl-5,6-dihydro-4*H*-thieno[2,3-c]pyrrol-3-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1352		(*S*)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-*N*-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzenesulfonamide
H1353		1-(1-acetylindolin-3-yl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1354		1-(1-acetylindolin-3-yl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1355		(*R*)-1-(4-(((7-fluoro-2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea









H1356		(*R*)-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1357		(*R*)-1-(1-phenylethyl)-3-(4-(((1,1,2-trimethylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1358		1-(indolin-3-yl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1359		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((5-methyl-4,5,6,7-tetrahydrothieno[3,2-*c*]pyridin-2-yl)methyl)sulfonyl)phenyl)urea
H1360		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(diethylamino)benzyl)sulfonyl)phenyl)urea
H1361		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((3-(diethylamino)propyl)sulfonyl)phenyl)urea
H1362		4-(3-((*R*)-1-(2,3-dichlorophenyl)ethyl)ureido)-N-(4-(*cis*-3,5-dimethylpiperazin-1-yl)-2-methoxyphenyl)benzenesulfonamide
H1363		(*R*)-1-(4-(((4-fluoro-2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea








H1364		(*R*)-*N*-(2-aminopyrimidin-4-yl)-4-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)benzenesulfonamide
H1366		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1367		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((5-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1368		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1369		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((5-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1371		1-(4-(((4-((cyclopropylmethyl)amino)cyclohexyl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1372		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-(diethylamino)cyclohexyl)methyl)sulfonyl)phenyl)urea
H1373		1-(4-(((4-aminocyclohexyl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea








H1374		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((piperidin-3-ylmethyl)sulfonyl)phenyl)urea
H1375		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1-((tetrahydrofuran-2-yl)methyl)piperidin-3-yl)methyl)sulfonyl)phenyl)urea
H1376		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((1-isopropylpiperidin-3-yl)methyl)sulfonyl)phenyl)urea
H1377		1-methyl-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1378		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((8-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1379		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-*c*]pyridin-2-yl)methyl)sulfonyl)phenyl)urea
H1380		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1381		1-methyl-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea








H1382		1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(2-methoxyphenyl)ethyl)urea
H1383		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-3-(1-phenylethyl)urea
H1384		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)methyl)sulfonyl)phenyl)urea
H1385		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1386		1-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1387		1-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1388		1-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea









H1389		1-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(2-fluorophenyl)ethyl)urea
H1390		1-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-(2-methoxyphenyl)ethyl)urea
H1391		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1392		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1393		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-3-(1-(2-methoxyphenyl)ethyl)urea
H1394		(R)-1-(4-(((7-fluoroisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1395		6-((isoindolin-5-ylmethyl)sulfonyl)-3-(1-phenylethyl)-3,4-dihydroquinazolin-2(1H)-one









H1396		(R)-1-(4-(((4-fluoroisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1397		N-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-3,4-dihydroisoquinoline-2(1H)-carboxamide
H1398		3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-1-methyl-1-(1-phenylethyl)urea
H1399		3-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1400		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-fluoro-4-(((8-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1401		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-fluoro-4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1402		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-fluoro-4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-methylurea
H1403		1-((S)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea









H1404		1-(2,6-difluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1405		1-(4-(((7-chloroisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1406		1-(4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1407		1-(4-(((2,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1408		1-(5-((isoindolin-5-ylmethyl)sulfonyl)pyridin-2-yl)-3-(1-phenylethyl)urea
H1409		3-(4-(((4-fluoroisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1410		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-(((4-fluoroisoindolin-5-yl)methyl)sulfonyl)phenyl)urea









H1411		1-(1-(2,6-difluorophenyl)ethyl)-3-(2-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1412		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)urea
H1413		3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1414		3-(2-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1415		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1416		1-benzyl-1-methyl-3-(4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1417		(R)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea









H1418		1-methyl-N-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3,4-dihydroisoquinoline-2(1H)-carboxamide
H1419		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1420		1-(1-(2-fluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)urea
H1421		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)urea
H1422		(R)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1423		(R)-1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(2-fluoro-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1424		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea









H1425		1-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(naphthalen-1-yl)ethyl)urea
H1426		1-(1-(2-fluorophenyl)ethyl)-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1427		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1428		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1429		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1430		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)phenyl)urea
H1431		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((2,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea
H1432		1-(1-(2,6-difluorophenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)-2-methoxyphenyl)urea









H1433		1-(4-((4-(hydroxymethyl)benzyl)sulfonyl)-2-methoxyphenyl)-3-(1-phenylethyl)urea
H1434		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)-2-methoxyphenyl)urea
H1435		1-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-3-(4-((4-(hydroxymethyl)benzyl)sulfonyl)-2-methoxyphenyl)urea
H1436		1-(1-(2,6-difluorophenyl)ethyl)-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1437		1-(1-(2,6-difluorophenyl)ethyl)-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1438		1-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-(2-methoxyphenyl)ethyl)urea
H1439		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((7-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea
H1440		1-(4-(((2,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)-3-(1-phenylethyl)urea









H1441		1-(2-methoxy-4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1442		1-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-(4-methoxyphenyl)ethyl)urea
H1443		1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-methylurea
H1444		1-(1-(3,4-dimethoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1445		1-(1-(3,5-difluorophenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1446		1-(1-(3,5-difluorophenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1447		1-(2-methyl-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1448		1-(2-hydroxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea








H1449		1-(1-(3,4-dimethoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1450		1-(1-(2,6-dimethoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1451		1-(1-(2,6-dimethoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1452		1-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1453		1-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1454		1-(1-(2-fluoro-6-methoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1455		1-(1-(2-fluoro-6-methoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1456		1-(2-chloro-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea






H1457		2-(3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)ureido)-2-phenylacetamide
H1458		1-hydroxy-1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1459		methyl 5-((isoindolin-5-ylmethyl)sulfonyl)-2-(3-(1-phenylethyl)ureido)benzoate
H1460		3-(2-hydroxy-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1461		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-methoxyphenyl)-3-(1-phenylethyl)urea
H1462		1-(3-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1463		(S)-1-(4-(((5,6-dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl)methyl)sulfonyl)-2-methoxyphenyl)-3-(1-phenylethyl)urea
H1464		(S)-1-(2-methoxy-4-(((5-methyl-5,6-dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea









H1465		(S)-1-(4-(((5,6-dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1466		methyl 5-(((2-methylisoindolin-5-yl)methyl)sulfonyl)-2-(3-(1-phenylethyl)ureido)benzoate
H1467		1-(2-(hydroxymethyl)-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1468		1-(2-(hydroxymethyl)-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1469		6-((isoindolin-5-ylmethyl)sulfonyl)-3-(1-phenylethyl)quinazoline-2,4(1H,3H)-dione
H1470		6-(((2-methylisoindolin-5-yl)methyl)sulfonyl)-3-(1-phenylethyl)quinazoline-2,4(1H,3H)-dione
H1471		1-hydroxy-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1472		1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea








H1473		1-hydroxy-1-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1474		3-(2-hydroxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-methyl-1-(1-phenylethyl)urea
H1475		1-(1-(3-chloro-4-methoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1476		1-(1-(3-chloro-4-methoxyphenyl)ethyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1477		1-(1-(3-chloro-4-methoxyphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1478		1-(3-chloro-4-methoxybenzyl)-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1479		N-(isoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzamide
H1480		N-(2-methylisoindolin-5-yl)-4-(3-(1-phenylethyl)ureido)benzamide








H1481		(R)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1482		(S)-1-(1-(2,3-dichlorophenyl)ethyl)-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1483		1-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1484		1-(2-cyclopropyl-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1485		1-(2-bromo-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1486		5-((isoindolin-5-ylmethyl)sulfonyl)-2-(3-(1-phenylethyl)ureido)benzoic acid
H1487		1-(3-hydroxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1488		1-(4-(((8-azabicyclo[3.2.1]oct-2-en-3-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea







H1489		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((8-methyl-8-azabicyclo[3.2.1]oct-2-en-3-yl)methyl)sulfonyl)phenyl)urea
H1490		1-(1-(2-fluorophenyl)ethyl)-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1491		1-(1-(2-fluorophenyl)ethyl)-1-hydroxy-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1492		1-(3-fluoro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1493		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-methylphenyl)-3-(1-phenylethyl)urea
H1494		1-(3-chloro-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1495		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)urea







H1496		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1497		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1498		1-hydroxy-3-(2-methoxy-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1499		5-((isoindolin-5-ylmethyl)sulfonyl)-N-methyl-2-(3-(1-phenylethyl)ureido)benzamide
H1500		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(oxazol-2-yl)phenyl)-3-(1-phenylethyl)urea








H1501		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)-2-(oxazol-2-yl)phenyl)-3-(1-phenylethyl)urea
H1502		1-benzyl-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1503		1-benzyl-1-hydroxy-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1504		1-(3-bromo-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1505		methyl 2-((isoindolin-5-ylmethyl)sulfonyl)-5-(3-(1-phenylethyl)ureido)benzoate
H1506		1-(3-cyclopropyl-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1507		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-(oxazol-2-yl)phenyl)-3-(1-phenylethyl)urea
H1508		1-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)-3-(oxazol-2-yl)phenyl)-3-(1-phenylethyl)urea








H1509		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1510		1-(1-(2-fluorophenyl)ethyl)-1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-methoxyphenyl)urea
H1511		1-(1-(2-fluorophenyl)ethyl)-1-hydroxy-3-(3-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)urea
H1512		1-(2-(2-hydroxypropan-2-yl)-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1513		1-(4-(((8-acetyl-8-azabicyclo[3.2.1]oct-2-en-2-yl)methyl)sulfonyl)phenyl)-3-(1-(2,3-dichlorophenyl)ethyl)urea
H1514		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((8-isopropyl-8-azabicyclo[3.2.1]oct-2-en-2-yl)methyl)sulfonyl)phenyl)urea
H1515		1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-3-methoxyphenyl)-1-(1-phenylethyl)urea

H1516		1-hydroxy-3-(3-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1517		1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-methoxyphenyl)-1-(1-phenylethyl)urea
H1518		1-hydroxy-3-(2-methoxy-4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1519		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(1H-pyrazol-3-yl)phenyl)-3-(1-phenylethyl)urea
H1520		1-(3-(hydroxymethyl)-4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1521		1-(1-(3-(difluoromethyl)-4-methylphenyl)ethyl)-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)urea
H1522		1-(2-(isoindolin-5-yl)-1,1-dioxido-3-oxo-2,3-dihydrobenzo[b]thiophen-6-yl)-3-(1-phenylethyl)urea


H1523		1-(1-(2,3-dichlorophenyl)ethyl)-1-hydroxy-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1524		1-hydroxy-3-(2-methoxy-4-(((3-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1525		1-hydroxy-3-(2-methoxy-4-(((2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1526		1-hydroxy-3-(4-((isoindolin-5-ylmethyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1527		1-hydroxy-3-(4-(((2-methylisoindolin-5-yl)methyl)sulfonyl)phenyl)-1-(1-phenylethyl)urea
H1528		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-3-(1-phenylethyl)urea

H1529		2-((isoindolin-5-ylmethyl)sulfonyl)-N-methyl-5-(3-(1-phenylethyl)ureido)benzamide
H1530		2-((isoindolin-5-ylmethyl)sulfonyl)-5-(3-(1-phenylethyl)ureido)benzoic acid
H1531		2-((isoindolin-5-ylmethyl)sulfonyl)-5-(3-(1-phenylethyl)ureido)benzamide
H1532		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(1H-pyrazol-4-yl)phenyl)-3-(1-phenylethyl)urea
H1533		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(pyridin-3-yl)phenyl)-3-(1-phenylethyl)urea
H1534		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(pyridin-4-yl)phenyl)-3-(1-phenylethyl)urea


H1535		1-(4-((isoindolin-5-ylmethyl)sulfonyl)-2-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-(1-phenylethyl)urea
H1537		1-((R)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1538		1-((R)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1539		1-(4-(((4-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-((R)-1-phenylethyl)urea
H1540		1-(4-(((4-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-((R)-1-phenylethyl)urea
H1541		2-(3-(1-phenylethyl)ureido)-5-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)benzoic acid
H1542		2-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-5-(((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)benzoic acid

H1543		1-((R)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea
H1544		1-((R)-1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)-2-methoxyphenyl)urea
H1545		1-(4-(((4,4-difluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1546		1-(4-(((4,4-difluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)-3-(1-phenylethyl)urea
H1547		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4,4-difluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1548		1-(1-(2,3-dichlorophenyl)ethyl)-3-(4-(((4,4-difluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)sulfonyl)phenyl)urea
H1549		2-(3-(1-(2,3-dichlorophenyl)ethyl)ureido)-5-((isoindolin-5-ylmethyl)sulfonyl)benzoic acid


75. A compound selected from the group consisting of:




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




,



,


or a pharmaceutically acceptable salt thereof.

76. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

77. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

77. A compound having the structure:




or a pharmaceutically acceptable thereof.

78. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

79. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

80. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

81. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

82. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

83. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

84. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

85. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

86. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

87. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

88. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

89. A compound having the structure:




or a pharmaceutically acceptable salt thereof.

90. A compound having the structure:



or a pharmaceutically acceptable salt thereof.

91. A compound having the structure:



or a pharmaceutically acceptable salt thereof.